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This	   dissertation	   represents	   the	   research	   developed	   during	   my	  
graduation	  course.	  
	  
Initially	  I	  spent	  some	  time	  in	  the	  laboratory	  of	  Professor	  Dennis	  J.	  Thiele,	  
Department	   of	   Pharmacology	   and	   Cancer	   Biology	   conducting	   studies	  
related	  to	  the	  importance	  of	  key	  repressive	  phosphorylation	  events	  in	  the	  
regulation	  of	  human	  Heat	  Shock	  Transcription	  Factor	  1	  (HSF1).	  The	  results	  
were	   published	   in	   PLos	   ONE	   in	   a	   paper	   that	   I	   co-­‐authored	   and	   are	  
described	  in	  Chapter	  2.	  	  
At	  the	  laboratory	  of	  Professor	  Claudina	  Rodrigues-­‐Pousada	  I	  have	  carried	  
out	   an	   extensive	   transcriptomic	   analysis	   to	   address	   the	   response	   of	  
Saccharomyces	  cerevisiae	   to	  arsenic	  stress.	  This	  work	  shows	  for	  the	  first	  
time	   that	   arsenic,	   a	   toxic	   metalloid	   also	   used	   as	   a	   chemotherapy	   drug	  
used	   to	   treat	   a	   specific	   type	   of	   acute	   promyelocytic	   leukemia	   (APL),	  
disrupts	  the	  cellular	  iron	  homeostasis.	  This	  disruption	  also	  seems	  to	  take	  
place	  in	  mammalian	  cells,	  which	  if	  confirmed	  could	  be	  a	  critical	  discovery	  
for	  clinical	  application.	  This	  study	  is	  described	  on	  Chapter	  1	  and	  will	  soon	  
be	  published.	  
Although	   these	   projects	   seem	   to	   be	   unrelated,	   both	   represent	   two	  
different	   ways	   of	   studying	   stress	   response,	   one	   through	   the	   effects	   of	  
cellular	   arsenic	   toxicity	   and	   the	  other	   through	   the	  understanding	  of	   the	  
mechanism	   of	   human	   HSF1	   regulation,	   the	   major	   stress-­‐activated	  
transcription	   factor.	   Moreover	   in	   both	   studies	   we	   employed	   the	   best	  
understood	  eukaryotic	  organism,	  Saccharomyces	  cerevisiae,	  which	  in	  the	  
last	  decade	  has	  been	  used	  as	  a	  model	  system	  to	  gain	   insights	  about	  the	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mechanisms	   occurring	   in	   many	   human	   diseases,	   in	   particular,	  
neurodegenerative	  disorders.	  This	  subject	   is	  addressed	   in	  more	  detail	   in	  
two	   reviews	   that	   I	   co-­‐author,	   presented	   in	   the	   appendix	   section	   of	   this	  
dissertation.	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 1 
The	   work	   presented	   in	   this	   thesis	   describes	   the	   use	   of	   yeast	  
Saccharomyces	  cerevisiae	  as	  a	  model	  system	  to	  study	  two	  different	  stress	  
response	  processes	  and	  its	  extrapolation	  to	  higher	  eukaryotes.	  	  
	  
In	  the	  Chapter	  1	  of	  this	  work	  we	  report	  the	  transcriptomic	  analysis	  of	  	  S.	  
cerevisiae	  response	  to	  arsenic,	  a	  highly	  toxic	  and	  carcinogenic	  metalloid.	  
This	  study	  shows	  that	  arsenic	  stress	  interferes	  with	  genes	  involved	  in	  iron	  
homeostasis	   including	   those	   encoding	   proteins	   that	   function	   in	   iron	  
uptake,	   incorporation	   into	   heme	   and	   Fe–S	   (iron–sulfur)	   clusters,	  
compartmentalization	   to	   and	  mobilization	   from	   intracellular	   stores	   and	  
other	   functions	   in	   iron	   balance.	   In	   S.	   cerevisiae	   iron	   metabolism	   is	  
balanced	   by	   two	   distinct	   iron	   transport	   systems,	   depending	   on	   the	  
bioavailability	  of	  the	  metal	  in	  the	  extracellular	  environment.	  Interestingly	  
mRNA	  levels	  encoding	  Fet3	  and	  Ftr1,	  a	  complex	  required	  for	  high-­‐affinity	  
iron	  uptake,	  are	  drastically	  decreased	  upon	  arsenic	  exposure.	  Moreover	  
the	   FET3	  mRNA	   decrease	   is	  mediated	   by	   the	  major	   pathway	   for	  mRNA	  
decay,	  the	  5’-­‐3’	  exonuclease	  Xrn1	  and	  is	  independent	  of	  the	  formation	  of	  
ROS.	   Strikingly,	   upon	   addition	   of	   arsenic	   Fet3	   does	   not	   localize	   in	   the	  
plasma	  membrane	  but	  rather	  resides	  in	  the	  endoplasmic	  reticulum.	  Also,	  
the	   fet3ftr1	   mutant	   shows	   increased	   arsenic	   resistance	   over	   the	   wild-­‐
type,	   suggesting	   that	  Fet3	  plays	  a	   role	   in	  arsenic	   toxicity.	  Unexpectedly,	  
arsenic	   treatment	   seems	   to	   activate	   the	   non-­‐reductive	   iron	   uptake	  
system.	   Finally,	   we	   provide	   data	   suggesting	   that	   arsenic-­‐mediated	  
disruption	   of	   iron	   homeostasis	   also	   occurs	   in	   mammalian	   cells,	   an	  
observation	  that	  can	  be	  relevant	  for	  clinical	  applications.	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In	  the	  Chapter	  2	  of	  this	  work	  we	  report	  on	  the	  repression	  mechanisms	  for	  
human	   Heat	   Shock	   Factor	   1	   (hHSF1)	   activity	   when	   expressed	   in	   S.	  
Cerevisiae.	  The	  heat	  shock	  transcription	  factor	  plays	  an	  important	  role	  in	  
the	  cellular	   response	   to	  proteotoxic	   stressors.	  Under	  normal	   conditions,	  
HSF1	   is	   maintained	   as	   an	   inactive	   monomer	   and	   lacks	   the	   ability	   to	  
activate	   gene	   expression.	   In	   response	   to	   stress,	   HSF1	   homotrimerizes,	  
accumulates	   in	   the	  nucleus,	   becomes	  hyper-­‐phosphorylated,	   binds	  DNA	  
and	   activates	   gene	   transcription.	   	   Upon	   passage	   of	   the	   stress,	   HSF1	  
becomes	   hypo-­‐phosphorylated	   and	   relocalizes	   to	   the	   cytoplasm	  
becoming	   re-­‐established	   as	   an	   inactive	   monomer.	   While	   significant	  
advances	  have	  been	  made	  to	  understand	  the	  mechanisms	  involved	  in	  the	  
HSF1	   activation,	   relatively	   little	   is	   known	   about	   the	   mechanisms	  
underlying	   	   repression.	   HSF1	   is	   a	   highly	   conserved	   protein	   amongst	  
eukaryotes	   and	   previous	   data	   have	   shown	   that	   hHSF1	   is	   unable	   to	  
complement	   for	   the	   loss	   of	   the	   essential	   yeast	   HSF,	   as	   hHSF1	   is	  
maintained	   in	  an	   inactive	  monomer	   in	  yeast.	   	   Interestingly,	  many	  of	   the	  
proteins	   linked	  to	  the	  repression	  of	  HSF1	  function,	   including	  the	  protein	  
chaperones	  HSP90	  and	  HSP70,	  as	  well	  as	  the	  kinases	  JNK,	  ERK	  and	  GSK3,	  
are	  conserved	  in	  yeast.	   	  We	  hypothesized	  that	  gaining	  an	  understanding	  
of	   the	  mechanisms	  by	  which	  hHSF1	   is	  maintained	   in	  an	   inactive	  state	   in	  
yeast	  would	  further	  our	  comprehension	  of	  HSF1	  regulation	  in	  metazoans.	  	  
To	   explore	   these	   mechanisms	   we	   used	   a	   variety	   of	   biochemical	   and	  
genetic	  approaches	   to	   identify	  potential	   inhibitory	  phosphorylation	  sites	  
as	   well	   as	   a	   screen	   of	  mutant	   yeast	   strains	   to	   identify	   potential	   hHSF1	  
repressor	  proteins.	  	  Here	  we	  show	  that	  when	  hHSF1	  is	  expressed	  in	  yeast	  
it	   is	   phosphorylated	   at	   S303	   by	   the	   MAP-­‐kinase	   Slt2	   and	   that	   this	  
phosphorylation	   occurs	   independent	   of	   a	   priming	   event	   previously	  
 3 
believed	   to	   be	   essential	   for	   this	   phosphorylation.	   	   In	   addition,	   while	  
previous	   studies	   have	   suggested	   that	   S303	   phosphorylation	   repressed	  
HSF1-­‐dependent	  transactivation,	  we	  show	  in	  both	  yeast	  and	  mammalian	  
cells	   that	   S303	   phosphorylation	   also	   represses	   HSF1	   multimerization.	  
Together,	  our	  data	  support	  the	  hypothesis	  that	  the	  yeast	  can	  be	  used	  to	  
simplify	   and	   elucidate	   complex	   regulatory	   mechanisms	   modulating	  
mammalian	   HSF1	   activity	   as	   well	   as	   identify	   novel	   regulatory	   aspects	  
controlling	  HSF1	  activity	  in	  yeast	  and	  mammalian	  cells.	  
	  
Taken	   together,	   this	   work	   suggests	   that	   yeast	   cells	   can	   be	   a	   powerful	  
experimental	  tool	  for	  investigating	  aspects	  as	  arsenic	  toxicity	  and	  human	  
HSF1	  regulation	  by	  providing	   	  a	  platform	  for	  the	  understanding	  of	   these	  
mechanisms	  in	  higher	  eukaryotes.	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O	   trabalho	   apresentado	   nesta	   tese	   descreve	   a	   utilização	   da	   levedura	  
Saccharomyces	   cerevisiae	   como	   um	   sistema	   modelo	   para	   estudar	   dois	  
processos	  diferentes	  da	   resposta	  ao	  stress	  e	  a	   sua	  extrapolação	  para	  os	  
eucariotas	  superiores.	  
	  
No	  Capítulo	  1	  deste	  trabalho,	  apresentamos	  a	  análise	  transcriptómica	  da	  
resposta	   S.	   cerevisiae	   ao	   arsénio,	   um	   metalóide	   altamente	   tóxico	   e	  
cancerígeno.	   Este	   estudo	  demonstra	  que	  o	   stress	   pelo	   arsénio	   interfere	  
com	  os	  genes	  envolvidos	  na	  homeostase	  do	  ferro,	  em	  particular,	  os	  genes	  
que	   codificam	   as	   proteínas	   que	   funcionam	   na	   absorção	   de	   ferro,	  
incorporação	   nos	   clusters	   de	   heme	   Fe-­‐S	   (ferro-­‐enxofre),	   na	  
compartimentalização	   e	   mobilização	   das	   reservas	   intracelulares	   entre	  
outras	   funções.	   Em	   S.	   cerevisiae	   o	   equilibrio	   do	   metabolismo	   do	   ferro	  
ocorre	   atraves	   de	   dois	   sistemas	   distintos	   de	   transporte	   do	   ferro,	  
dependendo	  da	  biodisponibilidade	  deste	  metal	  no	  ambiente	  extracelular.	  
Curiosamente	  os	  níveis	  de	  mRNA	  que	  codificam	  Fet3	  e	  Ftr1,	  um	  complexo	  
de	   alta	   afinidade	   para	   a	   absorção	   de	   ferro,	   estão	   drasticamente	  
diminuidos	  após	  exposição	  ao	  arsénio.	  Além	  disso	  a	  diminuição	  do	  FET3	  
mRNA	  é	  mediada	  pela	  via	  principal	  de	  degradação	  do	  mRNA	  através	  da	  
5'-­‐3	   'exonuclease	   Xrn1	   e	   é	   independente	   da	   formação	   de	   ROS.	  
Surpreendentemente,	  após	  a	  adição	  de	  arsénio	  Fet3	  não	  está	   localizado	  
na	   membrana	   plasmática	   mas	   sim	   no	   retículo	   endoplasmático.	   Além	  
disso,	   o	   mutante	   fet3ftr1	   apresenta	   mais	   resistência	   ao	   arsénio	   que	   a	  
estirpe	  do	  tipo	  selvagem,	  sugerindo	  que	  o	  Fet3	  desempenha	  um	  papel	  na	  
toxicidade	   do	   arsénio.	   Curiosamente,	   o	   tratamento	   com	   arsénio	   parece	  
ativar	  a	  via	  não-­‐redutora	  da	  absorção	  do	   ferro.	  Finalmente,	  este	  estudo	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apresenta	  dados	  que	  sugerem	  que	  a	  perturbação	  da	  homeostase	  do	  ferro	  
pelo	   arsénio	   também	   ocorre	   em	   células	   de	  mamífero,	   uma	   observação	  
que	  pode	  ser	  relevante	  para	  aplicações	  clínicas.	  
	  
No	   Capítulo	   2	   deste	   trabalho	   descrevemos	   alguns	   dos	   mecanismos	   de	  
repressão	   da	   atividade	   do	   factor	   de	   transcrição	   humano	   “Heat	   Shock	  
Factor”	   (HSF1)	  expresso	  na	  S.	   cerevisiae.	  O	  HSF1	  desempenha	  um	  papel	  
muito	   importante	  na	  resposta	  celular	  a	  factores	  de	  stress	  proteotóxicos.	  
Em	   condições	   fisiológicas,	   o	   HSF1	   é	   mantido	   como	   um	   monómero	  
inactivo	  e	  não	  tem	  a	  capacidade	  para	  activar	  a	  expressão	  de	  genes.	  Após	  
o	   stress,	   HSF1	   homotrimeriza,	   desloca-­‐se	   para	   o	   núcleo,	   torna-­‐se	  
hiperfosforilado,	  liga-­‐se	  DNA	  e	  activa	  a	  transcrição	  dos	  genes	  alvo.	  Após	  o	  
stress,	   HSF1	   torna-­‐se	   hipo-­‐fosforilado	   e	   regressa	   para	   o	   citoplasma,	  
voltando	   à	   forma	   de	  monómero	   inativo.	   Embora	   já	   tenham	   sido	   feitos	  
avanços	   significativos	   para	   compreender	   os	   mecanismos	   envolvidos	   na	  
ativação	   do	   HSF1,	   relativamente	   pouco	   se	   sabe	   sobre	   os	   mecanismos	  
subjacentes	  à	  sua	  repressão.	  HSF1	  é	  uma	  proteína	  altamente	  conservada	  
entre	   os	   eucariotas	   e	   dados	   anteriores	   demonstraram	   que	   o	   HSF1	  
humano	  (hHSF1)	  é	  incapaz	  de	  complementar	  a	  ausência	  do	  HSF,	  essencial	  
na	  levedura,	  visto	  que	  o	  hHSF1	  é	  mantido	  como	  um	  monómero	  inactivo.	  
Curiosamente,	  muitas	   das	   proteínas	   envolvidas	   na	   repressão	   da	   função	  
do	  HSF1,	   incluindo	  as	  proteínas	  chaperone	  Hsp90	  e	  Hsp70,	  bem	  como	  a	  
JNK	  quinases,	  ERK	  e	  GSK3	  estão	  conservados	  na	  levedura.	  Desta	  forma	  a	  
compreensão	  dos	  mecanismos	  pelos	  quais	  hHSF1	  é	  mantido	  num	  estado	  
inativo	   na	   levedura	   poderá	   aprofundar	   a	   nossa	   compreensão	   da	  
regulação	   do	   HSF1	   em	   metazoários.	   Para	   explorar	   estes	   mecanismos	  
utilizou-­‐se	   uma	   variedade	   de	   abordagens	   bioquímicas	   e	   genéticas	   para	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identificar	   potenciais	   sítios	   inibidores	   de	   fosforilação,	   bem	   como	   uma	  
série	  de	  mutantes	  na	  levedura,	  com	  o	  objectivo	  de	  identificar	  potenciais	  
proteínas	   repressoras	   do	   hHSF1.	   Neste	   trabalho	  mostra-­‐se	   que	   quando	  
HSF1	  humano	  é	  expresso	  em	  levedura	  está	  fosforilado	  na	  S303	  pela	  Slt2	  
MAP-­‐quinase	   e	   que	   esta	   fosforilação	   ocorre	   independentemente	   da	  
fosforilação	   prévia	   da	   S307	   que	   até	   então	   se	   acreditava	   ser	   essencial.	  
Além	  disso,	  enquanto	  que	  estudos	  anteriores	  sugeriam	  que	  a	  fosforilação	  
na	   S303	   reprime	  a	   transactivação	  dependente	  do	  HSF1,	  nós	  mostramos	  
em	  levedura	  e	  células	  de	  mamíferos	  que	  a	  fosforilação	  na	  S303	  também	  
reprime	   a	   multimerização	   do	   HSF1.	   Em	   suma,	   os	   nossos	   resultados	  
apoiam	  a	  hipótese	  de	  que	   a	   levedura	  pode	   ser	   usada	  para	   simplificar	   e	  
elucidar	   mecanismos	   complexos	   de	   regulação	   da	   actividade	   do	   HSF1	  
humano,	   bem	   como	   identificar	   novos	   aspectos	   reguladores	   que	  
controlam	  a	  actividade	  do	  HSF1	  na	  levedura	  e	  nas	  células	  de	  mamíferos.	  
Finalmente	   este	   trabalho	   sugere	   que	   as	   células	   de	   levedura	   podem	  
constituir	   uma	   poderosa	   ferramenta	   experimental	   para	   investigar	  
aspectos	  como	  a	  toxicidade	  de	  arsénio	  e	  regulação	  da	  actividade	  do	  HSF1	  
humano,	   fornecendo	   uma	   plataforma	   para	   a	   compreensão	   destes	  
mecanismos	  em	  eucariotas	  superiores.	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General	  Introduction	  
The	  Yeast	  Model	  System	  –	  Saccharomyces	  cerevisiae	  	  
YEAST	  CELLS	  -­‐	  “OUR	  RELATIVES”	  	  
Impressively	   nature	   keeps	   using	   the	   same	   building	   blocks	   to	   construct	  
organisms	  as	  different	  as	  yeast	  cells,	  worms,	  flies,	  mice,	  and	  humans.	  It’s	  
this	  simplicity	  that	  allows	  us	  to	  study	  our	  own	  genes	  using	  the	  blob-­‐like	  
cells	   of	   yeast.	   Due	   to	   their	   basic	   cellular	   mechanisms	   of	   replication,	  
recombination,	   cell	   division	   and	  metabolism	   conserved	   in	   mammals	   S.	  
cerevisiae	   is	   considered	   the	   model	   system	   for	   molecular	   genetic	  
research.	  Yeast	  is	  extremely	  easy	  to	  work	  with	  in	  the	  lab	  and	  the	  types	  of	  
experiments	  we	   can	   do	  with	   them	   are	   endless.	   They	   can	   help	   conduct	  
scientific	   research	   and	  make	   bread,	   beer,	   and	   other	   food	   stuffs.	   Can	   a	  
mouse,	  fish,	  or	  fly	  do	  that?	  
	  10	  
	  	  	  	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	   11	  
Saccharomyces	  cerevisiae:	  An	  experimental	  organism	  
Sixteen	  years	  ago,	   in	  1996,	   it	  was	   released	   the	  electronic	   version	  of	   the	  
first	   complete	   DNA	   sequence	   of	   a	   eukaryotic	   genome,	   the	   yeast	  
Saccharomyces	   cerevisiae	   [1,	   2],	   one	   of	   the	   oldest	   “domesticated”	  
organisms.	  Already	  at	  the	  time	  there	  was	  no	  doubt	  that	  this	  yeast	  would	  
be	   a	   fine	   “model	   organism”,	   useful	   for	   interpreting	   and	   understanding	  
human	  DNA	  sequences	  [3].	  	  
The	  yeast	  genome	  contains	  6000	  genes	  and	  at	  least	  60%	  have	  statistically	  
robust	  human	  homologues	  or	  one	  conserved	  domain	  with	  human	  genes.	  
Interestingly	  more	  than	  30%	  of	  human	  disease	  genes	  have	  counterparts	  
in	  yeast,	  and	  about	  71	  human	  genes	  complement	  yeast	  mutations	  (Table	  
1	   in	   Appendix)	   [4].	   Despite	   the	   tremendous	   achievement	   in	   sequencing	  
the	   entire	   human	   genome	   (3	   billion	   base	   pairs	   in	   human	   DNA),	  
researchers	  would	  not	  be	  able	  to	  use	  this	  “treasure”	  if	  they	  did	  not	  have	  
access	   to	   the	   information	   provided	   by	   model	   organisms	   like	   yeast.	  
Indeed,	   their	   genomic	   homology	   shows	   the	   conservation	   of	   the	  
fundamental	   cell	   biological	   processes	   between	   yeast	   and	   mammalian	  
cells.	  Furthermore	  yeast	  cells,	  just	  like	  our	  cells,	  have	  a	  nucleus	  containing	  
chromosomes	  and	  divide	  in	  a	  similar	  manner	  recapitulating	  fundamental	  
aspects	  of	  the	  eukaryotic	  biology.	  	  
Therefore	  S.	  cerevisiae	  as	  a	  simple	  eukaryote	  with	  a	  tractable	  genome,	  a	  
short	   generation	   time,	   and	   a	   large	   network	   of	   researchers	   who	   have	  
generated	  exquisite	  research	  tools,	  became	  a	  popular	  organism	  suited	  to	  
help	   reveal	   the	   function	   of	   genes	   implicated	   in	   human	   biology.	   Many	  
times	   the	   first	   clue	   about	   the	   function	   of	   higher	   eukaryotic	   genes	   has	  
risen	  from	  the	  homology	  to	  a	  yeast	  gene.	  S.	  cerevisiae,	   in	  particular,	  has	  
allowed	   the	   investigation	   of	   many	   important	   aspects	   of	   eukaryotic	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biology,	   including	   the	   process	   of	   cell	   division	   and	   genetic	   transmission,	  
transcriptional	   regulation,	  biogenesis	  and	   function	  of	  cellular	  organelles,	  
protein	   targeting	   and	   secretion,	   cytoskeletal	   dynamics	   and	   regulation,	  
and	  cellular	  metabolism	  [5].	  
Certainly,	  yeast	  does	  not	  have	  Parkinson	  or	  heart	  disease,	  but	  yet	  many	  
of	  the	  human	  genes	  that	  are	  malfunctioning	  in	  these	  and	  other	  disorders	  
have	   parallel	   genes	   in	   this	   model	   organism,	   where	   they	   can	   be	   more	  
easily	   studied.	   Therefore	   many	   researchers	   are	   now	   developing	   yeast	  
models	   of	  many	  human	  diseases.	   Also,	   the	  modern	   tools	   available	   in	   S.	  
cerevisiae	   make	   possible	   to	   perform	   systematic	   analysis	   of	   a	   cellular	  
process	   or	   phenotype,	   such	   us,	   genetic	   screening	   libraries,	  
transcriptomic,	  proteomic	  and	  metabolomic	  analysis,	  chemical	  genomics	  
and	  chemical	  genetics,	  and	  phenotypic	  microarray	  analysis	  [6].	  
Despite	   yeast	   cells	   don't	   have	   brains	   enormous	   attention	   has	   been	  
directed	   recently	   to	   their	   potential	   as	   an	   experimental	   model	   for	  
neurodegenerative	   diseases,	   such	   as	   Alzheimer,	   Parkinson	   and	  
Huntington	   (see	   reviews	   in	   appendix).	   Many	   of	   the	   problems	   in	   these	  
diseases	  derive	  from	  problems	  in	  protein	  folding	  and	  trafficking,	  which	  is	  
largely	   the	   same	   in	   yeast	   as	   it	   is	   in	   neurons	   [7].	   Additionally	   yeast	   has	  
been	  extensively	  used	  to	  study	  cancer	  and	  age-­‐related	  disorders.	  
Khurana	  and	   Lindquist	   [6]	  have	  described	   that	  depending	  on	  whether	  a	  
yeast	   homologue	   exists	   or	   not	   there	   are	   two	   approaches	   that	   can	   be	  
followed	   for	   modeling	   human	   disease	   in	   yeast.	   If	   there	   is	   a	   yeast	  
homologue,	   the	   gene	   can	   be	   disrupted	   or	   overexpressed	   to	   determine	  
the	   loss	   or	   gain	   of	   function	   phenotypes,	   respectively.	   In	   the	   case	   that	  
there	   is	   not	   a	   yeast	   homologue	   the	   human	   gene	   can	   be	   expressed	   in	  
yeast	   and	   any	   relevant	   phenotype	   that	   results	   from	   this	   expression	   can	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be	   analyzed.	   Thus	   conditions	   from	   cancer	   to	   neurodegenerative	   and	  
prion	  diseases,	  as	  well	  as	  biological	  processes	  such	  as	  cell	  death	  and	  DNA	  
repair	   are	   currently	   studied	   in	   yeast	   cells	   and	   then	   scaled	   up	   in	   more	  
complex	  animals.	  Furthermore,	   screening	   libraries	  of	  yeast	  varieties	  and	  
mutants	   is	   widely	   used	   to	   find	   potential	   gene	   targets	   for	   drug	  
development.	  
Strikingly	  according	  to	  McGary	  K.	  L.	  et	  al	  work	   [8],	   that	  describes	  a	  new	  
system	   biology	   approach	   for	   identifying	   model	   organisms	   for	   human	  
diseases,	   yeast	   could	   also	   be	   a	   powerful	   model	   organism	   for	   studying	  
angiogenesis,	  although	  they	  don’t	  have	  blood	  vessels.	  
Throughout	  this	  dissertation	  we	  report	  the	  use	  of	  the	  yeast	  assay	  system	  
to	   further	  understand	   two	   types	  of	   stress	   response.	   The	   first,	   regarding	  
how	   arsenic	   stress	   induces	   a	   global	   metabolic	   reprogramming	   of	   the	  
cellular	   iron	   homeostasis	   both	   in	   S.	   cerevisiae	   and	   mammals	   and	   the	  
second	   concerning	   the	   mechanisms	   that	   regulate	   human	   Heat	   Shock	  
Factor	   1,	   a	   stress-­‐activated	   transcription	   factor,	   via	   post-­‐translational	  
modifications.	   Given	   the	   tools	   available	   in	   S.	   cerevisiae,	   this	   is	   an	   ideal	  
system	  to	  begin	  to	  decipher	  these	  biological	  phenomena.	  
	  
The	  Response	  to	  Stress	  	  
All	   living	  organisms	  are	  subject	  to	  changes	   in	  the	  environment,	  to	  which	  
they	  must	   adapt	   in	   order	   to	   survive.	   Yeast	   cell	   homeostasis	   is	   achieved	  
through	   the	   activation	   of	   several	   transcription	   factors,	   each	   one	   acting	  
singly	   or	   in	   combination	   to	   perform	   specific	   functions.	   In	   the	   yeast	   S.	  
cerevisiae,	  cell	  stress	  response	  is	  determined	  by	  the	  action	  of	  three	  major	  
	  14	  
types	   of	   activators,	   the	   partially	   redundant	   zinc-­‐finger	   transcription	  
factors	   Msn2	   and	   Msn4,	   the	   Heat	   Shock	   Factor	   (HSF),	   and	   the	   basic-­‐
leucine	  zipper	  (b-­‐Zip)	  transcription	  factors	  Yap	  family	  (Yeast-­‐specific	  AP-­‐1	  
like	  factors)	  [9].	  	  
The	   response	   mediated	   by	   the	   transcription	   factors	   Msn2	   and	   Msn4	  
happens	  via	  stress	  response	  element	  (STREs)	  present	  on	  the	  target	  gene	  
promoters.	  The	  STRE	  was	  the	  first	  common	  cis-­‐element	  identified	  in	  a	  set	  
of	   genes	   that	   sense	   a	   broad	   array	   of	   stress	   conditions	   determined	   by	  
general	   stress	   response.	   It	   is	   estimated	   that	   over	   186	   genes	  
(approximately	  3%	  of	  the	  yeast	  genome)	  are	  potentially	  subject	  to	  STRE-­‐
mediated	   regulation	   [10].	  Msn2/4	   are	   controlled	   by	   high	   osmolarity	   via	  
the	  HOG	  signal	  pathway,	  which	  comprises	  a	  MAP	  kinase	  module.	  Some	  of	  
the	   important	   aspects	   of	   Msn2/Msn4	   regulation	   include	   nuclear-­‐
cytoplasmic	   shuttling	  and	   targeted	  degradation	  of	   these	   factors	  at	  gene	  
promoters	   during	   transcriptional	   activation	   [11].	   The	   intracellular	  
distribution	   of	   Msn2/4	   is	   highly	   correlated	   with	   their	   phosphorylation	  
state.	   It	   has	   been	   suggested	   that	   cAMP-­‐dependent	   PKA	   inhibits	   nuclear	  
import	   of	   Msn2/4,	   through	   direct	   phosphorylation	   of	   their	   nuclear	  
localization	   signal	   (NLS).	   A	   second	   mechanism	   for	   PKA-­‐mediated	  
regulation	   of	   STRE-­‐controlled	   gene	   expression	   involves	   the	   Ccr4-­‐Not	  
complex,	   a	   global	   transcriptional	   regulator	   that	   affects	   genes	   positively	  
and	  negatively	  [12].	  	  
HSF	   mediates	   the	   transcriptional	   response	   to	   heat,	   infection	   and	  
inflammation,	   pharmacological	   agents,	   and	  other	   stresses	   by	   binding	   to	  
the	  heat	  shock	  elements	  (HSEs),	  5’-­‐nGAAn-­‐3’,	  present	  in	  its	  target	  genes,	  
mainly	   heat	   shock	   proteins	   (Hsps)	   and	   activating	   their	   transcription,	  
thereby	   playing	   a	   central	   role	   in	   the	   cellular	   homeostatic	   control	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mechanisms	   [13].	   HSF	   and	   HSEs	   are	   among	   the	   most	   highly	   conserved	  
transcriptional	   regulatory	   elements	   in	   nature.	   Indeed,	   previous	   studies	  
have	   demonstrated	   that	   both	   mammalian	   HSF1	   and	   HSF2	   expressed	  
together	   can	   rescue	   the	   viability	   defect	   of	   S.	   cerevisiae	   cells	   lacking	  
endogenous	   yeast	   HSF	   [14].	   HSF	   is	   essential	   for	   cell	   viability	   in	   S.	  
cerevisiae,	  oogenesis	  and	  early	  development	  in	  Drosophila	  melanogaster,	  
extended	   life	   span	   in	   Caenorhabditis	   elegans,	   and	   extraembryonic	  
development	  and	  stress	  resistance	  in	  mammals.	  	  
In	   yeast	   Hsf1	   is	   constitutively	   bound	   as	   a	   trimer	   to	   high	   affinity	   HSEs	  
present	   on	   several	   promoters	   leading	   to	   a	  moderate	   expression	   of	   the	  
heat	  shock	  genes.	  Upon	  stress	  the	  occupancy	  of	  specific	  HSEs	  in	  the	  yeast	  
HSP82	  promoter	  increases,	  suggesting	  that	  some	  yeast	  HSEs	  are	  inducibly	  
bound,	   as	   observed	   in	   higher	   eukaryotes	   [15].	   Moreover,	   the	  
identification	   of	   genome-­‐wide	   Saccharomyces	   cerevisiae	  HSF	   targets	   by	  
chromatin	  immunoprecipitation,	  combined	  with	  DNA	  microarray	  analysis,	  
demonstrated	   global	   heat-­‐stimulated	   binding	   of	   HSF	   to	   many	   target	  
genes	   [16].	   Furthermore,	   similar	   to	   mammalian	   HSF1,	   yeast	   HSF	   is	  
activated	  by	  multiple	  stresses,	  including	  heat	  shock,	  oxidative	  stress,	  and	  
glucose	  starvation	  [17].	  	  
Recent	   studies	  have	  also	  provided	  novel	   insights	   into	   the	   role	  of	  HSF	   in	  
growth,	   development,	   disease,	   and	   aging	   and	   in	   the	   complex	  metabolic	  
reprogramming	  that	  occurs	  in	  all	  cells	  in	  response	  to	  stress	  [18].	  	  
The	   Yap	   family	   has	   a	   total	   of	   eight	   members	   and	   belongs	   to	   the	   bZIP	  
family	   of	   transcription	   factors	   that	   is	   widely	   conserved	   from	   yeast	   to	  
human	  [19].	  Functionally,	  the	  Yap	  family	  is	  involved	  in	  a	  variety	  of	  stress-­‐
related	  programs,	   including	  the	  response	  to	  DNA	  damage	  and	  oxidative,	  
osmotic,	  and	  toxic	  metal	  stresses.	  For	  instance	  Yap1	  plays	  the	  major	  role	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in	   oxidative	   stress,	   Yap2	   in	   cadmium	   stress,	   Yap4	   and	   Yap6	   in	   osmotic	  
stress,	   and	  Yap8	   in	   arsenic	   stress	  nevertheless	   there	   is	   also	   evidence	  of	  
cross-­‐talk	  between	  the	  Yap	  members.	  For	  example,	  the	  yap1yap2	  double	  
mutant	   is	   more	   sensitive	   to	   oxidative	   stress	   than	   either	   single	   mutant	  
alone,	  as	   is	  the	  yap1yap8	  double	  mutant	  to	  arsenic	  stress	  [9].	  Moreover	  
at	   least	   four	   Yap	   proteins	   (Yap1,	   Yap2,	   Yap4	   and	   Yap5)	   bind	   most	  
efficiently	   to	   the	   Yap	   Responsive	   Element	   (YRE)	   TTAC/GTAA.	   Both	   Yap1	  
and	   Yap8	   bind	   to	   the	   sequence	   GATTTAATAATCA,	   in	   which	   the	   bases	  
flanking	   the	   core	   sequence	   (underlined)	   are	   essential	   for	   Yap8	  
recognition	   [20].	   So	   far,	   only	   the	   corresponding	   binding	   site	   for	   Yap3,	  
Yap6	  and	  Yap7	  has	  not	  been	  characterized	  yet.	  	  
The	   three	   types	  of	   stress	  control	   seem	  to	  have	  overlapping,	  but	  distinct	  
functions.	   Some	   stress	   proteins	   encoded	   by	   HSE-­‐regulated	   genes	   are	  
necessary	   for	  growth	  of	  yeast	  under	  moderate	  stress,	  products	  of	  STRE-­‐
activated	  genes	  appear	   to	  be	   important	   for	   survival	  under	   severe	   stress	  
and	  YRE-­‐controlled	  genes	  may	  mainly	  function	  during	  oxidative	  stress	  and	  
in	  the	  response	  to	  toxic	  conditions,	  such	  as	  caused	  by	  heavy	  metal	  ions.	  	  
While	  our	  understanding	  of	  these	  processes	  in	  higher	  eukaryotes	  remains	  
incomplete,	   earlier	   studies	   have	   suggested	   that	   many	   of	   these	  
phenomena	  may	  be	  conserved	  in	  yeast.	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Chapter	  1	  
Introduction	  
Dealing	  with	  Arsenic	  
ARSENIC	  
Arsenic,	  a	  metalloid,	  has	  a	  long	  history	  of	  use	  in	  human	  civilization.	  The	  use	  
of	   arsenical	   therapeutics	   dates	   back	   to	   the	   times	   of	   ancient	   Rome,	   when	  
Galen	   and	   Hippocrates	   used	   them	   to	   treat	   ulcers.	   Arsenic	   trioxide	   is	   now	  
used	   as	   a	   cancer	   chemotherapeutic	   against	   hematopoietic	   tumors.	   Acute	  
arsenic	   poisoning	   is	   less	   common	   but	   it	   has	   been	   documented	   after	  
attempted	  suicides	  or	  murders.	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The	  presence	  of	  nonessential	  metals	  like	  arsenic	  (As)	  in	  the	  environment	  
is	  prevalent.	  Since	  these	  metals	  are	  highly	  toxic,	  they	  pose	  a	  considerable	  
threat	  to	  nature	  and	  to	  human	  health.	  The	  main	  routes	  of	  poisoning	  are	  
through	   occupational	   exposure	   or	   through	   ingestion	   of	   contaminated	  
food	   and	   water.	   The	   contamination	   of	   drinking	   water	   by	   arsenic	   is	   a	  
major	  health	  concern	  because	  of	  the	  large	  number	  of	  contaminated	  sites	  
and	   people	   at	   risk	   of	   exposure.	   These	  metals	   are	   implicated	   in	   a	   broad	  
spectrum	  of	  degenerative	  conditions	   in	  humans,	   including	  neurotoxicity,	  
nephrotoxicity,	   genotoxicity	   and	   carcinogenesis.	   Chronic	   As	   exposure	  
induces	   cardiovascular	   diseases,	   neurological	   disorders	   and	   liver	   injury,	  
and	  is	  associated	  with	  cancers	  of	  the	  skin,	  bladder,	  liver	  and	  lung	  [1].	  The	  
mechanism	  of	  As	  toxicity	  is	  not	  fully	  understood	  at	  the	  molecular	  level.	  In	  
general,	   it	   may	   act	   by	   targeting	   signaling	   or	   regulatory	   proteins	   that	  
control	  cell	  proliferation,	  differentiation	  and	  cell	  cycle	  regulation.	  Due	  to	  
its	  complex	  chemistry	  and	  ability	  to	  form	  many	  different	  compounds	  As	  is	  
an	   intricate	  element	   to	  understand.	  Arsenic	   is	  most	   commonly	   found	   in	  
two	   oxidation	   states,	   AsIII	   and	   AsV.	   The	   most	   common	   inorganic	   AsIII	  
compounds	   found	   are	   arsenic	   trioxide,	   sodium	   arsenite,	   and	   arsenic	  
trichloride.	  AsV	  compounds	  such	  as	  arsenic	  pentoxide,	  arsenic	  acid,	  and	  
arsenates	   are	   also	   quite	   common.	   Arsenic	   is	   methylated	   by	  
microorganisms,	   but	   inorganic	  AsIII	   and	  AsV	   compounds	   are	   considered	  
the	  most	   toxic	   [2].	   A	   common	   property	   of	   As	   is	   its	   high	   reactivity	   with	  
sulphydryl	   groups.	  Hence,	   it	   can	  bind	   to	  and	  affect	   the	  activity	  of	  many	  
proteins.	  AsIII	  can	  inhibit	  more	  than	  200	  enzymes,	  in	  events	  such	  as	  DNA	  
repair,	  methylation	  of	  DNA,	  and	  increase	  radical	  formation	  and	  activation	  
of	   the	   protooncogene	   c-­‐myc	   [3,	   4].	   In	   addition,	   this	   metal	   is	   known	   to	  
generate	   oxidative	   stress	   in	   cells	   and	   its	   toxicity	   has	   partly	   been	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attributed	  to	  its	  capability	  to	  induce	  formation	  of	  reactive	  oxygen	  species	  
(ROS).	  The	  damage	  caused	  by	  ROS	  to	  lipids,	  proteins	  and	  DNA	  are	  likely	  to	  
contribute	   to	   As	   toxicity	   [3].	   	   Nevertheless,	   neither	   the	   exact	   details	   of	  
metal-­‐induced	  ROS	  generation	  nor	  the	  full	  set	  of	  toxicity	  targets	  is	  known.	  	  
Drugs	  containing	  arsenicals	  such	  as	  arsenic	  trioxide	  (Trisenox®)	  have	  been	  
used	   to	   treat	   acute	   promyelocytic	   leukaemia	   (APL)	   and	   other	  
haematological	   and	   solid	   cancers	   [5].	   However,	   the	   development	   of	  
resistance	  threatens	  the	  efficacy	  of	  medical	  treatment	  and	  hence,	  there	  is	  
an	   increasing	   demand	   to	   identify	   tolerance	  mechanisms.	   Tolerance	   and	  
detoxification	  mechanisms	  often	  involve	  extrusion	  of	  the	  toxic	  ions	  from	  
the	   cell,	   sequestration	   within	   internal	   organelles,	   chelation	   by	   metal-­‐
binding	   proteins,	   and	   reduction	   of	   uptake.	   As	   shown	   in	   Figure	   1,	  
organisms	   take	   up	   AsV	   via	   phosphate	   transporters	   (Pho84	   and	   Pho87)	  
and	  AsIII	  by	  aquaglyceroporins	  (GlpF	  in	  E.	  coli,	  Fps1	  in	  yeast,	  and	  AQP7/9	  
in	  mammals)	  and	  hexose	  permeases	  (HXT	  family	  in	  yeast,	  and	  GLUT1/4	  in	  
mammals).	   Once	   inside	   the	   cell	   AsV	   is	   reduced	   to	   AsIII	   by	   the	   Acr2	  
(arsenate-­‐reductase)	   enzyme,	  with	   glutathione	   and	   glutaredoxin	   serving	  
as	  a	  source	  of	  reducing	  potential	  [7].	  	  
In	   vertebrates,	   five	   sodium/phosphate	   transporters	   NaPiIIa,	   NaPiIIb,	  
NaPiIIc,	   Pit-­‐1	   and	   Pit-­‐2,	   which	   constitute	   the	   mammalian	   phosphate	  
uptake	   system,	  were	   recently	   identified	  as	  arsenic	   transporters.	  NaPiIIa,	  
NaPiIIc,	   Pit-­‐1	   and	   Pit-­‐2	   correspond	   to	   the	   low-­‐affinity	   and	   NaPiIIb	  
represent	  the	  high-­‐affinity	  AsV	  transport.	  Next,	  AsV	  is	  reduced	  to	  AsIII	  by	  
CDC25	  phosphatases/arsenate	  reductases	  [8].	  	  
AsIII	   is	   then	   extruded	   from	   S.	   cerevisiae	   cells	   by	   the	   Acr3	   (plasma	  
membrane	   arsenite-­‐efflux	   protein),	   and	   compartmentalized	   into	   the	  
vacuole	  by	  Ycf1,	  a	  member	  of	  the	  MRP	  family	  of	  the	  ABC	  superfamily	  of	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drug-­‐resistance	   pumps.	   In	   mammals,	   Mrp	   isoforms,	   such	   as	   Mrp1	   and	  
Mrp2,	  pump	  AsIII	  out	  of	  cells	  [7,	  9].	  	  
Studies	  with	   the	   budding	   yeast	   S.	   cerevisiae	   have	   demonstrated	   that	   in	  
response	   to	   arsenic	   stress	   cells	   utilize	   two	   b-­‐Zip	   transcription	   factors,	  
Yap1	  and	  Yap8,	  members	  of	  the	  Yap	  (Yeast	  AP-­‐1	  like)	  family.	  Yap8	  is	  the	  
master	   regulator	   of	   this	   response,	   mediating	   the	   transcriptional	  
activation	  of	  ACR2	  and	  ACR3	  [10,	  11]	  and	  Yap1	  regulates	  YCF1	  expression	  
and	   helps	   to	  maintain	   the	   cellular	   redox	   homeostasis	   [12].	   In	   addition,	  
arsenic	   can	   be	   methylated	   [13],	   although	   this	   process	   may	   increase	  
arsenic	   toxicity	   rather	   than	   contributing	   toward	   detoxification	   [7].	  
Moreover,	   AsIII,	   the	   most	   toxic	   form	   of	   As,	   triggers	   increased	   ROS	  
production	   in	   mammals	   [14],	   but	   not	   to	   any	   large	   extent	   in	   wild-­‐type	  
yeast	  [12].	  	  
Nevertheless,	   AsIII-­‐induced	   oxidative	   stress	   and	   lipid	   peroxidation	   are	  
detected	  in	  mutants	  with	  impaired	  AsIII	  detoxification	  (yap8	  mutant	  cells)	  
or	   oxidative	   stress	   defense	   (yap1	   mutant	   cells)	   systems,	   indicating	   that	  
AsIII	  enhances	  ROS	  levels	  also	  in	  yeast	  [12],	  
Arsenic	   toxicity	  has	   therefore	  been	  suggested	   to	  be	  caused	  by	  oxidative	  
stress,	   impaired	   DNA	   repair,	   inhibition	   of	   enzyme	   function	   and	   by	  
disturbing	   the	   function	  of	   proteins	   that	   regulate	   proliferation,	   cell	   cycle	  
progression,	  apoptosis	  or	  differentiation	  [15-­‐19]	  (Figure	  2).	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Figure	  1:	  Arsenic	  detoxification	  in	  prokaryotes	  (E.coli)	  and	  eukaryotes	  (S.	  
cerevisiae	   and	   mammals).	   AsV	   is	   taken	   up	   by	   phosphate	   and	  
sodium/phosphate	   transporters,	   and	   AsIII	   is	   taken	   up	   by	  
aquaglyceroporins	   (GlpF	   in	  E.	  coli,	  Fps1p	   in	  yeast	  and	  Aqp7	  and	  Aqp9	   in	  
mammals).	  AsV	  is	  reduced	  to	  AsIII	  by	  the	  bacterial	  ArsC,	  the	  yeast	  Acr2p	  
or	   the	  mammal	   CDC25	  enzymes.	  Glutathione	   and	   glutaredoxin	   serve	   as	  
the	  source	  of	  reducing	  potential.	  In	  E.	  coli,	  AsIII	  is	  extruded	  from	  the	  cells	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by	  ArsB	  alone	  or	  by	   the	  ArsAB	  ATPase	  and	   in	  yeast	  by	  Acr3,	   the	  plasma	  
membrane	  AsIII	  efflux	  protein,	  and	  Ycf1,	  a	  member	  of	  the	  MRP	  family	  of	  
the	   ABC	   superfamily	   of	   drug-­‐resistance	   pumps	   that	   transports	   As(GS)3	  
into	   the	   vacuole.	   In	  mammals	  Mrp	   isoforms	   pump	   As(GS)3	   out	   of	   cells.	  
Adapted	  form	  [6]	  and	  [7].	  
	  
	  
	  
	  
Figure	   2:	   Arsenic	   response	   and	   toxicity	   mechanisms.	   Arsenic	   triggers	  
oxidative	   stress	   in	   cells,	   interferes	   with	   protein	   function	   and	   activity	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and/or	   impair	   DNA	   repair	   mechanisms	   either	   directly	   or	   indirectly.	   In	  
response	   to	   As	   exposure,	   cells	   arrest	   cell	   cycle	   progression,	   alter	   gene	  
expression	  and	  metabolism,	  and	  adjust	  transport	  processes	  to	  safeguard	  
cellular	  and	  genetic	  integrity.	  Adapted	  from	  [20].	  
	  
	  
Since	  in	  mammals	  the	  proteins	  responsible	  for	  As	  reduction	  have	  not	  yet	  
been	  identified,	  it	  is	  likely	  that	  additional	  pathways	  contribute	  to	  the	  full	  
As	   tolerance	   in	   cells.	   Our	   work	   shows	   for	   the	   first	   time	   that	   arsenic	  
disrupts	  the	  cellular	  iron	  (Fe)	  homeostasis.	  	  
Many	   of	   the	   genes	   and	   biological	   systems	   that	   function	   in	   yeast	   Fe	  
homeostasis	   are	   conserved	   throughout	   eukaryotes	   to	   humans	   [21].	   S.	  
cerevisiae	   expresses	   three	   genetically	   distinct	   transport	   systems	   for	   Fe,	  
two	   reductive	   systems	   and	   one	   non-­‐reductive	   system	   (Figure	   3).	   The	  
reductive	  Fe	  uptake	  system	  consists	  in	  a	  low-­‐affinity	  pathway	  defined	  by	  
Fet4,	  that	  can	  also	  transport	  other	  metals	  and	  in	  a	  high-­‐affinity	  pathway	  
that	   is	   mediated	   by	   a	   protein	   complex	   composed	   of	   a	   multicopper	  
ferroxidase	  Fet3,	  the	  mammalian	  Ceruloplasmine	  (Cp)	  homologue,	  and	  a	  
permease	  Ftr1.	  The	  Fet3-­‐Ftr1	  complex	   is	   specific	   for	  Fe	  and	   is	   regulated	  
both	   transcriptionally	   and	   post-­‐transcriptionally	   by	   this	   metal	   [22-­‐24].	  
The	  non-­‐reductive	  Fe	  uptake	  system	  is	  mediated	  by	  the	  ARN	  family	  (Arn1-­‐
4)	   of	   membrane	   permeases	   that	   transport	   siderophore-­‐Fe3+	   complexes	  
[22-­‐24].	  Additionally	  Harris	  et	  al,	  [25]	  showed	  for	  the	  first	  time	  that	  Fet3,	  
can	   functionally	   replace	   Cp	   in	   restoring	   Fe	   homeostasis.	  Moreover	   cells	  
are	  able	  to	  spare	  Fe	  through	  the	  regulation	  of	  Tis11	  homologues,	  Cth1/2-­‐
mediated	  degradation	  of	  mRNAs	  coding	  for	  Fe-­‐binding	  proteins,	  thereby	  
facilitating	   the	   utilization	   of	   limited	   cellular	   Fe	   levels	   [26,	   27].	   Since	   S.	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cerevisiae,	  lacks	  the	  Fe	  storage	  protein,	  ferritin,	  during	  Fe	  overload	  this	  is	  
sequestered	  into	  the	  vacuole	  by	  the	  Ccc1	  transporter,	  which	  is	  under	  the	  
control	   of	   the	   Yap5	   transcription	   factor	   [28].	   On	   the	   other	   hand,	  
Fet5/Fth1	   complex	   mobilizes	   Fe	   out	   of	   the	   vacuole	   for	   use	   during	   Fe	  
limitation	  [29].	  	  	  
Given	   the	   similarities	   between	   yeast	   and	   mammals	   unveiling	   metal	  
toxicity	   and	   tolerance	   mechanisms	   in	   yeast	   may	   prove	   of	   value	   for	  
identifying	  similar	  mechanisms	  in	  higher	  eukaryotes.	  	  
	  
	  
	  
Figure	  3:	  Yeast	  Iron	  Uptake	  Systems.	  Yeast	  has	  distinct	  transport	  systems	  
for	   Fe,	   the	   reductive	   systems	   and	   the	   non-­‐reductive	   system.	   The	  
reductive	   iron	   uptake	   pathway	   consists	   in	   a	   low-­‐affinity	   system	  defined	  
by	  Fet4	  and	  in	  a	  high-­‐affinity	  system	  mediated	  by	  Fet3	  and	  Ftr1.	  The	  non-­‐
reductive	  iron	  uptake	  is	  mediated	  by	  the	  ARN	  family	  (Arn1-­‐4)	  membrane	  
permeases	  that	  transport	  siderophore-­‐ferric	  iron	  complexes.	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Abstract	  
	  
Arsenic	   is	   a	   double-­‐edge	   sword.	   On	   the	   one	   hand	   it	   is	   powerful	  
carcinogen	   and	   on	   the	   other	   it	   has	   been	   used	   therapeutically	   in	   the	  
treatment	  of	   acute	  promyelocytic	   leukemia.	   In	   this	   study	  we	   report	   the	  
genome-­‐wide	  response	  of	  Saccharomyces	  cerevisiae	  to	  arsenic.	  Our	  data	  
suggest	   that	   this	   metalloid	   interferes	   with	   the	   expression	   of	   genes	  
involved	   in	   iron	   homeostasis	   including	   those	   encoding	   proteins	   that	  
function	   in	   iron	   uptake,	   trafficking	   and	   utilization.	   Interestingly	   arsenic	  
activates	   the	   iron	   responsive	   transcription	   factor,	   Aft1,	   but	   the	   mRNA	  
levels	   encoding	   Fet3	   and	   Ftr1,	   a	   complex	   required	   for	   high-­‐affinity	   iron	  
uptake,	  are	  drastically	  decreased	  upon	  arsenic	  exposure.	  Moreover	  FET3	  
mRNA	  decay	  is	  mediated	  by	  the	  5’-­‐3’	  exonuclease	  Xrn1	  and	  independent	  
of	   the	   formation	   of	   ROS.	   Strikingly,	   upon	   addition	   of	   arsenic	   Fet3	   does	  
not	   localize	   in	   the	   plasma	   membrane	   but	   rather	   in	   the	   endoplasmic	  
reticulum.	   Also	   the	   fet3ftr1	   mutant	   shows	   arsenic	   resistance	   over	   the	  
wild-­‐type	   suggesting	   that	   Fet3	   plays	   a	   role	   in	   arsenic	   toxicity.	  
Unexpectedly,	   arsenic	   treatment	   seems	   to	   activate	   the	   non-­‐reductive	  
iron	   uptake	   system.	   Finally	   we	   provide	   data	   suggesting	   that	   arsenic	  
disruption	   of	   iron	   homeostasis	   also	   occurs	   in	   mammalian	   cells,	   an	  
observation	  that	  can	  be	  relevant	  to	  clinical	  applications.	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Introduction	  
	  
Arsenic	  (As),	  the	  20th	  most	  abundant	  element	  in	  the	  earth’s	  crust	  [1]	  is	  a	  
highly	   toxic	  metalloid	  with	   respect	   to	  human	  health.	  Arsenic	  can	   induce	  
skin	   lesions,	  hemorrhagic	  gastroenteritis,	   cardiac	  arrhythmia,	  psychiatric	  
disease,	   and	   cancer.	   Its	   toxicity	   and	   carcinogenicity	   are	   suggested	   to	  be	  
linked	  to	  oxidative	  stress.	  Although	  often	  synonymous	  of	  poison,	  it	  is	  one	  
of	   the	   oldest	   drugs	   in	   history	   of	  mankind,	   first	   used	   to	   treat	   cutaneous	  
ulcers,	  later	  periodic	  fever	  and	  malaria	  [2],	  and	  currently	  used	  as	  a	  potent	  
agent	   against	   acute	   promyelocytic	   leukemia	   [3].	   Due	   to	   its	   paradoxical	  
biological	  effects,	  cellular	  As	  metabolism	  has	  been	  studied	  to	  understand	  
its	  mechanisms	  of	  action.	  	  To	  date,	  it	  has	  never	  been	  shown	  a	  correlation	  
between	  As	  effects	  and	  iron	  (Fe)	  homeostasis.	  	  
Cells	   require	   Fe	   for	   a	   wide	   array	   of	  metabolic	   functions,	   which	   include	  
oxygen	   transport,	   cellular	   respiration,	   the	   tricarboxylic	   (TCA)	   cycle,	   lipid	  
metabolism,	  gene	  regulation,	  and	  DNA	  replication	  and	  repair	  [4],	  yet	  Fe	  is	  
toxic	   when	   present	   in	   excess.	   The	   yeast	   S.	   cerevisiae	   expresses	   three	  
distinct	   transport	   pathways	   for	   Fe,	   two	   reductive	   systems	   and	   a	   non-­‐
reductive	   one.	   The	   reductive	   pathways	   consists	   of	   a	   low-­‐affinity	   uptake	  
system	  operated	  by	   Fet4	   that	   can	  also	   transport	  other	  metals,	   and	  of	   a	  
high-­‐affinity	   Fe	   uptake	   system	   that	   is	   mediated	   by	   a	   protein	   complex	  
composed	   of	   the	  multicopper	   ferroxidase	   Fet3	   and	   the	   permease	   Ftr1.	  
The	   Fet3-­‐Ftr1	   complex	   is	   specific	   for	   Fe	   and	   is	   regulated	   both	  
transcriptionally	  and	  post-­‐transcriptionally	  by	  Fe	  [5-­‐7].	  The	  non-­‐reductive	  
Fe	  uptake	  pathway	  is	  mediated	  by	  the	  ARN	  family	  (Arn1-­‐4)	  of	  membrane	  
permeases	   that	   transport	   siderophore-­‐ferric	   iron	   complexes	   [8,	   9].	   In	  S.	  
cerevisiae,	  these	  Fe	  uptake	  systems	  are	  largely	  induced	  under	  iron	  scarce	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conditions	   by	   the	   Aft1	   transcription	   factor	   and	   its	   homologue	   Aft2,	   as	  
part	  of	  the	  iron	  regulon	  [10].	  
We	   have	   here	   conducted	   a	   genome-­‐wide	   mRNA	   profiling	   of	   the	   S.	  
cerevisiae	   response	   to	   As,	   which	   revealed	   a	   potent	   induction	   of	   the	   Fe	  
gene	  regulon.	  However,	  neither	  FET3	  nor	  FTR1	  appeared	  induced	  by	  this	  
treatment.	  We	   show	   that	   lack	  of	   the	   induction	  of	   these	   two	  genes	   is	   in	  
fact	  the	  consequence	  of	  a	  degradation	  of	  their	  respective	  mRNAs	  by	  the	  
major	  pathway	  for	  mRNA	  decay	  mediated	  by	  the	  5’-­‐3’	  exonuclease	  Xrn1.	  
Moreover	  our	  data	  suggest	  a	  role	  of	  Fet3	   in	  mediating	  As	  toxicity	  based	  
on	   the	   improved	   As	   tolerance	   of	   the	   corresponding	   null	  mutant.	   Taken	  
together	   this	  work	  provides	  a	  molecular	  connection	  between	  As	   toxicity	  
and	  Fe	  homeostasis,	  which	   could	  be	   relevant	   to	   further	  understand	   the	  
toxic	  and	  therapeutic	  effects	  of	  As	  at	  molecular	  level.	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Material	  and	  Methods	  
	  
Yeast	  Strains	  and	  Growth	  conditions	  	  
The	  plasmids	  and	  yeast	  strains	  used	   in	  this	  study	  are	   listed	   in	  Table	  1	   in	  
supplemental	  material.	  To	  produce	  the	  aft1	  or	  aft2	  mutants	  the	  complete	  
coding	  region	  of	  the	  AFT1	  and	  AFT2	  genes	  were	  deleted	  by	  homologous	  
recombination	  with	  HIS	  and	  KanMX	  cassettes,	  respectively.	  	  Deletion	  was	  
confirmed	   by	   PCR	   analysis	   of	   genomic	   DNA	   using	   upstream	   and	  
downstream	   AFT1	   and	   AFT2	   specific	   primers.	   Spot	   assays	   were	   carried	  
out	   by	   spotting	   5μl	   of	   early	   exponential	   phase	   cultures	   (A600=0.4)	  
sequentially	   diluted	   (approximately	   5×103	   to	   10	   cells)	   in	   medium	  
containing	   2mM	   Na2HAsO4	   (AsV),	   400uM	   H2O2,	   100uM	   Fe2SO4	   or	   10-­‐
100uM	  BPS.	  Growth	  was	  recorded	  after	  incubation	  for	  2	  days	  at	  30°C.	  
	  
Table	  1:	  Strains	  used	  in	  this	  study.	  
Strain	   Genotype	   Source	  
BY4742	   MATα	  his3Δ	  1	  leu2Δ	  0	  lys2Δ	  0	  ura3Δ	  0	   Euroscarf	  
aft1	   MATα	  his3Δ	  1	  leu2Δ	  0	  lys2Δ	  0	  ura3Δ	  0	  AFT1::kanMX4	   This	  Study	  
aft2	   MATα	  his3Δ	  1	  leu2Δ	  0	  lys2Δ	  0	  ura3Δ	  0	  AFT2::kanMX4	   This	  Study	  
DEY1457	   MATα	  can1	  his3Δ	  1	  leu2Δ	  trp1Δ	  ura3Δ	  ade6Δ	   D.	  Kosman	  
fet3ftr1	   MATα	  can1	  his3Δ	  1	  leu2Δ	  trp1Δ	  ura3Δ	  ade6Δfet3::HIS3ftr1::TRP1	   D.	  Kosman	  
YPH499	  	  
MATa	  ura3-­‐52lys2-­‐801_amberade2-­‐101_ochretrp1-­‐Δ63his3-­‐
Δ200leu2-­‐Δ1	   C.C.	  Philpott	  
arn1-­‐arn4	   MATa	  lys2-­‐801_amberade2-­‐101_ochretrp1-­‐Δ63his3-­‐Δ200leu2-­‐Δ1	   C.C.	  Philpott	  
BY4741	   MATa	  his3Δ	  1	  leu2Δ	  0	  met15Δ	  0	  ura3Δ	  0	   D.J.	  Thiele	  
cth2	   MATa	  his3Δ	  1	  leu2Δ	  0	  met15Δ	  0	  ura3Δ	  0	  CTH2::KanMX4	   D.J.	  Thiele	  
xrn1	   MATa	  his3Δ	  1	  leu2Δ	  0	  met15Δ	  0	  ura3Δ	  0	  XRN1::KanMX4	   D.J.	  Thiele	  
ccr4	   MATa	  his3Δ	  1	  leu2Δ	  0	  met15Δ	  0	  ura3Δ	  0	  CCR4::KanMX4	   D.J	  .Thiele	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Cell	  Survival	  Curves	  
	  Logarithmic-­‐phase	  yeast	  cells	  were	  grown	  in	  rich	  medium	  and	  incubated	  
on	   YPD	   plates	   containing	   different	   concentrations	   of	   AsV	   at	   30°C	   for	   2	  
days	  to	  allow	  formation	  of	  colonies.	  Data	  are	  expressed	  as	  percentages	  of	  
colonies	  formed	  compared	  with	  control	  cultures	  not	  exposed	  to	  AsV.	  	  
	  
DNA	  Microarray	  Analysis	  	  
Wild-­‐type	  (WT)	  cells	  were	  grown	  in	  triplicate	  in	  media	  containing	  2mM	  of	  
AsV	   for	   1	   hour,	   and	   RNA	   was	   extracted,	   labeled,	   and	   hybridized	   to	  
Affymetrix	  Yeast	  Genome	  S98	  arrays.	  (For	  further	   information	  about	  cell	  
preparation,	   synthesis	   of	   labeled	  DNA,	   hybridization,	   scanning	   and	   data	  
acquisition,	   and	   quality	   control	   steps,	   visit	   the	   Duke	   Microarray	   Core	  
Facility	   at	   http://www.genome.duke.edu/cores/microarray/).	   All	   data	  
were	   analyzed	   by	   Dr.	   Jörg	   Becker	   from	   Instituto	   Gulbenkian	   de	   Ciência	  
(IGC)	  using	  both	  Partek®	  Genomics	  SuiteTM	  and	  dChip	  softwares.	  	  	  	  	  	  	  	  
	  
Accession	  Numbers	  	  
Microarray	  data	  have	  been	  deposit	  in	  the	  NCBI	  Gene	  Expression	  Omnibus	  
(http://www.ncbi.nlm.nih.gov/geo/)	   and	   are	   accessible	   through	   GEO	  
Series	  accession	  number	  GSE33427.	  
	  
RNA	  blot	  Analysis	  	  	  
Cells	   were	   grown	   overnight	   in	   YPD	  medium	   until	   saturation,	   diluted	   to	  
OD600nm	   of	   0.1	   and	   allowed	   to	   grow	   until	   early	   exponential	   phase	  
OD600nm	  of	  0.4	  -­‐	  0.5.	  Aliquots	  of	  these	  cells	  were	  left	  untreated	  or	  were	  
treated	   with	   either	   2mM	   of	   AsV,	   100uM	   of	   Fe2SO4,	   100uM	   of	   BPS	   or	  
400uM	  H2O2.	  Total	  yeast	  RNA	  was	  isolated	  by	  the	  hot	  phenol	  method	  [4].	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PCR-­‐amplified	   fragments	   were	   gel	   purified	   and	   radiolabeled	   with	   32P-­‐
dCTP	  to	  be	  used	  as	  probes.	  U3,	  a	  small	  nuclear	  RNA	  (SNR17A)	  was	  used	  as	  
loading	  control.	  
	  
Real-­‐Time	  PCR	  Analysis	  	  	  
RNA	   was	   extracted	   from	   early	   log-­‐phase	   cultures	   that	   were	   either	  
untreated	  or	  exposed	  during	  60	  min	  to	  2mM	  AsV.	  DNA	  was	  removed	  by	  
on-­‐column	  DNAse	  I	  digestion	  (RNase-­‐Free	  DNase	  Set;	  Qiagen).	  Total	  RNA	  
(1μg)	   was	   reverse	   transcribed	   with	   Transcriptor	   Reverse	   Transcriptase	  
(Roche	   Diagnostics).	   qPCR	   reactions	   were	   performed	   in	   the	   LightCycler	  
480	   Instrument	   (Roche),	   using	   LightCycler	   480	   Green	   I	   Master	   (Roche)	  
and	  the	  oligonucleotides	  are	   listed	   in	  Table	  S2.	  Relative	  standard	  curves	  
were	  constructed	  for	  each	  gene,	  using	  triplicate	  serial	  dilutions	  of	  cDNA.	  
The	   relative	   expression	   of	   the	   genes	   was	   calculated	   by	   the	   relative	  
quantification	   method	   with	   efficiency	   correction,	   using	   the	   LightCycler	  
480	   Software	   1.	   Actin	   (ACT1)	   was	   used	   as	   a	   reference	   gene.	   All	   assays	  
were	  made	  in	  triplicate.	  
	  
β-­‐Galactosidase	  assay	  	  
WT	   cells	   and	   the	   isogenic	   aft1	   mutant	   were	   transformed	   with	   a	   β-­‐
galactosidase	   reporter	   plasmid	   containing	   the	   promoter	   sequence	   of	  
CTH2	   previously	   described	   [11],	   pCM64-­‐CTH2-­‐FeRE-­‐CYC1-­‐LacZ.	   WT	   was	  
also	  co-­‐transformed	  with	  the	  plasmids	  pEG202LexA-­‐AFT1	  and	  pSH18-­‐34.	  
Cells	  were	  grown	  in	  selective	  media	  to	  early	  log	  phase	  in	  the	  presence	  of	  
2mM	   AsV,	   100uM	   Fe2SO4	   or	   100μM	   of	   BPS.	   β-­‐galactosidase	   was	  
measured	  in	  triplicate	  using	  a	  96	  well	  plate	  by	  following	  the	  degradation	  
of	  the	  colorimetric	  substrate	  ONPG	  (o-­‐nitrophenyl-­‐b-­‐D-­‐galactopyraniside)	  
at	  A420	  and	  normalized	  against	  total	  protein	  concentration.	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Measurement	  of	  Total	  Iron	  	  	  
Strains	  were	  grown	  in	  YPD	  media	  with	  1mM	  of	  AsV	  for	  4	  hours,	  collected	  
by	   centrifugation	   and	  washed	   twice	   in	   10mM	  EDTA	   and	   once	   in	  metal-­‐
free	   water.	   The	   total	   Fe	   was	   measured	   by	   inductively	   coupled	   plasma	  
(ICP)	   atomic	  emission	   spectroscopy	  at	  CQFB	   -­‐	  Centro	  de	  Química	  Fina	  e	  
Biotecnologia	  (Caparica,	  Portugal)	  on	  cells	  suspended	  in	  0.1N	  Nitric	  acid.	  
	  
Protein	  Analysis	  	  
Protein	  extracts	  were	  generated	   from	  cell	   cultures	  using	  cell	   lysis	  buffer	  
(50mM	  HEPES,	  pH	  7.5,	  1mM	  EDTA,	  100mM	  KCl,	  10%	  glycerol,	  0.1%	  NP40)	  
supplemented	   with	   protease	   inhibitors	   (Roche).	   Protein	   concentrations	  
were	   quantified	   using	   the	   Bradford	   assay	   and	   80-­‐100μg	   of	   protein	  was	  
resolved	   by	   SDS-­‐PAGE,	   transferred	   to	   a	   nitrocellulose	   membrane	   (GE	  
Healthcare),	   and	   immunoblotted	   with	   Anti-­‐HA	   and	   Anti-­‐cMyc	   (Roche)	  
Anti-­‐TAP-­‐tag	   (Life	   Technologies).	  Anti-­‐Pgk1	   (Life	   Technologies)	  was	  used	  
as	  loading	  control.	  
	  
Fluorescence	  Microscopy	  	  
Microscopy	   experiments	   were	   carried	   out	   on	   live	   cultures	   using	   LEICA	  
DMRA2	  Microscope	  coupled	  with	  a	  CoolSNAPTM	  HQ	  Photometrics	  camera	  
(Roper	   Scientific).	   The	  analysis	  of	   fluorescence	   intensity	  was	  done	  using	  
the	   MetaMorph	   software	   package	   (MDS	   Analytical	   Technologies).	  
Overnight	   liquid	   cultures	   expressing	   Aft1-­‐GFP	   or	   Fet3-­‐GFP	   were	   re-­‐
inoculated	  to	  an	  optical	  density	  A600=0.1	  in	  YPD	  medium	  containing	  1mM	  
of	  AsV,	  or	  100uM	  of	  BPS.	  Cells	  were	  incubated	  for	  5	  minutes	  at	  30°C	  with	  
1ug/mL	   4’6-­‐diamidino-­‐2-­‐phenylindole	   (DAPI)	   to	   stain	   yeast	   nuclei.	   After	  
washing	  with	  phosphate-­‐buffered	  saline	  (PBS)	  cells	  were	  resuspended	  in	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DABCO	   solution	   (75%	   (v/v)	   glycerol,	   0.25X	   PBS	   and	   200mM	  
diazabicycloctane,	  Sigma–Aldrich)	  and	  visualized.	  
	  
Cells	  and	  Media	  
Mouse	   embryonic	   fibroblasts	   (MEF)	   cells	   were	   maintained	   in	   DMEM	  
(Sigma-­‐Aldrich)	  with	  10%	  of	  fetal	  bovine	  serum.	  Cells	  were	  Fe	   loaded	  by	  
addition	  of	  FAC	  (100uM)	  and	  Fe	  depleted	  by	  addition	  of	  Desferroxamine	  
(DFX)	  (5uM)	  and	  treated	  with	  Arsenic	  Trioxide	  [12]	  (5uM)	  for	  24	  hours.	  To	  
extract	   protein,	   cells	   were	   solubilized	   in	   1.0%	   of	   Triton	   X-­‐100,	   150mM	  
NaCl,	   10mM	   EDTA,	   and	   10mM	   Tris	   (pH7.4)	   with	   a	   protease	   inhibitor	  
cocktail	   (Roche).	   Protein	   concentrations	   were	   quantified	   using	   the	  
Bradford	  assay,	  80-­‐100μg	  of	  protein	  was	  resolved	  by	  12%	  SDS-­‐PAGE	  and	  
transferred	  to	  a	  nitrocellulose	  membrane	  (GE	  Healthcare).	  Ferritin	   levels	  
were	   detected	   using	   Mouse	   Anti-­‐Ferritin	   (Abcam),	   Css1	   levels	   using	  
Rabbit	  Anti-­‐Css	  (Santa	  Cruz	  Biotechnology,	  Inc),	  Dmt1	  levels	  using	  Rabbit	  
Anti-­‐NRAMP22-­‐S	   (Alpha	   Diagnostic	   International),	   and	   Rat	   Anti-­‐Tubulin	  
(Novus	  Biologicals)	  was	  used	  as	  a	  loading	  control.	  
	  
Results	  
	  
The	   Saccharomyces	   cerevisiae	   Genome-­‐wide	   Response	   to	   Arsenic	  
Exposure	  	  	  
In	   S.	   cerevisiae,	   resistance	   to	   As	   involves	   Yap1	   and	   Yap8,	   two	   AP-­‐1	   like	  
transcription	  factors	  that	  regulate	  the	  expression	  genes	  involved	  in	  redox	  
homeostasis	  and	  As	  detoxification	  processes,	  respectively	  [13].	  However,	  
additional	   pathways	   should	   most	   likely	   contribute	   to	   cellular	   As	  
tolerance.	   To	   identify	   novel	   As	   tolerance	   pathways,	   we	   analyzed	   the	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genome-­‐wide	   mRNA	   profile	   of	   yeast	   cells	   exposed	   to	   As.	   Fig.	   1	  
summarizes	   the	   results	   of	   these	   experiments	   (see	   data	   deposit	   in	  
http://www.ncbi.nlm.nih.gov/geo/).	   In	   total,	   1608	   genes	   had	   their	  
expression	  significantly	  altered	  upon	  As	  exposure.	  Classification	  of	  these	  
genes	   by	   Gene	   Ontology	   showed	   that	   the	   functional	   categories	   most	  
affected	   were	   related	   to	   the	   response	   to	   stress,	   metals	   and	   oxidative	  
stress,	   cell	   cycle,	   mRNA	   processing,	   mitochondrial	   processes,	  
transcriptional	   and	   translational	   activity,	   transporter	   activity,	  
endoplasmic	  reticulum	  processes,	  protein	  folding,	  among	  others	  (Fig.1A).	  
Many	  of	  these	  genes	  have	  already	  been	  shown	  to	  respond	  to	  As	  [14,	  15],	  
however	  genes	  responsive	  to	  metals,	  such	  as,	  zinc,	   iron	   (Fe)	  and	  copper	  
(Fig.	  1B),	   are	  here	   shown	   for	   the	   first	   time	   to	  be	  affected	  by	  As.	  Within	  
the	   cellular	   Fe	   homeostasis	   category,	   82	   genes	   showed	   changes	   of	   at	  
least	   1.2-­‐fold	   in	   their	   expression	   levels	   in	   response	   to	  As	   stress	   (Fig.	   1C	  
and	  Table	  S3	  in	  supplemental	  material).	  Among	  these,	  many	  of	  the	  genes	  
of	  the	  Aft1/2	  regulon	  [16-­‐18]	  were	  present,	  such	  as	  CTH2,	  the	  ARN	  family	  
genes	   and	   FIT3	   that	   encode	   cell	   wall	   mannoproteins	   involved	   in	  
siderophore-­‐Fe	  uptake	  (Fig.	  1D	  and	  Table	  2).	  Surprisingly,	  despite	  a	  large	  
induction	  of	  the	  Aft1/2	  regulon,	  the	  mRNA	  levels	  encoding	  Fet3	  and	  Ftr1	  
appeared	   significantly	   decreased	  upon	  As	   exposure	   (Fig.	   1D)	   and	   (Table	  
S3	  in	  the	  supplemental	  material).	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Figure	  1:	  Genome-­‐wide	  response	  of	  S.	  cerevisiae	  upon	  arsenic	  exposure.	  
A.	   Representation	   of	   the	   results	   from	   triplicate	   Affymetrix	   DNA	  
microarray	   studies	   showing	   the	   Gene	   Ontology	   of	   the	   main	   categories	  
with	   at	   least	   15%	   of	   the	   mRNAs	   changed	   between	   WTAsV	   vs	   WT.	   B.	  
Representation	   of	   the	   percentage	   of	   metal	   related	   mRNAs	   changed	   in	  
response	  to	  arsenate	  treatment.	  C.	  Representation	  of	  the	  total	  number	  of	  
mRNAs	  corresponding	  to	  Fe-­‐dependent	  processes	  up-­‐	  or	  down-­‐regulated	  
in	  a	  wild-­‐type	  strain	  upon	  addition	  of	  arsenic.	  D.	  Microarray	  validation	  by	  
RT-­‐PCR	   of	   mRNAs	   representative	   of	   iron	   homeostasis.	   All	   assays	   were	  
made	  in	  triplicate.	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Table	  2:	  Iron	  transport	  systems	  genes	  whose	  mRNA	  levels	  were	  down-­‐	  
or	  up-­‐regulated	  in	  a	  WT	  upon	  As	  treatment.	  
Aft1	  targets	   	  	   	  	  
Iron	  Transport	  Systems	   	  
Reductive	  Pathway	   	  
GENE	   FUNCTION	   FOLD	  	  
FET3	  
Multicopper	  ferroxidase	  involved	  in	  high-­‐affinity	  Fe	  
uptake	   -­‐2.14	  
FTR1	  
High-­‐affinity	  Fe	  permease,	  forms	  a	  complex	  with	  
Fet3	   -­‐1.55	  
FET4	   Low-­‐affinity	  Fe	  transport	  protein	   -­‐2.94	  
	   	   	  
Non-­‐reductive	  Pathway	   	  
GENE	   FUNCTION	   FOLD	  	  
FIT3	   Cell	  wall	  mannoprotein	  -­‐	  siderophore-­‐iron	  uptake	   1.73	  
ARN1	  
Ferrirubin,	  ferrirhodin,	  and	  Fe-­‐siderophores	  
transporter	   2.17	  
ARN2	   Triacetylfusarinine	  C	  transporter	   2.07	  
ARN4	   Enterobactin	  transporter	   1.63	  
The	  average	  fold	  induction	  of	  triplicate	  samples	  is	  represented.	  	  
An	  increase	  of	  1.5-­‐fold	  and	  a	  p-­‐value	  <0.005	  were	  used.	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Aft1	  is	  activated	  by	  arsenic	  stress	  	  
Except	   for	  FET3	  and	  FTR1,	   the	  mRNA	  profiling	  analysis	   indicated	  that	  As	  
exposure	   mimics	   the	   genomic	   response	   to	   Fe	   deficiency	   (23-­‐25,49,50).	  
Yeast	   cells	   respond	   to	   Fe	   deprivation	   by	   the	   Aft1/2-­‐dependent	  
transcriptional	  activation	  of	  the	  Fe	  regulon	  that	  encode	  proteins	  involved	  
in	  Fe	  uptake,	  trafficking	  and	  utilization	  [19].	  Aft1	  is	  controlled	  at	  the	  level	  
of	   its	   nucleocytoplasmic	   distribution.	   To	   confirm	   that	   As	   can	   activate	  
Aft1/2,	  we	  monitored	  by	  fluorescence	  microscopy	  the	  cellular	  localization	  
of	  an	  Aft1-­‐GFP	   fusion	   in	   cells	  exposed	   to	  As	   (Fig.	  2A).	   Indeed	  As	   caused	  
the	   redistribution	   of	   Aft1	   from	   a	   diffuse	   fluorescence	   pattern	   to	   a	  
punctuated	  one	  corresponding	  to	  the	  nucleus,	  similarly	  to	  what	  was	  seen	  
in	   controlled	   cells	   treated	   with	   the	   iron	   chelator	   BPS.	   Subcellular	  
localization	  of	  a	  Myc-­‐Aft1	  fusion	  by	  cellular	  fractionation	  similarly	  showed	  
that	   in	   As-­‐treated	   lysates,	   Aft1	   was	   almost	   exclusively	   found	   in	   the	  
nucleus,	   as	   also	   seen	  with	   BPS,	  whereas	   in	   the	   absence	   of	   treatment	   it	  
was	  equally	  present	  in	  the	  cytosolic	  and	  nuclear	  fraction	  (Fig.	  2B).	  Arsenic	  
also	   induced	   the	   expression	  of	   the	  Aft1-­‐dependent	   gene	  CTH2	   to	   levels	  
similar	   to	   those	   triggered	   by	   BPS,	   as	   monitored	   using	   a	   promoter-­‐LacZ	  
fusion	   (Fig.	   2C).	   In	   the	   aft1	   mutant,	   CTH2	   induction	   was	   abolished,	   as	  
expected	   [11].	   To	   question	   the	   functional	   relationship	   between	   As	   and	  
the	  Aft1/2	  regulon,	  we	  next	  analyzed	  the	  tolerance	  to	  As	  of	  aft1	  and	  aft2	  
single	  mutants	  by	  growth	  in	  the	  presence	  of	  AsV	  (2mM).	  The	  aft1	  mutant	  
was	  unable	  to	  grow	  under	  this	  condition,	  while	  the	  aft2	  mutant	  displayed	  
normal	   growth	   (Fig.	   2D).	   Interestingly	   As-­‐induced	   growth	   inhibition	   of	  
aft1	  could	  be	  totally	  reversed	  by	  addition	  of	  Fe	  (Fig.	  2D),	  which	  indicates	  
not	  only	  that	  As	  activates	  the	  Aft1/2-­‐dependent	  Fe-­‐deprivation	  response,	  
but	  also	  causes	  a	  depletion	  of	  cellular	  iron.	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FIGURE	   2:	   Aft1	   activation	   in	   response	   to	   arsenic	   stress.	   A.	  
Representation	   of	   AFT1-­‐GFP	   fusion	   expressed	   diffusely	   throughout	   the	  
nucleus	  and	  cytoplasm	  under	  physiological,	  while	  in	  presence	  of	  arsenate	  
Aft1	   localizes	   to	   the	   nucleus.	   B.	   Nucleus-­‐cytoplasm	   fractionation.	   In	  
presence	   of	   arsenate	   Aft1	   localizes	   within	   the	   nucleus.	   Aft1-­‐cMyc	   in	  
presence	   of	   arsenate	   is	   found	   in	   the	   nuclear	   fraction.	   Cytosolic	   fraction	  
was	   identified	  by	   incubation	  with	  an	  antibody	  against	  Pgk1.	  C.	  Arsenate	  
induces	   the	   expression	   of	   CTH2-­‐lacZ	   reporter	   construct.	  Wild-­‐type	   cells	  
transformed	  with	  both	  plasmids	  pSH18-­‐34	  and	  pCM64-­‐CTH2-­‐FeRE-­‐CYC1-­‐
LacZ	   were	   grown	   in	   media	   containing	   BPS	   100uM	   or	   AsV	   2mM	   and	   β-­‐
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galactosidase	   activity	   was	   measured.	   Bars	   represent	   the	   average	   plus	  
standard	  deviation	  of	   three	   independent	  experiments.	  D.	  aft1	  mutant	   is	  
sensitive	   to	   arsenate	   and	   recovers	   upon	   supplementation	   with	   Fe2SO4.	  
yap1,	  aft1,	  aft2	  mutants,	  and	  the	  respective	  WT	  were	  spotted	  on	  YPD	  or	  
YPD	  plus	  AsV	  2mM,	  BPS	  50uM,	  or	  FeSO4	  100uM.	  
	  
	  
Arsenic	  triggers	  degradation	  of	  the	  FET3	  mRNA	  by	  the	  5’-­‐3’	  exonuclease	  
Xrn1	  	  
	  
As	   shown	   above,	   As	   caused	   a	   potent	   induction	   of	   the	   genes	   of	   the	   Fe	  
regulon,	   except	   for	   FET3	   and	   FTR1	   that	   were	   paradoxically	   down-­‐
regulated	  (Fig.	  1D,	  Figs.	  S1	  A,	  B,	  Table	  S1).	  Fet3	  is	  the	  multicopper	  oxidase	  
that	   oxidizes	   ferrous	   (Fe2+)	   to	   ferric	   iron	   (Fe3+),	   for	   subsequent	   cellular	  
uptake	  by	  the	  transmembrane	  permease	  Ftr1	  [20,	  21].	  In	  response	  to	  Fe	  
starvation,	   S.	   cerevisiae	   induces	   the	   expression	   of	   the	   Cth1	   and	   Cth2	  
mRNA-­‐binding	  proteins,	  which	  promote	  decay	  of	  mRNAs	  encoding	  for	  Fe	  
binding	   proteins	   [4].	   However,	   in	   a	   cth2	   mutant	   FET3	   mRNA	   levels	  
remained	  undetectable	  in	  the	  presence	  of	  As,	  similar	  to	  what	  was	  seen	  in	  
As-­‐treated	  WT	  cells	   (Fig.	  3A),	   in	  keeping	  with	   the	  notion	   that	  FET3	  does	  
not	  carry	  any	  Cth1/2	  AREs	  in	  its	  3′	  UTR.	  	  
Another	   major	   route	   for	   mRNA	   degradation	   in	   eukaryotic	   cells	   begins	  
with	   poly-­‐A	   deadenylation	   by	   Ccr4,	   followed	   by	   decapping,	   by	   Dcp1/2,	  
and	  5’-­‐3’	  exonucleotidic	  decay	  by	  Xrn1	  [22,	  23].	  To	  test	  the	  possible	  role	  
of	   this	   pathway	   in	  mediating	   As-­‐dependent	   FET3	  mRNA	   decay	  we	   used	  
ccr4	  and	  xrn1	  mutants.	   Importantly,	  the	  xrn1	  mutation	  had	  the	  effect	  of	  
increasing	  the	  FET3	  mRNAs	  from	  the	  very	  low,	  undetectable	  levels	  seen	  in	  
As	  treated	  cells	  to	  those	  of	  untreated	  wild	  type	  cells	  (Fig.	  3B),	   indicating	  
that	  As	  triggers	  degradation	  of	  this	  messengers	  by	  the	  5’-­‐3’	  exonuclease	  
Xrn1.	   Because	   oxidative	   stress	   has	   been	   associated	  with	   changes	   in	   the	  
stability	   of	   the	   Aft1	   regulon	   mRNAs	   [24]	   and	   As	   compounds	   induce	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oxidative	  stress,	  we	  also	  analyzed	  FET3	  expression	  levels	  in	  the	  presence	  
of	  H2O2.	  	  As	  shown	  in	  Fig.	  3C	  we	  did	  not	  observe	  any	  decrease	  of	  the	  FET3	  
mRNAs	  upon	  addition	  of	  H2O2,	  suggesting	  that	  FET3	  degradation	  by	  Xrn1	  
is	   independent	   of	   ROS	   formation.	   Taken	   together,	   these	   results	  
demonstrate	  that	  As	  triggers	  FET3	  mRNA	  degradation	  by	  Xrn1.	  
	  
	  
	  
FIGURE	  3:	  Exonuclease	  Xrn1	  mediates	  FET3	  mRNA	  degradation	  upon	  As	  
addition.	  cth2,	  xrn1,	   and	  ccr4	  mutant	   cells	   and	   the	   correspondent	  wild-­‐
type	  were	  grown	   in	  media	  containing	  AsV	  2mM	  or	  H2O2	  400uM	  for	  one	  
hour.	   Cells	   were	   harvested,	   RNA	   extracted	   and	   analyzed	   for	   FET3	  
expression.	   U3	   was	   used	   as	   loading	   control.	   A.	   FET3	   mRNA	   down-­‐
regulation	   is	   Cth2	   independent.	   B.	   Upon	   arsenate	   addition	   FET3	  
expression	   levels	   remain	   stable	   only	   in	   the	   absence	   of	   XRN1.	   C.	   FET3	  
mRNA	  degradation	  is	  independent	  of	  the	  ROS	  formation.	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Arsenic	   impairs	  high	  affinity	  Fe	  uptake	  by	   reducing	  FET3	  protein	   levels	  
and	  plasma	  membrane	  expression	  	  
To	   explore	   the	   functional	   consequences	   of	   the	   decrease	   of	   FET3	  mRNA	  
levels	   of	   As-­‐treated	   cells,	   we	   first	   measured	   Fet3	   protein	   levels.	   These	  
also	  appeared	  decreased	  in	  lysates	  of	  cells	  treated	  for	  4	  hours	  by	  As,	  but	  
not	   as	   much	   as	   under	   Fe	   repletion	   (Fe)	   (Fig.	   4A).	   As	   control,	   the	   Fet3	  
protein	  levels	  observed	  in	  Fe-­‐depleted	  cells	  (BPS)	  are	  shown.	  Felice	  et	  al	  
reported	  that	  high	  Fe	  levels	  cause	  not	  only	  the	  repression	  of	  the	  Aft1	  Fe	  
regulon,	   but	   also	   the	   internalization	   and	   degradation	   of	   the	   Fet3/Ftr1	  
transport	   system	   [7].	   Thus	   as	   another	  way	   of	   checking	   Fet3	   expression,	  
we	  examined	  its	  cellular	  localization	  (Fig.	  4B).	  In	  untreated	  cells,	  Fet3	  was	  
largely	  localized	  at	  the	  plasma	  membrane,	  while	  upon	  1	  hr	  exposure	  to	  As	  
it	   was	   essentially	   concentrated	   in	   an	   internal	   compartment	   resembling	  
the	   endoplasmic	   reticulum	   (ER)	   [25].	   To	   evaluate	   the	   functional	  
consequence	   of	   loss	   of	   Fet3	   protein	   expression,	  we	   then	   examined	   the	  
effect	  of	  As	  on	  the	  Fe	  total	  cellular	  content.	  A	  4	  hrs	  treatment	  with	  As	  at	  
1mM	   caused	   a	   70%	   decrease	   on	   the	   Fe	   cellular	   content	   (Fig.	   4C).	   To	  
further	   evaluate	   whether	   the	   decrease	   in	   Fe	   was	   a	   result	   of	   the	  
impairment	  of	  the	  Fet3-­‐Ftr1	  Fe	  reductive	  pathway,	  we	  checked	  whether	  
addition	   of	   various	   siderophores	   to	   the	   medium	   could	   restore	   the	   Fe	  
cellular	   content	   of	   As-­‐treated	   cells	   by	   recruitment	   of	   the	   non-­‐reductive	  
pathway	   of	   the	   Arn	   proteins	   family	   of	   siderophore-­‐Fe	   transporters,	   the	  
expression	  of	  which	   is	   induced	  rather	   than	  repressed	  by	  As	   (Fig.	  1D	  and	  
Table	   2).	   Addition	   of	   5	   uM	   siderophores	   indeed	   fully	   restored	   the	   Fe	  
cellular	  content	  of	  As-­‐treated	  cells,	  and	   this	  effect	  was	  dependent	  upon	  
the	   presence	   of	   Aft1	   and	   Arn1-­‐4,	   as	   it	   was	   not	   observed	   in	   the	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corresponding	  mutants	  (Fig.	  4C).	  The	  data	  thus	  indicate	  that	  As	  decreases	  
Fet3	   protein	   levels	   and	   expression	   at	   the	   plasma	   membrane	   thereby	  
causing	  defective	  Fe	  uptake	  by	  the	  Fet3-­‐Ftr1	  Fe	  reductive	  pathway	  and	  Fe	  
deficiency.	  Furthermore,	  they	  are	  totally	  consistent	  with	  the	  induction	  of	  
the	   Aft1	   regulon	   and	   with	   the	   effect	   of	   exogenous	   Fe	   of	   mitigating	   As	  
toxicity	  in	  aft1	  cells	  (Fig.	  2D).	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FIGURE	   4:	   Arsenic	   exposure	   reduces	   Fet3	   protein	   levels	   and	  
mislocalization	   at	   the	   endoplasmic	   reticulum.	   A.	   Fet3	   levels	   decrease	  
after	  4hrs	  of	  arsenate	  treatment.	  Protein	  was	  extracted	  from	  cells	  grown	  
in	  media	  containing	  AsV	  2mM,	  Fe2SO4	  100uM	  or	  BPS	  100uM	  for	  2,	  4	  and	  
6	   hours	   and	   analyzed	   by	   western	   blot.	   B.	   Representation	   of	   FET3-­‐GFP	  
strain	   expressed	   diffusely	   throughout	   the	   plasma	   membrane	   while	   in	  
presence	   of	   arsenate	   localizes	   mainly	   to	   the	   endoplasmic	   reticulum.	   C.	  
Upon	  arsenate	  exposure	  yeast	  cells	   redirect	   iron	   internalization	   through	  
the	  non-­‐reductive	  transport	  system.	  The	   intracellular	   iron	  content	   levels	  
determined	  by	  ICP	  in	  the	  wild-­‐type	  strain	  upon	  exposure	  of	  AsV	  1mM	  for	  
4	   hours	   are	   remarkably	   decreased.	   After	   addition	   of	   siderophores	   5uM	  
(ferrichrome,	   ferrirubin,	   enterobactin	   and	   desferroxamin)	   the	   wild-­‐type	  
cells	  recover	  the	  iron	  uptake.	  As	  expected	  aft1	  mutant	  and	  arn1-­‐4	  mutant	  
are	  unable	   to	   consume	  enough	   iron	  comparing	  with	   the	  wild-­‐type	  cells.	  
Values	   are	   made	   relative	   to	   100	   in	   physiological	   conditions.	   Bars	  
represent	   the	   average	   plus	   standard	   deviation	   of	   three	   independent	  
experiments.	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The	  fet3ftr1	  double	  mutant	  is	  resistant	  to	  arsenic	  
	  	  
To	  test	   the	  possible	   relevance	  of	  Fet3	   in	  mediating	  As	  biological	  effects,	  
we	   assayed	   the	   As	   plate	   tolerance	   of	   the	   fet3ftr1	   double	   mutant.	  
Surprisingly,	  this	  mutant	  appeared	  significantly	  more	  resistant	  to	  As	  than	  
its	  WT	  counterpart,	  whereas	  the	  xrn1	  mutant	  that	  stabilizes	  FET3	  mRNA	  
levels	   was	   much	   less	   resistant	   than	   the	  WT	   (Fig.	   5A).	   In	   a	   cell	   survival	  
assay	  the	  fet3ftr1	  was	  also	  significantly	  more	  resistant	  to	  As-­‐induced	  cell	  
death	  (~	  20%	  vs	  90	  %	  at	  1mM	  As),	  (Fig.	  5B).	  These	  data	  suggest	  that	  Fet3	  
mediates,	  directly	  or	  indirectly	  As	  toxicity.	  	  
Considering	  that	  the	  expression	  of	  FET3-­‐FTR1	  is	  inversely	  proportional	  to	  
cell	   resistance	   to	   As,	   their	   inhibition	   by	   As	   could	   be	   interpreted	   as	   a	  
defense	   response	   mechanism	   which	   consequently	   induces	   the	  
deprivation	   of	   Fe	   by	   the	   loss	   of	   import	   as	   high	   affinity	   pathway.	   To	  
address	   whether	   Fe	   deficiency,	   which	   in	   turn	   leads	   to	   Aft1	   activation,	  
occurs	   as	   a	   consequence	   of	   impaired	   high	   affinity	   Fe	   uptake,	   we	  
performed	  a	  time	  course	  study	  of	  CTH2	  and	  FET3	  expression	  during	  1hr	  of	  
exposure	   to	  As	   (Fig.	  5C).	  While	  FET3	  mRNA	  expression	  starts	  decreasing	  
right	   after	   the	   first	   10	   minutes	   of	   exposure,	   becoming	   almost	  
undetectable	   over	   the	   time,	   CTH2	   mRNA	   levels	   are	   inversely	   induced	  
reaching	   their	   peak	   at	   60	  minutes.	   This	   suggests	   that	  upon	  As	   addition,	  
Aft1	   activation	   occurs	   as	   a	   secondary	   event	   triggered	   by	   defective	   high	  
affinity	  Fe	  uptake.	  This	  result	  is	  also	  consistent	  with	  the	  sensitivity	  of	  the	  
aft1	  mutant	  to	  As	  and	  its	  recovery	  by	  addition	  of	  Fe.	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FIGURE	  5:	  fet3ftr1	  mutant	   is	  tolerant	  to	  arsenate	  exposure.	  A.	   fet3ftr1,	  
xrn1	  mutants	  and	  the	  respective	  wild-­‐type	  cells	  were	  spotted	  on	  YPD	  or	  
YPD	   plus	   AsV	   1mM	   and	   BPS	   100uM.	   B.	   Arsenic	   cell	   survival	   curve.	  	  
Logarithmic-­‐phase	  fet3ftr1	  mutant	  and	  wild-­‐type	  cells	  were	  grown	  in	  YPD	  
and	   incubated	  on	  YPD	  plates	   containing	  different	   concentrations	  of	  AsV	  
at	  30°C	  for	  2	  days	  to	  allow	  formation	  of	  colonies.	  Data	  are	  expressed	  as	  
percentages	   of	   colonies	   formed	   compared	   with	   control	   cultures.	   C.	  
Kinetic	  study	  of	  CTH2	  and	  FET3	  expression	  upon	  addition	  of	  AsV	  2mM	  by	  
RT-­‐PCR.	  All	  assays	  were	  made	  in	  triplicates.	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Arsenic	  trioxide	  causes	  Fe	  uptake	  destabilization	  in	  mammalian	  cells	  	  
	  
Arsenic	   trioxide	   [12]	   is	   a	   small	  molecule	   arsenic	   compound	   used	   in	   the	  
treatment	   of	   acute	   promyelocytic	   leukemia	   (PML).	   Although	   this	  
compound	   was	   shown	   to	   cause	   damage	   to/or	   degradation	   of	   the	   PML	  
protein/retinoic	  acid	   receptor-­‐alpha	   (PML/RARa)	   fusion	  protein,	   thereby	  
inducing	  apoptosis	  of	  acute	  PML	  cells	  [26],	  its	  mechanism	  of	  action	  is	  not	  
well	   understood.	   To	   extend	   the	   results	   obtained	   in	   yeast,	   we	   checked	  
whether	   ATO	   could	   also	   perturb	   Fe	   uptake	   in	   mammalian	   cells,	   using	  
mouse	   embryo	   fibroblasts	   (MEFs).	   Ferritin	   is	   an	   Fe-­‐storage	   protein	   that	  
has	  also	  been	  implicated	  in	  Fe-­‐transport	  pathways	  [27].	  Ferritin	  synthesis	  
is	  regulated	  post-­‐transcriptionally	  by	  cytosolic	  Fe.	  In	  cells	  that	  are	  replete	  
with	   Fe,	   the	   Iron	   Regulatory	   Protein	   (IRP)	   is	   released	   from	   the	   5’	   Iron	  
Response	   Element	   (IRE)	   of	   the	   ferritin	   mRNA,	   thereby	   allowing	   its	  
translation,	   whereas	   in	   Fe	   deplete	   cells	   IRP	   binds	   the	   ferritin	   mRNA	   5′	  
UTR	  IRE	  preventing	  its	  translation	  [27].	  As	  shown	  in	  Fig.	  6	  the	  expression	  
of	  ferritin	  is	  reduced	  under	  low	  Fe	  conditions	  (DFX	  5uM)	  and	  increased	  in	  
the	   presence	   of	   Fe	   (FAC	   100uM).	   Interestingly	   when	   ATO	   is	   added	  
together	  with	   FAC	   the	   ferritin	   levels	   decrease	   significantly	   compared	   to	  
Fe	   replete	  conditions	   (FAC).	  Most	   importantly,	   the	  ATO	  effect	   is	   specific	  
for	   Fe	   since	   the	   Copper	   Chaperone	   for	   superoxide	   dismutase	   (Ccs1)	  
levels,	   that	   change	   inversely	   with	   copper	   (Cu)	   concentration	   [12,	   28],	  
remain	  similar	  among	  the	  samples.	  This	  result	  is	  consistent	  with	  the	  data	  
obtained	  from	  yeast	  demonstrating	  that	  As	  compounds	  disrupt	  either	  the	  
Fe	  uptake	  or	  its	  intracellular	  regulation.	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FIGURE	  6:	  Arsenic	  trioxide	  destabilizes	  iron	  uptake	  in	  mammals.	  A.	  MEF	  
cells	  were	  incubated	  with	  iron	  chelator	  5uM	  DFX,	  5uM	  ATO,	  and	  100uM	  
FAC,	   or	   5uM	   ATO	   together	   with	   100uM	   FAC.	   After	   24hr	   media	   were	  
collected	  and	   cells	  were	   lysed.	   Ferritin	   levels	  were	  detected	  by	  western	  
blot	  using	  a	  mouse	  anti-­‐Ferritin.	  Protein	  extracts	  were	  also	  analyzed	   for	  
Ccs1	   levels	   using	   rabbit	   anti-­‐Ccs1	   as	   well	   as	   Dmt1	   using	   a	   rabbit	   anti-­‐
Nramp22D.	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Discussion	  	  
Over	   the	   past	   decade	   extensive	   studies	   on	   As	   toxicity	   have	   suggested	  
several	   modes	   of	   action	   such	   as	   production	   of	   chromosomal	  
abnormalities,	   promotion	  of	   carcinogenesis	   and	  oxidative	   stress,	   among	  
others	  [29,	  30].	  To	  date	  studies	  have	  not	  shown	  a	  link	  between	  As	  and	  Fe	  
homeostasis.	  	  
Our	   DNA	   microarray	   data	   indicate	   that	   As	   exposure	   disturbs	   the	  
expression	  of	  a	  battery	  of	  genes	  that	  encode	  for	  proteins	  involved	  in	  the	  
Fe	  homeostasis	  by	  inducing	  a	  cellular	  response	  similar	  to	  that	  induced	  by	  
Fe	  deficiency	  [16-­‐18,	  31,	  32].	  Upon	  As	  addition	  Aft1	  translocates	  into	  the	  
nucleus	  and	  activates	   the	  expression	  of	   the	  genes	   collectively	  known	  as	  
the	  Fe	  regulon	  with	  the	  exception	  of	  FET3	  and	  FTR1	  genes	  related	  to	  the	  
high	   affinity	   Fe	   uptake.	   Moreover	   upon	   As	   exposure	   the	   aft1	   mutant	  
shows	   a	   defect	   in	   growth	   that	   is	   recovered	   by	   addition	   of	   Fe.	   These	  
observations	  support	  the	  idea	  that	  when	  As	  is	  present	  in	  the	  environment	  
cells	   undergo	   Fe	   deficiency,	   which	   is	   caused	   by	   FET3-­‐FTR1	   degradation	  
mediated	  by	  the	  Xrn1	  pathway.	  	  
Similarly	  in	  presence	  of	  As	  Fet3	  protein	  levels	  also	  decrease	  after	  4	  hours	  
of	   exposure.	   Most	   importantly	   Fet3	   upon	   As	   exposure	   is	   unable	   to	  
localize	   in	   the	   plasma	   membrane	   getting	   restrained	   in	   the	   ER.	   This	  
observation	   together	   with	   the	   decrease	   of	   the	   mRNA	   levels	   seem	   to	  
indicate	   that	   As	   induced-­‐Fe	   deficiency	   is	   caused	   by	   impairment	   of	   the	  
high-­‐affinity	  Fe	  uptake	  system	  is	  compromised.	  Indeed	  WT	  cells	  exposed	  
to	  As	  for	  4	  hours	  are	  unable	  to	  consume	  as	  much	  Fe	  as	  in	  the	  absence	  of	  
As.	   The	   Fe	   assimilation	   is	   then	   achieved	   through	   the	   non-­‐reductive	  
pathway,	  mediated	  by	   the	  ARN	   family	  genes,	  as	  WT	  cells	  exposed	   to	  As	  
together	  with	  siderophores	  show	  higher	  levels	  of	  intracellular	  Fe	  content.	  	  	  
Interestingly	   fet3ftr1	   mutant	   is	   resistant	   to	   As	   while	   xrn1	   mutant	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expressing	  high	  levels	  of	  FET3	  is	  sensitive,	  which	  indicates	  that	  FET3-­‐FTR1	  
expression	  is	  deleterious	  in	  the	  presence	  of	  As.	  These	  results	  suggest	  that	  
FET3	   has	   a	   pivotal	   role	   in	   As	   toxicity.	   An	   intriguing	   possibility	   is	   that	  
Fet3/Ftr1	  complex	  might	  also	  have	  affinity	  to	  transport	  As	  inside	  the	  cells	  
and	   FET3	  mRNA	   degradation	   by	   Xrn1	   is	   a	   negative	   feedback	   regulation	  
specific	   for	  As	   stress	   adaptation.	   The	   impairment	  of	   the	  high	   affinity	   Fe	  
uptake	   by	   As	   is	   followed	   by	   the	   activation	   of	  CTH2	   expression,	   thereby	  
allowing	   an	   mRNA	   decay-­‐mediated	   global	   metabolic	   reprogramming	   in	  
order	  to	  facilitate	  the	  utilization	  of	  limiting	  Fe	  pools.	  	  
Taking	   into	   consideration	   that	   As	   is	   a	   chemotherapeutic	   drug	   used	   to	  
treat	   APL,	   we	   investigated	  whether	   this	   compound	   could	   also	   interfere	  
with	   the	   Fe	   homeostasis	   in	  mammals.	   In	  mammals	   the	   response	   to	   Fe	  
deficiency	  is	  post-­‐trascriptionally	  controlled	  by	  the	  Fe-­‐regulatory	  proteins	  
IRP1	   and	   IRP2	   [27,	   33,	   34].	   Consistent	   with	   our	   data	   from	   yeast,	   when	  
arsenic	   trioxide	   is	   added	   together	   with	   Ferric	   Ammonium	   Citrate	   the	  
ferritin	   levels	   decrease	   significantly	   compared	   to	   Fe	   replete	   conditions,	  
confirming	  that	  As	  compounds	  impair	  the	  cellular	  Fe	  uptake.	  Finally	  in	  our	  
study	  we	  have	  found	  novel	  effects	  of	  As	   in	  Fe	  metabolism	   in	  both	  yeast	  
and	  mammalian	   cells.	   These	   observations	  might	   shed	   new	   light	   on	   the	  
mechanism	   of	   action	   of	   arsenic,	   which	   may	   be	   relevant	   to	   better	  
understand	  its	  toxicity	  and	  possibly	  its	  effect	  when	  used	  as	  chemotherapy	  
in	  cancer	  patients.	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Introduction	  
Hsf1,	  the	  Molecular	  Thermometer	  
HSF1,	  OUR	  OLDEST	  FOUNTAIN	  OF	  YOUTH!	  
In	   1962,	   Ferruccio	   Ritossa	   at	   the	   Genetics	   Institute	   in	   Pavia,	   Italy,	   made	   a	  
discovery	  that	  gave	  birth	  to	  the	  heat	  shock	  research	  field.	  After	  someone	  had	  
accidentally	  turned	  up	  the	  temperature	  in	  an	  incubator	  holding	  fruit	  flies	  he	  
noticed	  that	  their	  chromosomes	  had	  puffed	  up	  at	  discrete	  locations	  a	  puffing	  
pattern	   in	   the	   polytene	   chromosomes	   of	   Drosophila	   larvae.	   This	   puffy	  
appearance	  was	  a	  sign	  that	  genes	  were	  being	  activated	  to	  give	  rise	  to	  their	  
encoded	  proteins,	  the	  heat	  shock	  proteins.	  These	  proteins	  were	  detected	  in	  
mammals	  only	  15	  years	  later.	  Since	  then	  the	  heat	  shock	  proteins	  have	  been	  
recognized	  as	  part	  of	  the	  central	  role	  in	  life	  protecting	  the	  cells	  from	  several	  
types	  of	  stress.	  Newly	  recognized	  roles	  in	  cancer	  and	  immunity	  as	  well	  as	  in	  
ageing	  make	  them	  potential	  therapeutic	  allies.	  
	  64	  
	  
	  
	  
	  
	  
	  
	  
	  
The	   author	   of	   this	   dissertation	   had	   a	   major	   contribution	   in	   this	   work,	  
namely	   in	   the	   planning	   of	   the	   experimental	   work	   and	   in	   the	   execution	  
and	  analysis	  of	  the	  experiments.	  	  
	   65	  
	  
Hsf1,	  the	  Molecular	  Thermometer	  	   	   	   	   63	  
Abstract	  	   	   	   	   	   	   	   79	  
Introduction	  	   	   	   	   	   	   	   80	  
Material	  and	  Methods	  	  	   	   	   	   	   83	  
Results	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  85	  
Phosphorylation	  of	  S303	  contributes	  to	  repression	  of	  	  
human	  HSF1	  in	  yeast	  	   	   	   	   	   	   	   	  	  	  	  85	  
S303	  represses	  trimer	  formation	  of	  HSF1	  in	  yeast	  and	  	  
mammalian	  cells	   	   	   	   	   	   	   	   	  	  	  	  89	  
S303	  phosphorylation	  and	  coiled-­‐coil	  interactions	  	  
synergize	  in	  HSF1	  repression	  	   	   	   	   	   	   	  	  	  	  92	  
Gsk3	  regulates	  human	  HSF1	  activity	  in	  yeast	  independent	  of	  S303	  	  
phosphorylation	  	   	   	   	   	   	   	   	   	  	  	  	  94	  	  	  	  
Slt2	  represses	  human	  HSF1	  activity	  via	  S303	  	  
phosphorylation	  in	  yeast	   	   	   	   	   	   	  	  	  	  	  98	  	  	  
Expression	  of	  S303A	  and	  S307A	  mutants	  in	  hsf1	  -­‐/-­‐	  cells	  results	  in	  	  
constitutive	  activation	  of	  Hsp70	  expression	   	   	   	  	  	  	  	  100	  
Discussion	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  103	  
Acknowledgments	   	   	   	   	   	   	  106	  
References	  	   	   	   	   	   	   	   	  106	  
	  
	  
	  
	  
	  66	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	   67	  
For	   successful	   adaptation	   and	   survival	   to	   extreme	   proteotoxic	   insults	  
such	   as	   heat,	   oxidative	   stress,	   heavy	   metals,	   toxins	   and	   bacterial	  
infections,	   all	   living	   organisms	   must	   maintain	   a	   cellular	   quality	   control.	  
One	  way	  they	  do	  this	  is	  through	  the	  activation	  of	  the	  heat	  shock	  response	  
(HSR)	  via	  the	  heat	  shock	  transcription	  factor	  1	  (Hsf1),	  leading	  to	  increased	  
expression	   of	   heat	   shock	   proteins	   (HSPs)	   which	   are	   involved	   in	  
maintaining	   protein	   homeostasis/proteostasis,	   a	   hallmark	   of	   stressed	  
cells.	   The	   heat	   shock	   response	   is	   a	   highly	   conserved	   mechanism	   in	   all	  
organisms	   from	   yeast	   to	   human,	   which	   suggests	   that	   this	   response	   is	  
essential	   for	  survival	   in	  a	  stressful	  environment.	  Upon	  stress,	  Hsf1	  binds	  
to	   an	   heat	   shock	   element	   (HSE)	   composed	   of	   at	   least	   three	   contiguous	  
inverted	   repeats,	   nTTCnnGAAnnTTCn	   [1]	   (Figure	   1)	   found	   on	   its	   target	  
genes.	   The	   promoters	   of	   HSF	   target	   genes	   can	   also	   contain	  more	   than	  
one	  HSE,	  thereby	  allowing	  the	  simultaneous	  binding	  of	  multiple	  HSFs.	  	  
	  
	  
Figure	  1:	  HSF1	  is	  activated	  by	  proteotoxic	  stress,	  trimerizes	  and	  binds	  to	  
HSEs,	   consisting	   in	   inverted	   repeats	   of	   the	   nGAAn	   pentamer	   in	   the	  
promoters	  of	  hsps	  and	  other	  target	  genes.	  Taken	  from	  [2].	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In	   yeast,	   nematodes,	   and	   fruit	   flies	   Hsf	   is	   encoded	   by	   a	   single	   gene	  
whereas	   vertebrates	   have	   evolved	   a	   family	   of	   four	  HSF	  members,	  HSF1	  
that	   is	   the	   stress-­‐activated	   prototype	   of	   this	   transcription	   family,	   and	  
three	  more	  members,	  HSF2	  that	  has	  mainly	  been	  linked	  to	  development	  
and	   differentiation	   events,	   HSF4	   and	   the	   avian-­‐specific	   HSF3.	   HSFs	  
possess	   unique	   and	   overlapping	   functions	   (Figure	   2),	   exhibit	   tissue-­‐
specific	   patterns	   of	   expression	   and	   have	   multiple	   interacting	   protein	  
partners	  [3].	  	  
	  
Figure	  2:	  Overview	  of	  the	  mammalian	  HSF	  machinery.	  HSF1	  is	  recognized	  
as	   the	   principal	   stress-­‐responsive	   regulator	   of	   the	   HSR,	   and	   HSF2	  
modulates	   HSF1-­‐mediated	   expression	   of	   HSP	   through	   heterocomplex	  
formation.	   Both	   HSF1	   and	   HSF2	   have	   regulatory	   functions	   in	  
developmental	   processes,	   such	   as	   oogenesis,	   spermatogenesis	   and	  
corticogenesis.	  HSF4	   is	   involved	   in	  the	  development	  of	  different	  sensory	  
organs	  in	  cooperation	  with	  HSF1.	  HSF3	  is	  the	  most	  recently	  identified	  HSF	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and	   participates	   in	   the	   HSR.	   Currently,	   HSF3	   is	   not	   known	   to	   crosstalk	  
with	  any	  member	  of	  the	  HSF	  family.	  Taken	  from	  [2].	  
In	  plants	  the	  Hsf	  family	  has	  so	  far	  been	  fully	  described	  only	  in	  few	  model	  
species	   such	   as	   Arabidopsis	   and	   rice.	   A.	   thaliana,	   that	   serves	   as	   the	  
prototype	  for	  the	  Hsf	  family,	  has	  a	  set	  of	  21	  Hsf.	  Recent	  analyses	  of	  Hsfs	  
in	   other	   species	   indicated	   that	   both	   size	   and	   composition	   of	   the	   Hsf	  
family	  is	  subject	  to	  evolutionary	  change.	  It	  is	  thought	  that	  plants	  evolved	  
such	   an	   extended	   family	   of	   HSFs	   so	   as	   to	   withstand	   the	   constant	   and	  
often	   severe	   environmental	   aggressions	   as	   those	   faced	   by	   immotile	  
organisms.	  The	  wide	  multiplicity	  of	  plant	  Hsfs	   is	   in	  sharp	  contrast	  to	  the	  
situation	  in	  most	  other	  organisms	  [4,	  5].	  
Mammalian	   HSF1	   is	   the	   master	   regulator	   of	   chaperone	   expression	   in	  
vertebrates,	   as	   mice	   and	   cell	   models	   lacking	   hsf1	   gene	   are	   unable	   to	  
elevate	   Hsp	   levels	   in	   response	   to	   thermal	   insult	   displaying	   reduced	  
survival	   after	   challenge	   with	   the	   bacterial	   toxin	   lipopolysaccharide	   [6].	  
Hsf1	   is	   the	   best	   characterized	   member	   of	   the	   HSF	   family,	   it	   is	  
constitutively	  expressed	  in	  most	  tissues	  and	  cell	  types	  [7],	  and	  is	  kept	  as	  
an	   inactive	   monomer	   through	   post-­‐translational	   modifications	   (PTMs)	  
that	  include	  protein	  acetylation,	  sumoylation	  and	  phosphorylation	  (Figure	  
3)	  and	  through	  the	  activity	  of	  the	  chaperone	  proteins	  HSP90,	  HSP70,	  and	  
HSP40	  and	  other	  co-­‐chaperones	  (Figure	  4).	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Figure	  3:	  Overview	  of	  HSF1	  post-­‐translational	  modifications	  (PTMs).	  Sites	  
for	   acetylation	   (Ac),	   phosphorylation	   (P)	   and	   sumoylation	   (Su)	   are	  
indicated.	  Taken	  from	  [8].	  	  
	  
HSF,	   like	   many	   other	   transcription	   factors,	   are	   composed	   of	   functional	  
domains.	   All	   HSF	   contain	   two	   conserved	   domains,	   the	   amino-­‐terminal	  
DNA	  binding	  domain	  (DBD)	  and	  an	  adjacent	  oligomerization	  domain.	  The	  
DBD	   is	   the	   only	   functional	   domain	   of	   HSFs	   being	   considered	   as	   the	  
signature	   domain	   for	   HSFs	   target-­‐gene	   recognition.	   DBD	   consists	   on	   a	  
loop	  that	  allows	  protein–protein	   interface	  between	  adjacent	  subunits	  of	  
the	  HSF	  trimer	  that	  enhances	  high-­‐affinity	  binding	  to	  DNA	  [9].	  	  
HSF1	  trimerization	  is	  regulated	  by	  the	  hydrophobic	  heptad	  repeats	  (LZ1-­‐
3)	  (Figure	  3)	  that	  form	  a	  coiled	  coil,	  which	   is	  characteristic	  for	  many	  Leu	  
zippers	   [10].	   The	   suppression	   of	   HSF1	   spontaneous	   trimerization	   is	  
mediated	   by	   the	   additional	   hydrophobic	   heptad	   repeat	   region,	   LZ4	  
(Figure	  3).	  The	  LZ4	  domain	   is	   thought	  to	   fold	  back	  and	   interact	  with	  the	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LZ1-­‐3	   domain	   to	   keep	   HSF1	   in	   an	   inactive	   state	   as	   introduction	   of	  
mutations	  in	  this	  domain	  allows	  constitutive	  HSF1	  trimerization	  and	  DNA-­‐
binding	  activity	  [11,	  12].	  Saccharomyces	  cerevisiae	  HSF1	  and	  mammalian	  
HSF4	   lack	   the	   LZ4	   domain,	   which	   might	   explain	   its	   constitutive	  
trimerization	   and	   DNA	   binding	   activity	   at	   normal	   growth	   temperatures	  
[13,	  14].	  In	  response	  to	  stress	  HSF1	  homotrimerizes,	  accumulates	  into	  the	  
nucleus,	   binds	   DNA,	   becomes	   hyper-­‐phosphorylated	   and	   activates	   the	  
expression	  of	  stress	  response	  genes	  (Figure	  4)	  [8,	  15].	  The	  conversion	  of	  
the	   inactive	  monomeric	  HSF1	  to	  high-­‐affinity	  DNA-­‐binding	   trimers	   is	   the	  
initial	  step	  in	  the	  multistep	  activation	  process	  and	  is	  a	  common	  feature	  of	  
all	   eukaryotic	   HSFs	   [16].	   Hsp90	   has	   been	   shown	   to	   have	   a	   role	   in	  
maintaining	  HSF1	   in	  an	   inert	   state,	  as	   its	   immunodepletion	  or	   inhibition	  
by	  geldamycin	  let	  to	  activation	  of	  HSF1	  DNA	  binding	  domain.	  Hsp70	  effect	  
on	  trimer	  formation	  is	  minor	  since	  it	  rather	  suppresses	  the	  transcriptional	  
activity	   of	   HSF1	   by	   binding	   to	   its	   activation	   domain.	   Elevated	   levels	   of	  
both	   HSP90	   and	   HSP70	   negatively	   regulate	   HSF1	   and	   prevent	   trimer	  
formation	   during	   heat	   shock.	   Activated	   HSF1	   trimers	   also	   interact	   with	  
HSP70	  and	  the	  co-­‐chaperone	  HSP40,	  but	  instead	  of	  suppressing	  the	  DNA-­‐
binding	   activity	   of	   HSF1,	   this	   interaction	   inhibits	   its	   transactivation	  
capacity	  [17].	  Regardless	  of	  how	  HSF1	  is	  converted	  from	  a	  monomer	  to	  a	  
trimer	  the	  DNA-­‐bound	  HSF1	  is	  insufficient	  for	  transcriptional	  induction	  of	  
hsp	  genes,	  suggesting	  that	  other	  mechanisms	  operate	  to	  facilitate	  gain	  of	  
HSF1	  trans-­‐activating	  competence.	  A	  prominent	  feature	  of	  HSF1	  is	  that	  its	  
conversion	   into	   a	   transcriptionally	   active	   trimer	   occurs	   with	   extensive	  
hyper-­‐phosphorylation	  of	  serine	  residues	  [2],	  most	  of	  which	  reside	  within	  
the	  Regulatory	  Domain	  (RD)	  (Figure	  3)	  [18].	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Figure	   4:	   HSF1	   multistep	   activation	   and	   attenuation	   process.	   In	   the	  
resting	   state,	   HSF1	   is	   a	   monomer	   in	   both	   the	   cytoplasm	   and	   nucleus.	  
Monomeric	   HSF1	   is	   already	   a	   phosphoprotein	   under	   non-­‐stress	  
conditions	   and	   it	   interacts	   with	   HSP90.	   Upon	   stress,	   HSF1	   dissociates	  
from	  the	  HSP90	  complex,	  allowing	  HSF1	  to	  trimerize	  and	  bind	  to	  the	  HSEs	  
in	   HSP	   genes.	   HSF1	   undergoes	   phosphorylation	   and	   sumoylation	   and	  
acquires	   transcriptional	   activity.	   Attenuation	   involves	   two	   regulatory	  
steps:	  negative	  feedback	  from	  HSPs,	  which	  represses	  the	  transactivation	  
of	  DNA-­‐bound	  HSF1,	  and	  inhibition	  of	  DNA	  binding	  by	  the	  acetylation	  of	  
Lys80	  in	  the	  DBD	  of	  HSF1.	  Taken	  from	  [8].	  	  
	  
Results	   from	   mass	   spectrometry	   (MS)	   analyses	   combined	   with	  
phosphopeptide	   mapping	   experiments	   indicate	   that	   at	   least	   12	   Ser	  
residues	   are	   phosphorylated	   [19]	   	   (Table	   1).	   As	   a	   monomer	   HSF1	   is	  
phosphorylated	   on	   at	   least	   Ser230,	   Ser303,	   Ser307	   and	   Ser363,	   and	   its	  
DNA-­‐binding	   and	   transcriptional	   activities	   are	   repressed.	   In	   contrast	   to	  
the	  repressive	  role	  of	  phosphoserines	  303,	  307	  and	  363,	  the	  Ser230	  was	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identified	   as	   a	   phosphorylation	   site	   that	   promotes	   the	   transcriptional	  
activity	   of	   HSF1	   (Figure	   3)	   [20].	   Equally	   important	   is	   that	   the	   basal	  
phosphorylation	  state	  of	  Ser230	  is	  enhanced	  upon	  heat	  shock,	  showing	  a	  
stoichiometric	   shift	   towards	   phosphoserine	   230	   in	   a	   subset	   of	   HSF1	  
molecules	  [21].	  Hong,	  Y.	  et	  al.	   [22]	  has	  also	  shown	  that	  HSF1	  undergoes	  
stress-­‐induced	   sumoylation	   on	   Lys298,	   which	   lies	   close	   to	   the	   residue	  
Ser303	  that	  needs	  to	  be	  phosphorylated	  before	  a	  small	  ubiquitin-­‐related	  
modifier	  can	  be	  conjugated.	  Recently	  Westerheide	  et	  al	  [23]	  showed	  that	  
HSF1	  is	  also	  subject	  to	  stress-­‐inducible	  acetylation.	  By	  mass	  spectrometry	  
it	   were	   identified	   at	   least	   9	   lysines	   in	   HSF1	   that	   were	   acetylated	   in	  
response	  to	  stress	   (Table	  1)	  of	  which	  Lys80	  appears	   to	  control	   the	  HSF1	  
binding	   to	   DNA.	   This	   stress-­‐inducible	   acetylation	   event	   seems	   to	   be	  
regulated	   by	   the	   balance	   of	   acetylation	   by	   p300–CBP	   (CREB-­‐binding	  
protein)	   and	   deacetylation	   by	   the	   NAD+-­‐dependent	   sirtuin,	   SIRT1.	  
Increased	  expression	  and	  activity	  of	  SIRT1	  enhance	  and	  prolong	  the	  DNA-­‐
binding	   activity	   of	   HSF1	   at	   the	   human	   HSP70.1	   promoter,	   whereas	  
downregulation	   of	   SIRT1	   enhances	   the	   acetylation	   of	   HSF1	   and	   the	  
attenuation	   of	   DNA-­‐binding	   without	   affecting	   the	   formation	   of	   HSF1	  
trimers	  [23].	  	  
Table	   1:	   Heat	   shock	   factor	   1	   (HSF1)	   post-­‐translational	   modifications	  
(PTMs)	  events	  [15].	  
Modification	   Enzyme	   Effect	  
Ac-­‐K80	   p300/SIRT1	   Inhibitory	  
Ac-­‐K116	   p300/SIRT1	   ?	  
Ac-­‐K118	   p300/SIRT1	   ?	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Modification	   Enzyme	   Effect	  
Ph-­‐S121	   MAPKAPK2	   Inhibitory	  (promotes	  Hsp90	  
binding)	  
Ac-­‐K126	   p300/SIRT1	   ?	  
Ph-­‐T142	   CK2	   Inhibitory	  
Ac-­‐K148	   p300/SIRT1	   ?	  
Ac-­‐K157	   p300/SIRT1	   ?	  
Ac-­‐K208	   p300/SIRT1	   ?	  
Ph-­‐S216	   Plk1	   Promotes	  mitotic	  progression	  
Ac-­‐K224	   p300/SIRT1	   ?	  
Ph-­‐S230	   CamKII	   Stimulatory	  
Ph-­‐S292	   ?	   ?	  
Su-­‐K298	   Ubc9	   Inhibitory	  
Ac-­‐K298	   p300/SIRT1	   ?	  
Ph-­‐S303	   MAPKGSK3β	   Inhibitory	  (promotes	  K298	  
sumoylation)	  
Ph-­‐S307	   MAPK	   ?	  
Ph-­‐S314	   ?	   ?	  
Ph-­‐S319	   ?	   ?	  
Ph-­‐S320	   ?	   ?	  
Ph-­‐T323	   ?	   ?	  
Ph-­‐S326	   ?	   Stimulatory	  (promotes	  Daxx	  
binding)	  
Ph-­‐S344	   ?	   ?	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Modification	   Enzyme	   Effect	  
Ph-­‐S363	   PKC,	  JNK	   Inhibitory	  
Ph-­‐T367	   ?	   ?	  
Ph-­‐S368	   ?	   ?	  
Ph-­‐T369	   ?	   ?	  
Ph-­‐S419	   PLK1	   Stimulatory	  
Ph-­‐S444	   ?	   ?	  
O-­‐glycosylation	   ?	   ?	  
	  
Finally,	   in	   the	   light	   of	   current	   knowledge,	   the	   attenuation	   phase	   of	   the	  
HSF1	  cycle	  is	  regulated	  by	  a	  dual	  mechanism:	  a	  dependency	  on	  the	  levels	  
of	   HSPs	   that	   feedback	   directly	   by	   weak	   interactions	   with	   HSF1,	   and	   a	  
parallel	   step	   that	   involves	   the	   SIRT1-­‐dependent	   control	   of	   the	   DNA-­‐
binding	   activity	   of	   HSF1.	   SIRT1	   is	   the	  mammalian	   ortholog	   of	   the	   yeast	  
Sir2,	   has	   been	   implicated	   in	   caloric	   restriction	   and	   ageing.	   Ageing	   and	  
cellular	  senescence	  reduce	  the	  organism’s	  ability	  to	  respond	  to	  stress	  and	  
maintain	   homeostasis	   [24].	   Whereas	   HSF1	   protein	   concentration	  
increases	   with	   age,	   the	   amount	   of	   SIRT1	   protein	   decreases.	   The	   age-­‐
dependent	   loss	   of	   SIRT1	   and	   impaired	   HSF1	   activity	   correlated	   with	   an	  
impairment	   of	   the	   heat	   shock	   response	   and	   proteostasis	   in	   senescent	  
cells,	  suggests	  that	  SIRT1	  and	  HSF1	  function	  together	  to	  protect	  cells	  from	  
various	  stresses,	  promote	  survival,	  and	  extend	   life	   span.	  Age-­‐dependent	  
onset	   applies	   to	  both	  degenerative	   conditions	   that	   have	   a	   clear	   genetic	  
determinant,	   such	   as	  Huntington’s	   disease,	   and	   to	   pathologies	   in	  which	  
sporadic	  forms	  are	  predominant,	  such	  as	  Parkinson’s,	  amyotrophic	  lateral	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sclerosis	   (ALS),	   and	   Alzheimer’s	   diseases.	   These	   neurodegenerative	  
diseases	   often	   occur	   later	   in	   life	   when	   heat	   shock	   genes	   seem	   to	   be	  
poorly	  induced	  [25].	  	  
Nevertheless	   tumor	   cells	   typically	   express	   higher	   levels	   of	   heat	   shock	  
proteins	   leading	   to	   the	   suggestion	   that	   the	   aberrant	   expression	   of	  
chaperones	  is	  associated	  with	  the	  tumorigenic	  state	  [26].	  Also	  tumor	  cells	  
might	  be	  dependent	  on	  elevated	  levels	  of	  Hsps,	  perhaps	  as	  a	  generalized	  
mechanism	   to	   suppress	   cumulative	   mutations	   that	   would	   otherwise	  
result	  in	  the	  expression	  of	  deleterious	  proteins.	  Given	  the	  unique	  role	  of	  
HSF1	   in	   stress	   biology	   and	   proteostasis,	   this	   has	   been	   considered	   as	   a	  
potential	   target	   for	   therapeutics	   and	   many	   academic	   researchers	   and	  
industrial	   laboratories	   have	   actively	   been	   searching	   for	   small	   molecule	  
regulators	  of	  HSF1	  [2].	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Abstract	  
	  
Heat	   shock	   transcription	   factor	   1	   (HSF1)	   plays	   an	   important	   role	   in	   the	   cellular	  
response	   to	   proteotoxic	   stresses.	   Under	   normal	   growth	   conditions	   HSF1	   is	  
repressed	  as	  an	  inactive	  monomer	  in	  part	  through	  post-­‐translation	  modifications	  
that	   include	   protein	   acetylation,	   sumoylation	   and	   phosphorylation.	   	   Upon	  
exposure	   to	   stress	   HSF1	   homotrimerizes,	   accumulates	   in	   nucleus,	   binds	   DNA,	  
becomes	   hyper-­‐phosphorylated	   and	   activates	   the	   expression	   of	   stress	   response	  
genes.	   	   While	   HSF1	   and	   the	   mechanisms	   that	   regulate	   its	   activity	   have	   been	  
studied	   for	   over	   two	   decades,	   our	   understanding	   of	   HSF1	   regulation	   remains	  
incomplete.	   	   As	   previous	   studies	   have	   shown	   that	   HSF1	   and	   the	   heat	   shock	  
response	  promoter	  element	  (HSE)	  are	  generally	  structurally	  conserved	  from	  yeast	  
to	  metazoans,	  we	  have	  made	  use	  of	  the	  genetically	  tractable	  budding	  yeast	  as	  a	  
facile	  assay	   system	   to	   further	  understand	   the	  mechanisms	   that	   regulate	  human	  
HSF1	  through	  phosphorylation	  of	  serine	  303.	  	  We	  show	  that	  when	  human	  HSF1	  is	  
expressed	   in	   yeast	   its	   phosphorylation	   at	   S303	   is	   promoted	   by	   the	  MAP-­‐kinase	  
Slt2	   independent	   of	   a	   priming	   event	   at	   S307	   previously	   believed	   to	   be	   a	  
prerequisite.	   	   Furthermore,	  we	   show	   that	  phosphorylation	  at	   S303	   in	   yeast	  and	  
mammalian	  cells	  occurs	  independent	  of	  GSK3,	  the	  kinase	  primarily	  thought	  to	  be	  
responsible	   for	   S303	   phosphorylation.	   Lastly,	   while	   previous	   studies	   have	  
suggested	  that	  S303	  phosphorylation	  represses	  HSF1-­‐dependent	  transactivation,	  
we	  now	  show	  that	  S303	  phosphorylation	  also	  represses	  HSF1	  multimerization	  in	  
both	   yeast	   and	   mammalian	   cells.	   	   Taken	   together,	   these	   studies	   suggest	   that	  
yeast	  cells	  will	  be	  a	  powerful	  experimental	  tool	  for	  deciphering	  aspects	  of	  human	  
HSF1	  regulation	  by	  post-­‐translational	  modifications.	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Introduction	  
	  
All	  organisms	  are	  exposed	  to	  proteotoxic	  stresses	  that	  result	  in	  the	  accumulation	  
of	  misfolded	  proteins.	   	   In	  response	  to	  these	  stresses	  cells	  have	  evolved	  adaptive	  
responses	   to	   protect	   and	   stabilize	   cellular	   proteins	   until	   more	   favorable	  
conditions	  for	  cell	  proliferation	  are	  encountered	  [1].	  	  The	  heat	  shock	  transcription	  
factor,	  HSF,	  is	  a	  homotrimeric	  transcription	  factor	  that	  activates	  gene	  expression	  
in	  response	  to	  a	  variety	  of	  stresses	  including	  heat	  and	  oxidative	  stress,	  as	  well	  as	  
inflammation	  and	  infection	  [2].	  	  Recent	  evidence	  has	  shown	  that	  the	  S.	  cerevisiae	  
HSF	   directly	   activates	   the	   expression	   of	   genes	   whose	   protein	   products	   are	  
involved	   in	   protein	   folding	   and	   degradation,	   ion	   transport,	   signal	   transduction,	  
energy	   generation,	   carbohydrate	   metabolism,	   vesicular	   transport,	   cytoskeleton	  
formation	  and	  other	  cellular	  functions	  [3].	  
While	  mammalian	   cells	   express	   four	   distinct	   HSF	   proteins	   encoded	   by	   separate	  
genes,	   HSF1	   is	   the	   primary	   factor	   responsible	   for	   stress	   responsive	   gene	  
transcription	  [2].	  	  In	  the	  absence	  of	  stress,	  mammalian	  HSF1	  is	  repressed	  through	  
mechanisms	  that	  are	  not	  well	  understood.	   	  HSF1	  is	  thought	  be	  maintained	  in	  an	  
inactive	   monomeric	   state	   through	   intramolecular	   interactions	   between	   a	  
hydrophobic	  coiled-­‐coil	  domain	  in	  the	  carboxyl-­‐terminus	  of	  the	  protein	  and	  three	  
amino-­‐terminal	   coiled-­‐coils	   required	   for	   homotrimerization	   and	   transcriptional	  
activation	  [4-­‐6].	   	  HSF1	  is	  also	  thought	  to	  be	  bound	  and	  repressed	  by	  the	  protein	  
chaperones	   Hsp90	   and	   Hsp70,	   though	   it	   is	   not	   clear	   how	   these	   chaperones	  
repress	  HSF1	  activity	  [7-­‐10].	   	  Studies	  suggest	  that	  during	  the	   initial	  phase	  of	  the	  
stress	   response,	   the	   inactive	   HSF1	   monomer	   dissociates	   from	   Hsp90,	  
homotrimerizes,	   is	  transported	  to	  the	  nucleus	  and	  binds	  to	  heat	  shock	  elements	  
(HSE)	   found	   in	   the	   promoters	   of	   HSF	   target	   genes	   [10,	   11].	   	   The	   DNA-­‐bound	  
homotrimer,	  remains	  relatively	  transcriptionally	  inert	  [12],	  potentially	  due	  to	  the	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continued	   interaction	   with	   Hsp70	   and	   the	   HSF1-­‐transactivation	   domain	   [9].	  
Stress-­‐dependent	   hyperphosphorylation	   of	   HSF1	   by	   potentially	  multiple	   protein	  
kinases	  has	  been	  proposed	  to,	   in	  part,	  promote	  HSF1	  dependent	  transactivation	  
[13-­‐15].	  
The	  activity	  of	  HSF1	  is	  also	  thought	  to	  be	  negatively	  regulated	  through	  a	  number	  
of	   post-­‐translational	   modifications	   including	   phosphorylation,	   sumoylation	   and	  
acetylation	   [16-­‐19].	   	   Mass	   spectrometry	   analyses	   have	   shown	   HSF1	   to	   be	  
phosphorylated	  on	  at	   least	  12	  serine	  residues	  [13]	  and	  phosphorylation	  of	  S121,	  
S303,	  S307	  and	  S363	  have	  been	  correlated	  with	  a	  repression	  in	  HSF1	  activity	  [18,	  
20,	  21].	  	  The	  most	  comprehensively	  studied	  of	  these	  phosphorylation	  events	  are	  
the	  phosphorylation	  of	  S303	  and	  S307.	  	  However,	  much	  of	  what	  is	  known	  about	  
S303	  and	  S307	  phosphorylation	  stems	  from	  in	  vitro	  phosphorylation	  experiments	  
and	   in	   vivo	   studies	   using	   either	   lexA	   or	   Gal4-­‐HSF1	   fusion	   proteins	   lacking	   the	  
native	  HSF1	  DNA	  binding	  domain.	  	  As	  such,	  many	  of	  the	  earlier	  studies	  exploring	  
S303	  and	  S307-­‐dependet	   regulation	  of	  HSF1	  activity	  have	   resulted	   in	   conflicting	  
results.	   	   For	   example,	   previous	   in	   vitro	   phosphorylation	   experiments	   suggested	  
that	   S307	   was	   phosphorylated	   by	   ERK	   which,	   in	   turn,	   acted	   as	   an	   essential	  
priming	   step	   for	   GSK3-­‐dependent	   phosphorylation	   of	   S303	   [22].	   	   However,	  
subsequent	  in	  vitro	  studies	  suggested	  that	  S303	  could	  also	  be	  phosphorylated	  by	  
a	   variety	   of	   mitogen	   activated	   protein	   kinases	   (MAPK)	   including	   the	   stress	  
responsive	  MAPK	   p38	   [17,	   18].	   	   In	   addition,	   subsequent	   in	   vivo	   data	   suggested	  
S303	  phosphorylation	  could	  occur	  independently	  of	  S307	  phosphorylation	  [16].	  	  
While	   the	   specific	  mechanism	  by	  which	  S303	  and	  S307	  phosphorylation	   repress	  
HSF1	   activity	   remains	   unclear,	   evidence	   has	   suggested	   that	   S303	   and	   S307	  
phosphorylation	   represses	   the	   transactivation	   potential	   of	   HSF1	   [18,	   22,	   23].	  	  
S303	   and	   S307	   are	   constitutively	   phosphorylated	   in	   the	   absence	   of	   stress	   and	  
S303	  phosphorylation	  levels	  increase	  after	  exposure	  to	  stress,	  suggesting	  that	  this	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phosphorylation	   event	   might	   also	   contribute	   to	   HSF1	   inactivation	   during	   the	  
recovery	   phase	   [16,	   17].	   	   Interestingly,	   phosphorylation	   of	   S303,	   but	   not	   S307,	  
promotes	   sumoylation	   of	   K298	   [16]	   which,	   like	   S303	   phosphorylation,	   also	  
increases	   in	   response	   to	   stress	   exposure	   and	   represses	   HSF1-­‐dependent	  
transactivation	  [24].	  	  However,	  it	  remains	  unclear	  if	  the	  repressive	  effects	  of	  S303	  
phosphorylation	   on	   HSF1	   activity	   are	   exclusively	   mediated	   through	   K298	  
sumoylation	  or	  occur	  through	  additional	  mechanisms.	  
While	  HSF1	  and	  the	  cognate	  HSEs	  are	  quite	  well	  conserved	  from	  yeast	  to	  humans,	  
our	  previous	  results	  demonstrated	  that	  human	  HSF1	  expressed	  in	  S.	  cerevisiae	  is	  
unable	  to	  complement	  for	  the	  loss	  of	  the	  essential	  yeast	  HSF	  protein	  [25].	  Further	  
analysis	   showed	   that	   human	   HSF1	   expressed	   in	   yeast	   was	   unable	   to	   form	   a	  
homotrimer	  and	  consequently	  unable	  to	  activate	  HSE-­‐dependent	  gene	  expression	  
to	   support	   cell	   viability.	   Human	   HSF1	   homotrimerized,	   became	   active	   and	  
complemented	   for	   the	   loss	   of	   yeast	   HSF	   when	   three	   derepressing	   mutations,	  
collectively	   known	   as	   LZ4m,	   were	   introduced	   into	   the	   repressive	   carboxyl-­‐
terminal	  coiled-­‐coil	  domain	  [6,	  25].	  	  Further	  studies	  in	  yeast	  identified	  an	  amino-­‐
terminal	  linker-­‐domain	  as	  well	  as	  a	  loop	  in	  the	  DNA	  binding	  domain	  as	  repressive	  
elements	  that	  contributed	  to	  HSF1	  repression	  in	  both	  yeast	  and	  mammalian	  cells	  
[26,	  27].	  	  We	  have	  also	  used	  to	  the	  yeast	  assay	  system	  to	  screen	  for	  and	  indentify	  
novel	   pharmacological	   activators	   of	   human	   HSF1	   [28].	   Together,	   these	   results	  
suggest	   that	   human	   HSF1	   expressed	   in	   yeast	   is	   maintained	   in	   a	   constitutively	  
repressed	   state	   through	   mechanisms	   similar	   to	   those	   of	   mammalian	   cells	   and	  
that	   the	   yeast	   system	   can	   serve	   as	   a	   simplified	   assay	   system	   to	   decipher	   the	  
complex	  mechanisms	  regulating	  human	  HSF1	  activity.	  	  	  
Here	   we	   report	   the	   use	   of	   the	   yeast	   assay	   system	   to	   further	   understand	   the	  
mechanisms	   that	   regulate	   human	  HSF1	   through	   phosphorylation	   of	   serine	   303.	  	  
Our	   results	   suggest	   that	   S303	   phosphorylation	   blocks	   human	   HSF1	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homotrimerization	   thereby	   preventing	   human	   HSF1	   activation	   and	  
complementation	   of	   the	   loss	   of	   yeast	  HSF.	   	   Furthermore,	  we	   demonstrate	   that	  
S303	   phosphorylation	   also	   blocks	   HSF1	   homotrimerization	   in	   mammalian	   cells.	  
We	  show	  that	  phosphorylation	  of	  HSF1	  S303	  in	  yeast	  occurs	  via	  the	  action	  of	  the	  
MAPK	  Slt2	  and	  not	  via	  the	  action	  of	  GSK3	  and	  we	  extend	  these	  findings	  to	  show	  
that	  S303	  phosphorylation	  also	  occurs	  independent	  of	  GSK3	  in	  mammalian	  cells.	  	  
	  
Materials	  and	  Methods	  
Yeast	  Strains,	  Plasmids	  	  
S.	   cerevisiae	   strains	   used	   in	   this	   study	   are	   listed	   in	   Table	   I.	   Yeast	   expression	  
plasmids	   pRS424-­‐GPD-­‐HSF1	   and	   pRS424-­‐GPD-­‐HSF1LZ4m	   were	   described	  
previously	  [25].	  	  Point	  mutations	  were	  introduced	  into	  the	  HSF1	  coding	  sequence	  
using	  the	  QuickChange	  Site-­‐directed	  mutagenesis	  kit	  (Stratagene)	  and	  confirmed	  
by	   DNA	   sequencing.	   Mammalian	   expression	   plasmids	   were	   generated	   by	  
subcloning	  the	  HSF1	  open	  reading	  frame	  from	  yeast	  vectors	  into	  the	  mammalian	  
vector	  pcDNA3.1.	  
	  
	  
Table	  1.	  	  Yeast	  strains	  used	  in	  this	  study.	  
Strain	   	   	   Genotype	  
PS145	   MATa	  ade2-­‐1	  trp1-­‐1	  can1-­‐100	  leu2-­‐3,	  112	  his3-­‐11,15	  
ura3-­‐1	  hsf1∆::LEU2	  	  Ycp50gal-­‐yHSF	  
YPH499	  	   	   MATa	  ura3-­‐52	  lys2-­‐801	  ade2-­‐101	  trp1-­‐Δ63	  his3-­‐Δ200	  
leu2-­‐Δ1	  
BY4741	  	   	   MATa	  his3∆1	  leu2∆0	  met15∆0	  ura3∆0	  
LNY1	   MATa	  ade2-­‐1	  trp1-­‐1	  can1-­‐100	  leu2-­‐3,	  112	  his3-­‐11,15	  
ura3-­‐1	  hsf1∆::LEU2	  	  Ycp50gal-­‐yHSF	  rim11∆::HIS3	  
LNY2	   MATa	  ade2-­‐1	  trp1-­‐1	  can1-­‐100	  leu2-­‐3,	  112	  his3-­‐11,15	  
ura3-­‐1	  hsf1∆::LEU2	  	  Ycp50gal-­‐yHSF	  slt2∆::HIS3	  
LNY3	   MATa	  ura3-­‐52	  lys2-­‐801	  ade2-­‐101	  trp1-­‐Δ63	  his3-­‐Δ200	  
leu2-­‐Δ1	  rim11∆::TRP1	  mck1∆::HIS3	  mrk1∆::URA3	  
ygk3∆::kanMX	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Cell	  culture	  maintenance,	  transfection	  and	  siRNA	  	  
Mammalian	  cell	  lines	  used	  in	  the	  study	  were	  hsf1-­‐/-­‐	  MEF	  cells	  [29]	  and	  HeLa	  cells	  
(ATCC,	  CCL-­‐2).	  	  The	  MEF	  cells	  were	  maintained	  in	  DMEM	  supplemented	  with	  10%	  
fetal	   bovine	   serum	   (FBS),	   0.1	   mM	   nonessential	   amino	   acids,	   100	   U/ml	  
penicillin/streptomycin	   and	   55	   µM	   2-­‐mercaptoethanol.	   	   HeLa	   cells	   were	  
maintained	   in	   DMEM	   supplemented	   with	   10%	   FBS	   and	   100	   U/ml	  
penicillin/streptomycin.	   	   MEF	   cells	   were	   transfected	   with	   HSF1	   expressing	  
plasmids	   using	   a	   Nucleofector	   (Lonza)	   and	   Nucleofector	   solution	  MEF2.	   	   siRNA	  
was	  purchased	   from	  Dharmacon	  and	  2	  nmoles	   	  of	  each	  siRNA	  were	   transfected	  
into	  HeLa	   cells	   using	  Dharmafect	   1.	   	   Knock-­‐down	  of	   proteins	  was	   assayed	   72	   h	  
after	  siRNA	  transfection	  by	  immunoblot	  analysis.	  	  
	  
Complementation	  assays	  	  
Growth	   curve	   experiments	   were	   carried	   out	   in	   96-­‐well	   plates	   as	   described	  
previously	   [28].	   	   For	   spot	   assays	   yeast	   cells	  were	   grown	  overnight	   in	   galactose-­‐
containing	   medium	   to	   allow	   for	   expression	   of	   GAL1-­‐yHSF	   and	   reseeded	   the	  
following	   day	   at	   O.D.600	   =	   0.2	   and	   spotted	   on	   either	   galactose	   or	   dextrose	  
supplemented	  growth	  media.	  
	  
Immunoblot	  and	  Crosslinking	  Analysis	  	  
Protein	  extracts	  were	  generated	  from	  yeast	  cultures	  using	  glass	  bead	  lysis	  in	  cell	  
lysis	  buffer	  (25	  mM	  Tris,	  150	  mM	  NaCl,	  1%	  Triton	  X-­‐100,	  0.1%	  SDS,	  1	  mM	  EDTA)	  
supplemented	   with	   protease	   inhibitors	   (Roche)	   and	   Halt	   phosphate	   inhibitor	  
cocktail	   (Thermo	   Scientific	   Pierce).	   	   Proteins	   extracts	   were	   generated	   from	  
mammalian	   cell	   culture	   using	   cell	   lysis	   buffer	   supplemented	  with	   protease	   and	  
phosphatase	   inhibitors.	   	   Protein	   concentrations	   were	   quantified	   using	   the	   BCA	  
assay	  and	  80-­‐100μg	  of	  total	  protein	  was	  resolved	  by	  SDS-­‐PAGE	  and	  transferred	  to	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a	  nitrocellulose	  membrane.	  HSF1	  oligomerization	  was	  assessed	  using	  the	  amine-­‐
specific	   cross-­‐linker	   ethylene	   glycol	   bis-­‐succinimidyl	   succinate	   (EGS)	   [30].	  
Crosslinking	   analysis	   were	   carried	   out	   as	   described	   previously	   [28].	   	   Antibodies	  
used	  in	  this	  study	  were	  anti-­‐phospho-­‐S303	  (pS303)	  (ab47369,	  Abcam),	  anti-­‐HSF1	  
[28],	   anti-­‐Pgk1,	   anti-­‐FLAG	   (M2,	   Sigma),	   anti-­‐Hsp70	   (C92,	   Stressmarq),	   anti-­‐β-­‐
catenin	   (6B3,	   Cell	   Signaling),	   anti-­‐GAPDH	   (6C5,	   Ambion)	   and	   anti-­‐GSK3α/β	  
(D75D3,	   Cell	   Signaling).	   	   Quantification	   of	   immunoblot	   data	   was	   done	   using	  
Photoshop.	  
	  
Results	  
Phosphorylation	  of	  S303	  contributes	  to	  repression	  of	  human	  HSF1	  in	  yeast.	  	  	  
When	  human	  HSF1	  is	  expressed	  in	  yeast	   it	   is	  unable	  to	  homotrimerize,	  promote	  
gene	  expression	  and	  complement	  for	  the	   loss	  of	  the	  essential	  yeast	  HSF	  protein	  
[25].	  	  	  Because	  our	  previous	  work	  suggested	  that	  when	  HSF1	  is	  expressed	  in	  yeast	  
it	  exists	  in	  a	  constitutively	  repressed	  monomeric	  state,	  we	  sought	  to	  use	  the	  yeast	  
assay	   system	   to	   better	   understand	   the	   complex	   mechanisms	   regulating	   HSF1	  
activity	  in	  mammalian	  cells.	  	  An	  important	  component	  of	  HSF1	  repression	  occurs	  
through	  the	  phosphorylation	  of	  serine	  303	  and	  serine	  307	  [17,	  18].	  	  Because	  S303	  
and	   S307	   are	   constitutively	   phosphorylated	   in	   mammalian	   cells	   and	   alanine	  
substitution	   of	   S303	   or	   S307	   promotes	   constitutive	   activation	   of	   HSF1	   in	  
mammalian	  cells	  in	  reporter	  assays	  [17,	  18]	  we	  tested	  whether	  S303	  and/or	  S307	  
contribute	  to	  HSF1	  repression	  in	  yeast.	   	  Wild-­‐type	  HSF1	  or	  the	  individual	  S303A,	  
S307A	  or	  S303/307A	  double	  mutants	  were	  expressed	  in	  yeast	  strain	  PS145	  which	  
lacks	   a	   chromosomal	   copy	   of	   the	   essential	   yeast	   HSF	   gene	   and	   constitutively	  
expresses	   yeast	   HSF	   episomally	   from	   a	   galactose	   inducible	   and	   dextrose	  
repressible	  promoter	  [31].	  	  When	  PS145	  is	  grown	  in	  the	  presence	  of	  dextrose	  as	  
the	  sole	  carbon	  source,	  yeast	  HSF	  expression	  is	  extinguished	  and	  growth	  becomes	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solely	   dependent	   on	  HSF1	  which	   is	   episomally	   expressed	   [28].	   	  While	  wild-­‐type	  
human	  HSF1	  was	  unable	  to	  complement	  for	  the	  loss	  of	  yeast	  HSF,	  expression	  of	  
the	   S303A,	   S307A	   or	   S303/307A	   HSF1	   mutants	   allowed	   for	   human	   HSF1-­‐
dependent	   yeast	   growth	   (Figure	   1A,	   B).	   	   Interestingly,	   the	   S303/307A	   double	  
HSF1	  mutant	  did	  not	  display	  enhanced	  activity	  over	  the	  S303A	  mutant	  (Figure	  1B)	  
suggesting	   that	   phosphorylation	   of	   both	   S303	   and	   S307	   modulate	   HSF1	  
repression	  through	  similar	  mechanisms.	  
To	   ascertain	   whether	   HSF1	   is	   being	   phosphorylated	   in	   yeast,	   we	   employed	   a	  
commercially	  available	  antibody	  specific	  for	  phospho-­‐S303	  (pS303).	  	  Because	  this	  
antibody	   has	   not	   previously	   been	   characterized	   in	   the	   literature,	   we	   tested	   its	  
specificity	   in	   human	   HeLa	   cells	   where	   S303	   is	   known	   to	   be	   constitutively	  
phosphorylated	  [17].	  	  As	  shown	  in	  Figure	  1C,	  using	  this	  antibody	  we	  detected	  that	  
endogenous	  HSF1	  was	  constitutively	  phosphorylated	  in	  HeLa	  cells	  in	  the	  absence	  
of	  stress.	  	  We	  also	  observed	  an	  increase	  in	  S303	  phosphorylation	  in	  response	  to	  a	  
heat	  shock,	  which	  correlated	  with	  previous	  reports	  [16].	  	  Importantly,	  the	  pS303-­‐
specific	   antibody	   did	   not	   detect	   HSF1	   when	   HeLa	   extracts	   were	   treated	   with	  
lambda	  protein	  phosphatase	  prior	  to	  immunoblot	  analysis	  (Figure	  1C),	  nor	  does	  it	  
detect	  HSF1	  when	  S303	   is	  mutated	   to	  alanine	   (Figure	  1D).	  Together,	   these	  data	  
suggest	  that	  the	  antibody	  is	  specific	  for	  HSF1	  that	  is	  phosphorylated	  on	  S303.	  	  The	  
detection	  of	  HSF1	  using	  a	  polyclonal	  anti-­‐HSF1	  antibody	  demonstrates	  that	  there	  
are	  no	  significant	  differences	  in	  the	  steady	  state	  levels	  of	  HSF1	  either	  treated	  or	  
untreated	  with	  lambda	  phosphatase	  (Figure	  1C).	  
Consistent	  with	  a	  contribution	  to	  HSF1	  repression	  (Figure	  1A,	  B)	  S303	  is	  robustly	  
phosphorylated	   when	   HSF1	   is	   expressed	   in	   yeast	   (Figure	   1D,	   E).	   	   Interestingly,	  
phosphorylation	   of	   S303	   was	   also	   observed	   when	   the	   S307A	   mutant	   was	  
expressed	  in	  yeast	  though	  it	  was	  reduced	  by	  approximately	  50%	  when	  compared	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to	   wild-­‐type	   HSF1	   (Figure	   1D,	   E).	   	   While	   this	   observation	   supports	   a	   previous	  
report	   indicating	   that	   S303	   phosphorylation	   could	   occur	   independently	   of	   S307	  
phosphorylation	   in	   mammalian	   cells	   [16],	   these	   data	   also	   suggests	   that	   under	  
certain	   circumstances	   S303	   phosphorylation	   may	   be	   enhanced	   by	   S307	  
phosphorylation.	   	   In	   addition,	   although	   a	   correlation	   between	   S303	   and	   S307	  
phosphorylation	  and	  HSF1	  protein	  stability	  has	  not	  been	  previously	  reported,	  we	  
repeatedly	   observed	   two	   to	   three-­‐fold	   higher	   steady	   state	   levels	   of	  HSF1	  when	  
the	  S303A,	  S307A	  and	  S303/307A	  mutants	  were	  expressed	  in	  yeast	  (Figure	  1D,	  F).	  	  
While	  an	  antibody	  specific	   for	  phospho-­‐S307	   is	  commercially	  available,	  we	  have	  
been	  unable	  to	  detect	  S307	  phosphorylation	  of	  human	  HSF1.	  	  As	  such	  we	  focused	  
our	  investigation	  on	  S303-­‐phosphorylation	  dependent	  repression	  of	  human	  HSF1.	  
Human	  HSF1	   S303	   phosphorylation	   is	   known	   to	   promote	   sumoylation	   of	   lysine	  
298,	  which	  also	  contributes	  to	  the	  repression	  of	  HSF1	  activity	  [16].	  	  Therefore,	  to	  
further	  investigate	  the	  idea	  that	  human	  HSF1	  is	  being	  actively	  repressed	  in	  yeast,	  
we	  explored	  the	  possibility	  that	  K298,	  like	  S303,	  contributes	  to	  HSF1	  repression	  in	  
yeast.	   	   However,	   unlike	   the	   S303A	   HSF1	   mutant,	   the	   K298R	   mutant	   did	   not	  
promote	   HSF1-­‐dependent	   growth	   (Figure	   1E),	   suggesting	   that	   at	   least	   in	   yeast,	  
K298	   does	   not	   significantly	   contribute	   to	   HSF1	   repression.	   	   We	   also	   did	   not	  
observe	   a	   reduction	   in	   human	   HSF1-­‐dependent	   yeast	   growth	   for	   the	  
S303A/K298R	  double	  mutant,	   indicating	   that	  K298	   is	  also	  not	   required	   for	  HSF1	  
activity	  in	  yeast	  (Figure	  1E).	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Figure	  1.	  S303	  phosphorylation	  represses	  HSF1	  activity	  in	  yeast.	  (A)	  PS145	  yeast	  
strains	   expressing	   wild-­‐type	   HSF1	   [18]	   or	   the	   S303A,	   S307A	   or	   S303/307A	  
mutants	  were	  plated	  on	  either	  galactose	  or	  dextrose	  supplemented	  medium.	  	  (B)	  
PS145	  expressing	  either	  wild-­‐type	  HSF1	  or	  the	  S303A	  or	  S303/307A	  mutants	  were	  
grown	   in	   dextrose	   containing	   medium	   for	   4	   d.	   Growth	   was	   monitored	   by	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measuring	  O.D.600.	  (C)	  HeLa	  cells	  were	  grown	  at	  37˚C	  (C)	  or	  heat	  shocked	  for	  2	  h	  
at	   42˚C	   (HS).	   	   Total	   protein	   extracts	   were	   treated	   with	   lambda	   protein	  
phosphatase	   and	   analyzed	   for	   phospho-­‐S303	   (pS303)	   and	   total	   HSF1	   levels	   by	  
immunoblotting.	  (D)	  PS145	  was	  transformed	  with	  a	  plasmid	  expressing	  wild-­‐type	  
HSF1	  [18]	  or	  mutant	  alleles	  of	  HSF1	  and	  grown	  on	  galactose	  containing	  medium.	  	  
Total	   protein	   extracts	   were	   analyzed	   for	   pS303,	   HSF1	   and	   Pgk1	   by	  
immunoblotting.	  (E)	  Levels	  of	  HSF1	  phosphorylated	  at	  S303	  were	  quantified	  and	  
are	   shown	   as	   a	   percent	   of	   total	   HSF1,	   from	   panel	   D.	   (F)	   Protein	   levels	   of	   HSF1	  
were	   normalized	   to	   Pgk1,	   from	  panel	  D.	   	   (G)	   PS145	   expressing	   either	  wild-­‐type	  
HSF1	  or	  mutant	  HSF1	  alleles	  were	  assayed	  for	  HSF1-­‐dependent	  growth	  as	  in	  B.	  
	  
S303	  represses	  trimer	  formation	  of	  HSF1	  in	  yeast	  and	  mammalian	  cells	  
Previous	   reports	   have	   suggested	   that	   phosphorylation	   of	   S303	   represses	   the	  
ability	  of	  HSF1	  to	  transactivate	  gene	  expression	  [18,	  22,	  23].	  	  Here	  we	  show	  that	  
the	   HSF1	   S303A	   mutant	   functionally	   complements	   for	   the	   lost	   of	   yeast	   HSF	  
(Figure	   1A,	   B).	   	   Based	   on	   our	   previous	   work	   this	   indicates	   that	   S303	  
phosphorylation	  might	  also	  regulate	  the	  ability	  of	  human	  HSF1	  to	  homotrimerize	  
[25].	   To	   test	   this	   hypothesis	   we	   carried	   out	   EGS	   cross-­‐linking	   experiments	   in	  
conjunction	   with	   immunoblot	   analysis	   to	   ascertain	   if	   S303	   phosphorylation	  
regulates	  the	  homotrimerization	  of	  human	  HSF1	  in	  yeast.	  	  When	  the	  S303A	  HSF1	  
mutant	  was	  expressed	  in	  yeast	  we	  detected	  approximately	  2-­‐fold	  higher	  levels	  of	  
trimerized	  HSF1	  at	  the	  intermediate	  EGS	  concentration	  than	  when	  wild-­‐type	  HSF1	  
was	   expressed	   in	   yeast	   (Figure	   2A).	   	   However,	   trimerization	   of	   the	   S303A	  HSF1	  
mutant	   was	   lower	   than	   trimerization	   of	   the	   LZ4	   HSF1	   mutant,	   previously	  
demonstrated	   to	  be	   constitutively	   trimerized	   in	   yeast	   and	  mammalian	   cells	   and	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able	  to	  complement	  for	  the	  loss	  of	  yeast	  HSF	  [6,	  25].	  We	  observed	  similar	  results	  
for	  the	  S307A	  and	  S303/307A	  HSF1	  mutants	  (data	  not	  shown)	  further	  supporting	  
the	   notion	   that	   S303	   and	   S307	   phosphorylation	   repress	   HSF1	   activity	   through	  
similar	   mechanisms.	   We	   next	   evaluated	   whether	   HSF1	   S303	   phosphorylation	  
could	  also	  function	  to	  repress	  homotrimer	  formation	  in	  mammalian	  cells.	  	  To	  test	  
this	  hypothesis	  we	  expressed	  wild-­‐type	  HSF1	  or	  the	  S303A,	  S307A	  or	  S303/307A	  
mutants	   in	  hsf1-­‐/-­‐	  mouse	  embryonic	   fibroblasts	   (MEF)	   [29]	  and	  assayed	  for	  HSF1	  
trimerization	   in	   the	   absence	   of	   thermal	   stress	   by	   EGS	   crosslinking	   and	  
immunoblotting.	  	  While	  wild	  type	  HSF1	  could	  be	  detected	  as	  a	  multimer	  in	  these	  
extracts,	  we	  observed	  approximately	  2-­‐fold	  higher	   levels	  of	   the	  HSF1	   trimer	   for	  
the	  HSF1	  S303A	  mutant	  (Figure	  2B)	  as	  well	  as	  the	  S307A	  and	  S303/307A	  mutants	  
(data	  not	  shown).	  	  
	  
Deciphering	  Human	  Heat	  Shock	  Transcription	  Factor	  1	  Regulation	  Via	  Post-­‐Translational	  
Modification	  In	  Yeast	  
	  	   91	  
	  
Figure	   2.	   S303	   represses	   trimer	   formation	   of	   HSF1	   in	   yeast	   and	   mammalian	  
cells.	   (A)	   PS145	  was	   transformed	  with	  wild-­‐type	  HSF1,	   the	   LZ4m	  mutant	   or	   the	  
S303A	  mutant	  and	  grown	  on	  galactose	  containing	  medium.	  	  Total	  protein	  extracts	  
were	   evaluated	   for	   HSF1	   multimerization	   by	   EGS	   crosslinking,	   SDS-­‐PAGE,	   and	  
immunoblotting	   using	   an	   HSF1	   specific	   antibody.	   The	   positions	   of	   molecular	  
weight	   markers	   are	   indicated	   on	   the	   left,	   and	   circles	   indicating	   the	   expected	  
migration	  of	  HSF1	  monomers	  and	  trimers	  are	  on	  the	  right.	  	  Levels	  of	  HSF1	  trimer	  
as	  percent	  of	  total	  HSF1	  are	  shown	  below.	  (B)	  hsf1-­‐/-­‐	  MEFs	  were	  transfected	  with	  
a	  plasmid	  expressing	  wild-­‐type	  HSF1	  or	  the	  S303A	  mutant	  and	  analyzed	  for	  HSF1	  
multimerization	  by	  EGS	  cross-­‐linking	  as	  in	  A.	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S303	  phosphorylation	  and	  coiled-­‐coil	  interactions	  synergize	  in	  HSF1	  repression.	  	  	  
In	  addition	  to	  post-­‐translational	  modifications,	  HSF1	  activity	  is	  also	  thought	  to	  be	  
repressed	   through	   intramolecular	   interactions	   between	   carboxyl-­‐	   and	   amino-­‐
terminal	   coiled-­‐coil	   domains	   and	   mutations	   in	   these	   domains	   render	   HSF1	  
constitutively	  trimerized,	  nuclear	  localized	  and	  bound	  to	  DNA	  in	  mammalian	  cells	  
[6].	   	  Because	  our	   results	   suggest	   that	  S303	  phosphorylation	  might	  also	   regulate	  
homotrimer	  formation,	  we	  tested	  the	  combined	  affects	  of	  both	  the	  S303A	  as	  well	  
as	   the	  LZ4m	  mutations	  on	  human	  HSF1	  activity	   in	  yeast.	  A	  human	  HSF1	  mutant	  
containing	   both	   the	   S303A	   and	   LZ4m	  mutations	   was	   created	   and	   its	   ability	   to	  
promote	  human	  HSF1-­‐dependent	   yeast	   growth	  was	   compared	   to	   the	   individual	  
HSF1	  mutants	  as	  well	  as	  wild-­‐type	  HSF1	   in	  quantitative	  cell	  growth	  assays.	   	  The	  
individual	   S303A	   and	   LZ4m	   HSF1	   mutants	   promoted	   human	   HSF1-­‐dependent	  
yeast	  growth	  to	  a	  similar	  extent,	   though	  neither	   the	  LZ4m	  nor	   the	  S303	  mutant	  
were	   fully	   derepressed,	   as	   the	   S303A/LZ4m	  double	  mutant	   displayed	   enhanced	  
human	   HSF1-­‐dependent	   yeast	   growth	   (Figure	   3A).	   	   While	   we	   currently	   do	   not	  
know	   if	   the	   S303A/LZ4m	   double	   HSF1	   mutant	   has	   an	   increased	   propencity	   to	  
trimerize,	  previous	  studies	  have	  shown	  that	  the	  LZ4m	  mutant,	  when	  expressed	  in	  
yeast	   is	  not	  maximally	   trimerized	  and	  trimerization	  can	  be	   further	  enhanced	  via	  
the	  addition	  of	  pharmacological	  HSF1	  activators	  [28].	  	  While	  we	  observed	  higher	  
steady	  state	  protein	   levels	  for	  both	  the	  S303A	  and	  LZ4m	  mutants	   in	  comparison	  
to	  wild-­‐type	  HSF1	  when	  expressed	  in	  yeast,	  no	  further	  increases	  in	  protein	  levels	  
were	  observed	  for	  the	  double	  mutant	  (Figure	  3B,	  C).	   	  These	  results	  suggest	  that	  
while	   both	   HSF1	   S303	   phosphorylation	   and	   coiled-­‐coil	   interactions	   regulate	  
human	  HSF1	  multimerization	   in	   yeast,	   they	  do	   so	   via	  distinct	  mechanisms.	   	  We	  
also	   did	   not	   observe	   changes	   in	   HSF1	   S303	   phosphorylation	   when	   the	   LZ4m	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mutant	   was	   expressed	   in	   yeast,	   consistent	   with	   the	   notion	   that	   HSF1	  
trimerization	  does	  not	  affect	  HSF1	  S303	  phosphorylation.	  	  
	  
	  
	  
Figure	   3.	   Phosphorylation	   of	   S303	   and	   coiled-­‐coil	   domains	   synergize	   in	   the	  
repression	   of	   HSF1	   in	   yeast.	   (A)	   PS145	   expressing	   either	   wild-­‐type	   HSF1	   or	  
mutant	   alleles	   of	  HSF1	  were	   grown	   in	   dextrose	   supplemented	  medium	   for	   4	   d.	  
Growth	  was	  monitored	  by	  measuring	  O.D.600.	   (B)	  PS145	  was	  transformed	  with	  a	  
plasmid	  expressing	  wild-­‐type	  HSF1	   [18]	  or	  mutant	  alleles	  of	  HSF1	  and	  grown	  on	  
galactose	   containing	  medium.	   	   Total	   protein	   extracts	   were	   analyzed	   for	   pS303,	  
total	   HSF1	   and	   Pgk1	   by	   immunoblotting.	   (C)	   Protein	   levels	   of	   HSF1	   were	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normalized	   to	   Pgk1,	   from	   panel	   B.	   (D)	   Levels	   of	   HSF1	   phosphorylated	   at	   S303	  
were	  quantified	  and	  are	  shown	  as	  a	  percent	  of	  total	  HSF1,	  from	  panel	  B.	  
	  
Gsk3	   regulates	   human	   HSF1	   activity	   in	   yeast	   independent	   of	   S303	  
phosphorylation.	  	  	  
Previous	  reports	  using	   in	  vitro	  phosphorylation	  experiments	  have	  suggested	  that	  
HSF1	  is	  phosphorylated	  at	  S303	  by	  glycogen	  synthase	  kinase	  3	  (GSK3)	  [20,	  22,	  32].	  	  
However,	  it	  remains	  unclear	  if	  GSK3	  phosphorylates	  and	  represses	  HSF1	  via	  S303	  
phosphorylation	   in	   vivo.	   	   To	   test	   if	   GSK3	   contributes	   to	   HSF1	   repression,	   we	  
assayed	  human	  HSF1-­‐dependent	   yeast	   growth	   in	   a	   strain	   also	   lacking	   the	   yeast	  
GSK3	  homolog	  Rim11.	  	  Supporting	  the	  notion	  that	  yeast	  GSK3	  can	  repress	  human	  
HSF1	  activity	  in	  yeast	  we	  observed	  human	  HSF1-­‐dependent	  yeast	  growth	  as	  well	  
as	   HSF1	   multimerization	   in	   the	   rim11∆	  strain	   (Figure	   4A,	   B).	   	   However,	   HSF1-­‐
dependent	   yeast	   growth	   in	   the	   rim11∆	   strain	  was	   less	   robust	   than	   growth	  of	   a	  
wild-­‐type	   strain	   expressing	   the	   S303A	   HSF1	   mutant	   (Figure	   4A).	   	   Furthermore,	  
when	  we	   expressed	   the	   S303A	  HSF1	  mutant	   in	   the	   rim11∆	   strain	  we	   observed	  
HSF1-­‐dependent	  growth	  at	  a	   rate	   similar	   to	   the	  growth	  of	   the	  S303A	  mutant	   in	  
wild-­‐type	   cells.	   	   This	   suggested	   the	   possibility	   that	   HSF1	   might	   not	   be	   fully	  
derepressed	  in	  the	  rim11∆	  strain.	  	  Consistent	  with	  this	  idea,	  we	  did	  not	  detect	  a	  
reduction	  in	  S303	  phosphorylation	  in	  the	  rim11∆	  strain	  (Figure	  4C).	  	  S.	  cerevisiae	  
encodes	   four	   separate	   yet	   partially	   functionally	   redundant	   GSK3	   homologues	  
[33],	   suggesting	   the	  possibility	   that	  S303	   remains	  phosphorylated	   in	   the	  rim11∆	  
strain	   due	   to	   phosphorylation	   through	   other	   GSK3	   proteins.	   	   To	   test	   this	  
hypothesis	  we	  assayed	  the	  phosphorylation	  state	  of	  HSF1	  at	  S303	  in	  a	  yeast	  strain	  
lacking	  all	   four	   isoforms	  of	  yeast	  GSK3.	   	  As	   shown	   in	  Figure	  4D,	  no	   reduction	   in	  
S303	  phosphorylation	  was	  observed	   in	   the	  4xgsk3∆	  strain	   suggesting	   that	  while	  
Deciphering	  Human	  Heat	  Shock	  Transcription	  Factor	  1	  Regulation	  Via	  Post-­‐Translational	  
Modification	  In	  Yeast	  
	  	   95	  
yeast	  GSK3	  does	  contribute	  to	  HSF1	  repression,	  it	  does	  so	  independently	  of	  S303	  
phosphorylation.	  
	  
	  
	  
Figure	  4.	  GSK3	  represses	  HSF1	  activity	  in	  yeast	  independent	  of	  S303.	  (A)	  PS145	  
[18]	   expressing	   wild-­‐type	   HSF1	   or	   the	   S303A	   HSF1	   mutant	   and	   LNY1	   (rim11∆)	  
expressing	  wild-­‐type	  HSF1	  were	  grown	   in	  dextrose	  supplemented	  medium	  for	  4	  
d.	  Growth	  was	  monitored	  by	  measuring	  O.D.600.	  (B)	  PS145	  [18]	  and	  LNY1	  (rim11∆)	  
expressing	  wild-­‐type	  HSF1	  were	  grown	  on	  galactose	  containing	  medium	  and	  were	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evaluated	   for	   HSF1	   multimerization	   by	   EGS	   crosslinking,	   SDS-­‐PAGE,	   and	  
immunoblotting	   using	   an	   HSF1	   specific	   antibody.	   The	   positions	   of	   molecular	  
weight	   markers	   are	   indicated	   on	   the	   left,	   and	   circles	   indicating	   the	   expected	  
migration	  of	  HSF1	  monomers	  and	  trimers	  are	  on	  the	  right.	  Levels	  of	  HSF1	  trimer	  
as	  percent	  of	  total	  HSF1	  are	  shown	  below.	  (C)	  PS145	  [18]	  and	  LNY1	  (rim11∆)	  were	  
transformed	   with	   a	   plasmid	   expressing	   wild-­‐type	   HSF1	   and	   were	   grown	   on	  
galactose	   containing	  medium.	   	   Total	   protein	   extracts	  were	   analyzed	   for	   pS303,	  
total	   HSF1	   and	   Pgk1	   by	   immunoblotting.	   (D)	   YPH499	   [18]	   and	   LNY3	   (4xgsk3∆)	  
were	   transformed	  with	  a	  plasmid	  expressing	  wild-­‐type	  HSF1	  and	  were	  grown	   in	  
dextrose	   containing	   medium.	   	   Total	   protein	   extracts	   were	   analyzed	   for	   pS303,	  
total	  HSF1	  and	  Pgk1	  by	  immunoblotting.	  	  
	  
Results	  shown	  here	  for	  the	  S303A	  HSF1	  mutant	  and	  previously	  published	  for	  the	  
LZ4m	  HSF1	  mutant	   suggest	   that	  mechanisms	   that	   regulate	  HSF1	   in	  mammalian	  
cells	  are	  at	  least	  partially	  conserved	  with	  regulation	  of	  human	  HSF1	  expressed	  in	  
yeast	  cells.	  	  Therefore,	  we	  carried	  out	  experiments	  to	  ascertain	  if	  GSK3	  might	  also	  
repress	   HSF1	   independently	   of	   S303	   phosphorylation	   in	   mammalian	   cells.	   	   To	  
explore	  this	  possibility	  HeLa	  cells	  were	  treated	  with	  the	  GSK3	  inhibitor	  SB-­‐216763	  
[34]	   and	   assayed	   for	   HSF1	   S303	   phosphorylation	   as	   ascertained	   by	  
immunoblotting	   with	   the	   anti-­‐pS303	   antibody.	   	   While	   SB-­‐216763	   treatment	  
strongly	   inhibited	  GSK3	   activity	   as	   shown	  by	   increased	  β-­‐catenin	   levels	   [35],	   no	  
reduction	  in	  S303	  phosphorylation	  was	  observed	  (Figure	  5A).	  	  However,	  similar	  to	  
the	   results	   obtained	   from	   our	   yeast	   experiments,	   SB-­‐216763	   did	   promote	  
activation	   of	   HSF1	   under	   normal	   growth	   conditions,	   as	   determined	   by	  
immunoblot	   analysis	   of	   Hsp70	   expression	   (Figure	   5A).	   	   This	   result	   is	   consistent	  
with	  a	  previous	  report	  showing	  increased	  Hsp70	  expression	  in	  response	  to	  lithium	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treatment,	  which	  also	   inhibits	  GSK3	   function	   [36].	   	   siRNA	  mediated	  knock-­‐down	  
of	   the	   two	   GSK3	   isoforms	   in	   mammals,	   GSK3α	   and	   GSK3β,	   either	   singly	   or	   in	  
combination,	   further	   confirmed	   that,	   while	   β-­‐catenin	   expression	   was	   elevated,	  
HSF1	   S303	   was	   not	   appreciably	   phosphorylated	   by	   GSK3	   in	   unstressed	  
mammalian	  cells	  (Figure	  5B).	  Together,	  data	  from	  experiments	  in	  both	  yeast	  and	  
mammalian	  cells	  support	  a	  model	  in	  which	  GSK3	  inhibits	  HSF1	  activity	  through	  a	  
mechanism	  that	  is	  independent	  of	  S303	  phosphorylation.	  
	  
	  
Figure	   5.	   GSK3	   represses	   HSF1	   activity	   in	   HeLa	   cells	   independent	   of	   S303	  
phosphorylation.	   (A)	   HeLa	   cells	   were	   treated	   with	   DMSO	   solvent	   or	   the	   GSK3	  
inhibitor	  SB-­‐216763	  (25	  µM)	  for	  15	  h.	  Total	  protein	  was	  analyzed	  for	  pS303,	  HSF1,	  
and	   β-­‐catenin	   by	   immunoblotting.	  GAPDH	   serves	   as	   a	   loading	   control.	   (B)	   HeLa	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cells	  were	  treated	  with	  siRNA	  specific	  for	  GSK3α	  and	  GSK3β	  either	  individually	  or	  
together	   or	   a	   scrambled	   siRNA	   for	   72h.	   	   Total	   protein	  was	   analyzed	   for	   pS303,	  
total	  HSF1,	  β-­‐catenin,	  GSK3α/β	  and	  GAPDH	  by	  immunoblotting.	  
	  
Slt2	  represses	  human	  HSF1	  activity	  via	  S303	  phosphorylation	  in	  yeast.	  	  	  
To	  begin	  to	   identify	  which	  protein	  kinase(s)	   in	  yeast	  phosphorylate	  human	  HSF1	  
at	  S303	  to	  promote	  HSF1	  repression,	  we	  assayed	  S303	  phosphorylation	  in	  several	  
previously	   generated	   protein	   kinase	   deletion	   strains	   obtained	   from	   the	   yeast	  
gene	  deletion	  collection	  [37].	  One	  strain	   in	  which	  we	  detected	  severely	  reduced	  
levels	   of	   human	   HSF1	   S303	   phosphorylation	   was	   a	   strain	   deleted	   for	   the	   SLT2	  
gene,	   encoding	   a	   stress-­‐responsive	   MAPK	   [38,	   39],	   consistent	   with	   S303	   lying	  
within	   a	   consensus	   site	   for	  MAPK-­‐dependent	   phosphorylation	   (Figure	   6A)	   [40].	  
This	  suggests	  that	  Slt2	  either	  directly	  or	  indirectly	  promotes	  the	  phosphorylation	  
of	  human	  HSF1	  expressed	  in	  yeast.	  	  This	  hypothesis	  was	  further	  supported	  by	  the	  
observation	  that	  an	  slt2∆	  strain	  allowed	  wild	  type	  human	  HSF1-­‐dependent	  yeast	  
growth	   at	   a	   rate	   similar	   to	   the	   HSF1	   S303A	   mutant,	   while	   no	   growth	   was	  
observed	  in	  the	  SLT2	  wild-­‐type	  strain	  (Figure	  6B).	  	  Homotrimerization	  of	  wild-­‐type	  
human	  HSF1	  was	  observed	   in	   the	  slt2∆	  strain	  at	   levels	  similar	   to	   the	  S303A	  and	  
LZ4m	  HSF1	  mutants,	  further	  supporting	  the	  notion	  that	  the	  Slt2	  MAPK	  represses	  
human	  HSF1	  multimerization	   in	   yeast	   (Figure	   6C).	   In	  mammalian	   cells	   the	  most	  
closely	   related	  homolog	  of	   Slt2	   is	   the	  MAPK	   ERK5	   [41].	   	   However,	   using	   siRNA-­‐
mediated	  knock-­‐down	  of	  ERK5	  we	  were	  unable	  detect	  an	  effect	  of	  ERK5	  on	  HSF1	  
S303	   phosphorylation	   in	  mammalian	   cells	   (data	   not	   shown).	   	   This	  may	   suggest	  
that	   in	  mammalian	   cells	   S303	   can	   be	   phosphorylated	   by	  multiple	  MAPKs.	   	   This	  
hypothesis	   is	   supported	   by	   previous	   data	   showing	   that	   ERK1/2	   as	   well	   as	   the	  
stress-­‐responsive	  MAPK	  p38	  could	  phosphorylate	  HSF1	  at	   S303	   in	   vitro	   [18].	   	   In	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addition,	  our	  data	  showing	  reduced,	  but	  not	  eliminated	  phosphorylation	  of	  S303	  
in	   the	   slt2∆	   strain	   (Figure	   6A)	   also	   support	   a	   model	   where	   S303	   may	   be	  
phosphorylated	  by	  multiple	  MAPKs.	  	  
	  
	  
Figure	  6.	  S303	  phosphorylation	  of	  HSF1	  in	  yeast	  is	  modulated	  by	  Slt2.	  (A)	  PS145	  
and	  LNY2	  (slt2∆)	  were	  transformed	  with	  a	  plasmid	  expressing	  wild-­‐type	  HSF1	  and	  
were	   grown	   on	   galactose	   containing	   medium.	   	   Total	   protein	   extracts	   were	  
Deciphering	  Human	  Heat	  Shock	  Transcription	  Factor	  1	  Regulation	  Via	  Post-­‐Translational	  
Modification	  In	  Yeast	  
	  	  100	  
analyzed	   for	   pS303,	   total	   HSF1	   and	   Pgk1	   by	   immunoblotting.	   (B)	   PS145	   [18]	  
expressing	  wild-­‐type	  HSF1	  or	  the	  S303A	  mutant	  or	  LNY2	  (slt2∆)	  expressing	  wild-­‐
type	  HSF1	  were	   grown	   in	  dextrose	   supplemented	  medium	   for	   4	  d.	  Growth	  was	  
monitored	   by	  measuring	   O.D.600.	   (C)	   PS145	   [18]	   expressing	  wild-­‐type	   HSF1,	   the	  
LZ4m	   mutant	   or	   the	   S303A	   mutant	   and	   LNY2	   (slt2∆)	   expressing	   HSF1	   were	  
evaluated	   for	   HSF1	   multimerization	   by	   EGS	   cross-­‐linking,	   SDS-­‐PAGE,	   and	  
immunoblotting.	  The	  positions	  of	  molecular	  weight	  markers	  are	  indicated	  on	  the	  
left	  and	  circles	  indicating	  the	  expected	  migration	  of	  HSF1	  monomers	  and	  trimers	  
are	  on	  the	  right.	  	  Levels	  of	  HSF1	  trimer	  as	  percent	  of	  total	  HSF1	  are	  shown	  below.	  
	  
Expression	   of	   S303A	   and	   S307A	  mutants	   in	   hsf1	   -­‐/-­‐	   cells	   results	   in	   constitutive	  
activation	  of	  Hsp70	  expression.	  	  	  
Previous	  studies	  have	  assayed	  the	  function	  of	  S303	  and	  S307	  phosphorylation	  in	  
HSF1	   regulation	   via	   in	   vitro	   phosphorylation	   experiments	   [22],	   in	   vivo	   using	  
lexA/Gal4-­‐HSF1	  fusion	  proteins	  lacking	  the	  native	  HSF1	  DNA	  binding	  domain	  [17,	  
18]	  or	  via	  overexpression	  of	  a	  S303A	  HSF1	  mutants	  in	  mammalian	  cells	  expressing	  
endogenous	  wild-­‐type	  HSF1	   [16].	   	  We	   tested	   the	   consequences	   of	   loss	   of	   S303	  
and	   S307	   phosphorylation	   on	  HSF1	   activity	   in	   the	   context	   of	   the	   entire	   protein	  
using	   hsf1-­‐/-­‐	   MEFs,	   which	   lack	   endogenous	   HSF1.	   	   When	   we	   expressed	   S303A,	  
S307A	   or	   S303/307A	   HSF1	   mutants	   in	   hsf1-­‐/-­‐	   MEFs	   we	   observed	   a	   modest	  
elevation	   of	   Hsp70	   expression	   under	   normal	   growth	   conditions	   (Figure	   7A,	   B)	  
consistent	   with	   the	   hypothesis	   that	   S303	   phosphorylation	   modulates	   both	  
homotrimerization	   as	  well	   as	   transactivation	   by	  HSF1.	   	   However,	   HSF1	  was	   not	  
fully	  activated	  through	  the	  S303A	  and	  S307A	  mutations,	  as	  expression	  of	  Hsp70	  
was	   further	  enhanced	  when	  the	   transfected	  cells	  were	  exposed	  to	   low	   levels	  of	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the	  proteasome	  inhibitor	  MG132	  (Figure	  7A,	  B).	  	  This	  is	  consistent	  with	  our	  data	  
generated	   in	   yeast	   demonstrating	   that	   while	   the	   S303A	   mutation	   did	   activate	  
human	   HSF1-­‐dependent	   yeast	   growth,	   this	   was	   further	   enhanced	   when	   the	  
S303A	   HSF1	   mutant	   was	   combined	   with	   the	   LZ4m	   mutation	   (Figure	   3A).	  
Interestingly,	  in	  hsf1-­‐/-­‐	  cells	  we	  observed	  a	  faster	  electrophoretic	  mobility	  on	  SDS-­‐
PAGE	   gels	   for	   the	   HSF1	   S303A	   and	   S303/307A	   mutant	   proteins	   that	   was	   not	  
observed	  for	  wild-­‐type	  HSF1	  or	  the	  S307A	  mutant	  (Figure	  7A),	  nor	  did	  we	  observe	  
this	  change	   in	  mobility	   in	  the	  yeast	  system	  (Figure	  1D).	  While	  the	  nature	  of	   this	  
electrophoretic	   mobility	   shift	   is	   unknown,	   the	   HSF1	   S303A	   and	   S303/S307A	  
mutant	  alleles	  also	  exhibited	  lower	  steady	  state	  levels	  when	  exposed	  to	  MG132,	  
suggesting	   that	   these	   proteins,	   despite	   having	   increased	   activity,	  might	   be	   less	  
stable	   (Figure	   7A,	   C).	   Because	   S303	   phosphorylation	   has	   been	   proposed	   to	  
promote	   HSF1	   sumoylation	   in	   mammalian	   cells	   [16]	   it	   is	   possible	   that	   lack	   of	  
sumoylation	  results	  in	  the	  altered	  electrophoretic	  mobility.	  	  Despite	  the	  fact	  that	  
equal	  amounts	  of	  plasmid	  DNA	  were	   transfected	   for	  each	  mutant,	  we	  observed	  
elevated	   steady	   state	   protein	   levels	   for	   the	   HSF1	   S307A	  mutant	   (Figure	   7A,	   C).	  	  
While	  we	  have	  not	  definitively	  demonstrated	  that	  the	  S307A	  mutant	  protein	  has	  
increased	   stability	   in	   comparison	   to	  wild-­‐type	  HSF1,	   this	   finding	   correlates	  with	  
the	  increased	  protein	  levels	  we	  observed	  for	  the	  HSF1	  mutants	  expressed	  in	  yeast	  
(Figure	   1D,	   F)	   and	   will	   require	   further	   investigation.	   	   Interestingly,	   when	   we	  
expressed	  the	  HSF1	  S307A	  mutant	  in	  hsf1-­‐/-­‐	  cells	  we	  did	  not	  observe	  a	  reduction	  
in	  S303	  phosphorylation	  (Figure	  7A,	  D)	  as	  was	  observed	  in	  yeast	  cells	  (Figure	  1D,	  
E)	  suggesting	  that	  priming	  requirements	  for	  S303	  phosphorylation	  may	  change	  in	  
different	  expression	  systems.	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Figure	   7.	   (A)	   hsf1-­‐/-­‐	   MEFs	   were	   transfected	   with	   an	   empty	   vector	   or	   plasmids	  
expressing	  wild-­‐type	  HSF1	  or	  the	  S303A,	  S307A	  or	  the	  S303/307A	  mutants.	   	  The	  
transfected	   cells	   were	   treated	   with	   DMSO	   solvent	   or	  MG132	   (10	   µM)	   for	   5	   h.	  	  
Total	   protein	   extracts	   were	   analyzed	   for	   Hsp70,	   pS303	   and	   HSF1	   by	  
immunoblotting.	   	  GAPDH	  serves	  as	  a	  loading	  control.	  (B)	  Protein	  levels	  of	  Hsp70	  
were	   normalized	   to	   GAPDH,	   from	   panel	   A.	   (C)	   Protein	   levels	   of	   HSF1	   were	  
normalized	  to	  GAPDH,	   from	  panel	  A.	   (D)	  Levels	  of	  HSF1	  phosphorylated	  at	  S303	  
were	  quantified	  and	  are	  shown	  as	  a	  percent	  of	  total	  HSF1,	  from	  panel	  A.	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Discussion	  
	  
Mammalian	   HSF1	   activity	   is	   regulated	   via	   complex	   regulatory	  mechanisms	   that	  
include	   post-­‐translation	   modifications	   as	   well	   as	   inter-­‐	   and	   intra-­‐molecular	  
protein-­‐protein	   interactions	   [2].	   	   While	   our	   understanding	   of	   these	   regulatory	  
mechanisms	  remains	  incomplete,	  earlier	  work	  has	  suggested	  that	  many	  of	  these	  
mechanisms	   may	   be	   conserved	   in	   yeast	   [25-­‐28].	   	   This	   is	   evident,	   in	   part,	   by	  
repression	   of	   the	   human	  HSF1	   protein	  when	   it	   is	   expressed	   in	   S.	   cerevisiae	   via	  
coiled-­‐coil	   domain	   and	   HSF1	   loop	   interactions.	   In	   this	   report	   we	   show	   that	  
evaluation	   of	   the	   mechanisms	   that	   regulate	   HSF1	   activity	   in	   yeast	   via	   post-­‐
translational	  modifications	   can	   lead	   to	   important	   insights	   into	   the	  mechanisms	  
that	  regulate	  HSF1	  in	  mammalian	  cells.	  
Previous	   experiments	   using	   HSF1	   fusions	  with	   the	   constitutively	   bound	  Gal4	   or	  
lexA	   DNA-­‐binding	   domains	   demonstrated	   that	   phosphorylation	   of	   S303	  
contributed	  to	  the	  repression	  of	  HSF1	  transactivation	  [17,	  18].	   	   In	  this	  report	  we	  
show	   that	   alanine	   substitution	   of	   S303,	   in	   the	   context	   of	   full	   length	   HSF1,	   also	  
results	   in	   increased	   levels	   of	   trimerized	   HSF1	   both	   in	   un-­‐stressed	   yeast	   and	   in	  
mammalian	  cells.	   	  This	  suggests	  that	  aside	  from	  repressing	  transactivation,	  S303	  
phosphorylation	   can	   also	   repress	   earlier	   points	   in	   the	  HSF1	   activation	  pathway.	  	  
Interestingly,	   we	   also	   show	   that	   repression	   of	   HSF1	   activity	   through	   S303	  
phosphorylation	   may	   occur	   independent	   of	   K298	   sumoylation	   in	   yeast,	   as	  
arginine	  substitution	  of	  K298	  does	  not	  promote	  HSF1	  activation	  in	  yeast.	  It	  should	  
be	  noted	  that	  not	  all	  of	  the	  mechanisms	  that	  regulate	  human	  HSF1	  in	  mammalian	  
cells	  are	  conserved	   in	  yeast.	   	  While	  human	  HSF1	   is	   repressed	   in	  both	  yeast	  and	  
mammalian	   cells	   through	   an	   amino-­‐terminal	   coiled-­‐coil	   as	   well	   as	   a	   carboxyl-­‐
terminal	   linker	   domain,	   the	   ability	   of	   wild	   type	   human	   HSF1	   to	   respond	   to	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proteotoxic	   compounds	  or	   thermal	   stress,	   for	   example,	   appears	   to	  be	   strikingly	  
absent	  in	  yeast	  [25,	  27,	  28].	  	  Nevertheless,	  the	  ability	  of	  S303	  phosphorylation	  to	  
promote	   repression	   of	   human	   HSF1	   in	   yeast	   independent	   of	   K298	   sumoylation	  
suggests	   that	   our	   understanding	   of	   the	   mechanisms	   by	   which	   S303	  
phosphorylation	  represses	  HSF1	  activity	  remains	  incomplete.	  	  S303	  and	  S307	  are	  
located	  in	  the	  regulatory	  domain	  of	  HSF1,	  a	  proposed	  binding	  site	  for	  the	  protein	  
chaperone	  Hsp90	  [42].	  	  As	  such,	  it	  is	  tempting	  to	  speculate	  that	  phosphorylation	  
of	  these	  residues	  might	  affect	  binding	  to	  Hsp90.	  
An	   understanding	   of	   how	   phosphorylation	   regulates	   HSF1	   activity	   and	   what	  
protein	   kinases	   phosphorylate	   HSF1	   remains	   largely	   incomplete	   [20,	   22].	   	   Early	  
reports	   showed	   that	   in	   vitro,	   HSF1	   S307	   phosphorylation	   acted	   as	   an	   essential	  
priming	   event	   for	   S303	   phosphorylation	   [22].	   	   However,	   a	   subsequent	   report	  
showed	   this	   priming	   event	   was	   not	   required	   in	   vivo	   and	   that	   HSF1	   S303	  
phosphorylation	   occurred	   independent	   of	   S307	   phosphorylation	   in	   K562	   cells	  
[16].	   	   The	   work	   presented	   here	   using	   the	   yeast	   model	   system	   furthers	   our	  
understanding	   of	   these	   regulatory	   mechanisms	   and	   may	   begin	   to	   clarify	   the	  
conflicting	  mechanisms	   underlying	   S303	   phosphorylation.	   	   Specifically,	   our	   data	  
suggest	   that	   while	   phosphorylation	   of	   S303	   can	   occur	   independently	   of	   S307	  
phosphorylation	   in	  both	   yeast	   and	  mammalian	   cells,	   S303	  phosphorylation	  may	  
be	  enhanced	  by	  S307	  phosphorylation	   in	   the	  non-­‐native	  yeast	   system.	   	  While	  a	  
mechanistic	   basis	   for	   this	   difference	   in	   the	   requirements	   for	   S303	  
phosphorylation	   remains	   unknown	  when	   HSF1	   is	   expressed	   in	   yeast,	   structural	  
differences	   could	   change	   the	   priming	   requirements	   for	   S303	   phosphorylation.	  	  
Such	   changes	   in	   HSF1	  might	   occur	   due	   to	   different	   protein	   interactions	   and	   as	  
such	  it	  is	  not	  surprising	  that	  in	  in	  vitro	  experiments,	  using	  only	  recombinant	  HSF1	  
protein,	   phosphorylation	   of	   S303	   is	   fully	   dependent	   on	   S307	   phosphorylation.	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However,	  further	  studies	  will	  be	  required	  to	  fully	  test	  these	  hypotheses.	  	  	  
Here,	  we	  demonstrate	  that	  in	  both	  yeast	  and	  mammalian	  cells	  phosphorylation	  of	  
HSF1	  S303	  appears	  to	  occur	  independently	  of	  GSK3,	  previously	  thought	  to	  be	  the	  
primary	   kinase	   responsible	   for	   S303	   phosphorylation	   [20,	   22].	   	   Rather,	   as	  
suggested	   by	   loss	   of	   function	   analysis,	   we	   propose	   that	   the	   MAPK	   Slt2	   is	   one	  
candidate	   that	   phosphorylates	   HSF1	   at	   S303	   in	   yeast	   though	   residual	  
phosphorylation	   of	   HSF1	   at	   S303	   in	   an	   slt2∆	   strain	   suggests	   that	   other	  MAPKs	  
may	   also	   contribute	   to	   S303	   phosphorylation.	   	   Differences	   in	   HSF1	   structure	  
between	  the	   in	  vivo	  and	   in	  vitro	   systems	  may	  also	  explain	  why	  different	  kinases	  
can	   target	   S303	   for	   phosphorylation	   under	   different	   conditions.	   	   We	   speculate	  
that	  under	  some	  cellular	  conditions,	  for	  example	  physiological	  stress	  or	  different	  
cell	   types,	   HSF1	   structure	   may	   be	   altered,	   thereby	   shifting	   the	   S303-­‐kinase	  
specificity	  from	  a	  MAPK	  to	  GSK3.	  	  This	  might,	  in	  part,	  contribute	  to	  the	  complexity	  
in	  identifying	  all	  of	  the	  mammalian	  kinases	  that	  phosphorylate	  S303.	  	  While	  GSK3	  
does	   not	   appear	   to	   phosphorylate	   HSF1	   at	   S303	   in	   vivo,	   data	   presented	   here	  
nevertheless	  support	  a	  role	  for	  GSK3	  as	  a	  repressor	  of	  HSF1	  activity.	  	  It	  should	  be	  
noted	  that	  several	  other	  serine	  residues	   in	   the	  HSF1	  coding	  sequence,	   including	  
S307,	  are	  located	  within	  putative	  GSK3	  consensus	  sites	  [40].	  
The	   importance	   in	   understanding	   HSF1	   regulation	   is	   underscored	   by	   recent	  
findings	   showing	   that	   pharmacological	   activation	   of	   HSF1	   can	   increase	   protein	  
chaperone	   expression	   and	   ameliorate	   cytotoxicity	   in	   models	   of	   protein	   folding	  
disease	   [28,	  43-­‐46].	  As	  such,	   it	   is	   important	   to	   further	  our	  understanding	  of	   the	  
mechanisms	   that	   repress	   HSF1	   activity	   as	   potential	   points	   of	   therapeutic	  
intervention	  in	  disease.	   	  For	  example,	  our	  data	  has	  shown	  that	  the	  loss	  of	  S303-­‐
dependent	  HSF1	  repression	  can	   lead	  to	  the	  accumulation	  of	  protein	  chaperones	  
and	  as	  such	  could	  be	  efficacious	  in	  the	  treatment	  of	  protein	  folding	  diseases.	  	  In	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support	  of	  this	  possibility	  Rimoldi	  et	  al	  showed	  that	  over-­‐expression	  of	  the	  HSF1	  
S303G	  mutant	   in	  HeLa	   cells	   reduced	   aggregation	   and	   inclusion	   formation	   of	   an	  
aggregation	   prone	   Ataxin1-­‐31Q	  mutant	   protein	   [47]	   In	   addition,	   Fujimoto	   et	   al	  
showed	   that	   overexpression	   of	   a	   constitutively	   active	   HSF1	  mutant	   lacking	   the	  
regulatory	   domain,	   which	   includes	   S303	   and	   S307,	   suppressed	   the	   aggregation	  
and	  cytotoxicity	  of	  a	  mutant	  Huntingtin	  protein	  in	  both	  cell	  culture	  and	  mice	  [48].	  	  
Furthermore,	  Carmichael	  et	  al	  suggested	  that	  GSK3-­‐inhibitors	  might	  prove	  useful	  
in	  the	  treatment	  of	  polyQ-­‐expansion	  diseases	  [49].	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Discussion	  
Arsenic	   is	  one	  of	   the	  most	  widely	  studied	  elements	   in	  the	  field	  of	  metal	  
intoxication	  after	  lead	  (Pb).	  As	  is	  a	  metalloid	  found	  in	  water,	  soil,	  and	  air	  
from	   natural	   and	   anthropogenic	   sources	   and	   exists	   in	   inorganic	   and	  
organic	   forms	   [1].	   The	  major	   inorganic	   forms	  of	  As	   include	   the	   trivalent	  
arsenite	   (AsIII)	   and	   the	  pentavalent	  arsenate	   (AsV).	  AsIII	   is	   known	   to	  be	  
more	   toxic	   than	   the	   AsV	   [2].	   Humans	   can	   be	   exposed	   to	   As	   via	   air	   and	  
food,	   but	   the	   major	   exposure	   route	   to	   As	   is	   through	   drinking	   water,	  
especially	   in	   India,	   Bangladesh,	   China,	   and	   some	   Central	   and	   South	  
American	   countries	   [3].	   For	   instance	   the	   As	   concentrations	   in	   drinking	  
water	   in	   Argentina	   are	   200	  ppb,	   Mexico	   400	  ppb,	   Taiwan	   50–1980	  ppb	  
and	   in	  the	   Indo-­‐Bangladesh	  region	  800	  ppb,	  values	  well	  above	  the	  WHO	  
guidelines'	  maximum	  permissible	  value,	  10	  ppb.	  	  Chronic	  arsenicosis	  due	  
to	   drinking	   arsenic-­‐contaminated	  water	   is	   reported	   to	   affect	  more	   than	  
200	   million	   people	   worldwide	   [4].	   Several	   studies	   have	   reported	   that	  
arsenic	   intoxication	  can	  cause	   internal	  cancers	  [5],	  blackfoot	  disease	  [6],	  
vascular	  diseases	  [7]	  and	  diabetes	  [8].	  	  
Although	   As	   is	   considered	   a	   human	   carcinogen	   it	   is	   also	   a	   therapeutic	  
agent	  and	  its	  cellular	  metabolism	  has	  been	  extensively	  studied	  to	  further	  
understand	   its	   mechanisms	   of	   action.	   It	   has	   been	   suggested	   that	   As	  
toxicity	  has	  several	  modes	  of	  action	  such	  as	  production	  of	  chromosomal	  
abnormalities,	   promotion	  of	   carcinogenesis	   and	  oxidative	   stress,	   among	  
others	  [9,	  10].	  To	  date	  studies	  have	  not	  shown	  a	  link	  between	  As	  and	  Fe	  
homeostasis.	   Our	   data	   in	   chapter	   1	   suggests	   for	   the	   first	   time	   that	   As	  
stress	   deregulate	   the	   expression	   of	   genes	   involved	   in	   cellular	   iron	  
homeostasis.	   It	   activates	   Aft1	   iron-­‐responsive	   transcription	   factor	   and	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promotes	   the	   uses	   of	   the	   non-­‐reductive	   pathway	  mediated	   by	   the	  ARN	  
family	  permeases,	  to	  uptake	  iron.	  Most	  Importantly	  it	  causes	  FET3	  mRNA	  
down-­‐regulation	  by	  the	  5’-­‐3’	  Xrn1	  and	  causes	  Fet3	  mislocalization	  in	  the	  
ER	  being	  degraded	  after	  4hrs	  of	  exposure.	  In	  conclusion	  As	  stress	  induces	  
a	  response	  similar	  to	  that	  induced	  by	  iron	  deficiency.	  Moreover,	  we	  also	  
obtained	   preliminary	   data	   suggesting	   that	   As	   disruption	   of	   iron	  
homeostasis	   also	   occurs	   in	   mammalian	   cells.	   This	   connection	   between	  
arsenic	   and	   iron	   might	   shed	   new	   light	   on	   the	   mechanism	   of	   action	   of	  
arsenic.	  
	  
	  
Over	  the	  past	  two	  decades,	  the	  role	  of	  HSF1	  has	  been	  solidly	  established	  
in	  several	  biochemical	  and	  genetic	  experiments.	  Yet,	  we	  are	  far	  from	  fully	  
understanding	   the	   biology	   of	   HSF1.	   HSF1	   is	   the	   major	   stress-­‐activated	  
transcription	   factor	   enhancing	   the	   expression	   of	  hsp	   genes	   that	   encode	  
molecular	  chaperones	  that	  facilitate	  protein	  folding	  and	  suppress	  protein	  
aggregation,	   this	   response	   plays	   a	   major	   role	   in	   maintaining	   protein	  
homeostasis	   and	   is	   called	   as	   the	   heat	   shock	   response	   (HSR)	   [11].	   The	  
requirement	   of	   an	   essential	   response	   to	   acute	   and	   chronic	   proteotoxic	  
damage	   imposes	   aspects	   as	   detection,	   signaling,	   and	   response	   to	  
misfolding.	   This	   is	   achieved	   by	   hierarchical	   regulation	   of	   HSF1.	   In	   the	  
chapter	  2	  of	  this	  work	  we	  emphasize	  the	  biochemistry	  of	  HSF1	  during	  its	  
complex	   multistep	   mechanism	   of	   regulation,	   in	   particular	   its	  
posttranslational	   signature.	   Several	   kinases	   have	   been	   linked	   to	   the	  
phosphorylation	   of	   HSF1.	   The	   specific	   kinases	   that	   phosphorylate	   at	  
Ser303	  and	  Ser307,	  serine	  residues	  involved	  in	  the	  HSF1	  repression	  step,	  
remain	   unknown.	   Early	   in	   vitro	  experiments	   suggested	   that	   Ser303	  was	  
phosphorylated	   via	   glycogen	   synthase	   kinase	   3	   (GSK3)	   and	   that	   Ser307	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was	   phosphorylated	   via	   extracellular	   signal-­‐regulated	   kinase	   1	   and	   2	  
(ERK1/2)	   [12].	   However,	   our	   data	   suggest	   that	   although	   GSK3	   does	  
repress	   HSF1	   activity,	   such	   happens	   independently	   of	   the	  
phosphorylation	  at	  Ser303.	  Moreover	  our	   results	   show	  that	  Ser303	  may	  
be	   phosphorylated	   by	   a	   mitogen-­‐activated	   protein	   kinase	   (MAPK).	   In	  
conclusion,	   the	   identification	   of	   the	   kinase(s)	   that	   phosphorylate	   these	  
residues	   in	   vivo	   could	   be	   important	   for	   developing	   agents	   to	   target	  
neurodegenerative	  diseases	  via	  HSF1	  activation.	  	  
 
 
Future	  Perspectives	  
The	  results	  obtained	  with	  this	  graduation	  work	  helped	  us	  to	  elucidate	  the	  
mechanisms	  regarding	  two	  different	  stress	  responses,	  the	  stress	  response	  
to	   arsenic	   exposure	   and	   the	   stress	   response	   to	   misfolding	   proteins.	  
However	   throughout	   this	   dissertation	   these	   stress	   mechanisms	   were	  
handle	  using	  different	  approaches	  a	  very	  recent	  study	  as	  just	  shown	  that	  
HSF1	   can	   be	   activated	   by	   arsenite	   (AsIII)	   [13].	   The	   authors	   show	   that	  
arsenic	   trioxide	   (ATO)	   promotes	   HSF1	   phosphorylation	   at	   S326	   and	  
induces	   the	   expression	   of	   the	   Hsp27	   and	   Hsp70,	   which	   in	   turn	   may	  
protect	   cells	   from	   ATO	   cytotoxicity.	   On	   the	   other	   side	   the	   inhibition	   of	  
HSF1	   function	   not	   only	   reduced	   ATO	   induction	   of	   HSP27	   and	   70,	   but	  
enhanced	   ATO	   cytotoxicity	   by	   increasing	   apoptosis.	   Moreover	   the	  
treatment	  of	  cells	  with	  ATO	  and	  PI103,	  an	  inhibitor	  of	  the	  members	  of	  the	  
phosphatidylinositol	   3-­‐kinase	   (PI3K)	   family,	   suppressed	   not	   only	   ATO-­‐
induced	  Hsp70	  expression	  but	  also	  the	  phosphorylation	  at	  S326.	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These	  findings	  represent	  a	  very	  promising	  discovery	  toward	  a	  new	  field	  of	  
research	   establishing	   a	   potential	   connection	   between	  HSF1	   and	   arsenic	  
toxicity	  with	  great	  impact	  for	  human	  diseases.	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Table	  1:	  Human	  disease	  genes	  that	  are	  found	  in	  Yeast.	  
Human Disease Gene Yeast Gene Brief disease description 
N-Acetylglucosamine 
phosphatidylinositol biosynthetic 
protein 
SPT14 Haemolytic blood disorder (venous thrombosis) 
Adenine 
phosphoribosyltransferase APT1/APT2 Urolithiasis 
Adenosine deaminase Yn1141w Immunodeficiency 
Adenylate kinase URA6/ADK1 Haemolytic anaemia 
S-Adenosylmethionine 
synthetase SAM1/SAM2 
Hypermethioninaemia; mental and 
motor retardation 
Adenylosuccinate lyase Y1r359w Purine nucleotide biosynthesis defect; autism features 
Aldehyde dehydrogenase ALD2 Delayed oxidation of acetaldehyde; acute alcohol intoxication 
δ-Aminolevulinate dehydratase HEM2 Hepatic porphyria 
Ankyrine defect (spherocytose) Yil112w Spherocytic anaemia 
Arginosuccinate lyase ARG4 Neonatal infantile chronic hyperammonaemia 
Arginosuccinate synthetase ARG1 Argininaemia; severe psychomotor retardation 
Bartter's syndrome (NKCC2 
cotransporter) Ybr235w 
Hypokalaemic alkalosis with 
hypercalciura 
Carbamoylphosphate synthase URA2/CPA2 Hyperammonaemia 
Carboxypeptidase C PRC1 Galactosialidosis 
Carnitine palmitoyltransferase YAT1 Lipid metabolism defect; cardiomyopathy 
Catalase CTA1 Acatalasia 
Coproporphyrinogen oxidase HEM6 Coproporphyria; psychiatric symptoms 
Cyclin Dl (CCND1) CGSG Oncogene; parathyroid adenomas 
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Human Disease Gene Yeast Gene Brief disease description 
Cystathionine-β-synthase Ygr155w Homocystinuria 
Dihydrolipoyl dehydrogenase LPD1 Lactic acidosis; `maple syrup' urine disease 
Ferrochelatase HEM15 Protoporphyria, erythropoietic 
Fumarate hydratase FUM1 Fumaric aciduria; encephalopathy 
Glucose-6-phosphate 
dehydrogenase ZWF1 Haemolytic anaemia 
α-Glucosidase Ybr229c Cardiomyopathy; muscular hypotonia 
Glucokinase HXK1/HXK2 Hyperglycaemia; diabetes 
γ-Glutamyltranspeptidase Y1r299w Glutathionuria 
Glutathione peroxidase HYR1 Haemolytic anaemia 
Glycine decarboxylase Ymrl89w Non-ketotic hyperglycinaemia; lethargy; severe mental retardation 
Guanine nucleotide binding 
protein GPA1 
Defect in adenylcyclase regulation; 
osteodystrophy 
Gulonolo-γ-lactone oxidase 
(pseudogene) Ydr305c Ascorbic acid biosynthesis defect 
Holocarboxylase synthetase ACC2 Biotin-responsive carboxylase deficiency; ataxia 
α-Ketoglutarate dehydrogenase 
(El) KGD1 Lactic acidosis; neurodisorders 
LIM kinase Yol113w Williams syndrome; brain development 
Lipoamide acyltransferase (E2) KGD2/PDA2 Lactic acidosis; `maple syrup' urine disease 
Methylene tetrahydrofolate 
reductase Ypl023c Homocystinuria; psychotic symptoms 
Mevalonate kinase ERG12 Mevalonicaciduria; variety of symptoms 
Monoamine oxidase FMS1 Mental retardation and keratocunjunctivis 
Nucleoside diphosphate kinase Ykl067w Tumour metastatic process 
Nucleotide pyrophosphatase Ycr026c Insulin resistance 
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Human Disease Gene Yeast Gene Brief disease description 
Ornithine-δ-aminotransferase CAR2 Hyperornithinemia; atrophy of choroid and retina 
Ornithine transcarbamylase ARG3 Hyperammonaemia in males 
Phosphatidylinositol glycan class 
A SPT14 
Haemolytic blood disorder (venous 
thrombosis) 
Phosphoglycerate mutase GPM1 Myopathy 
Phospholipid-
cholesterolacyltransferase Ynr008w 
Cholesterol esterification defects; 
cornea lipid deposits 
Porphobilinogen deaminase HEM3 Acute intermittent porphyria 
Propionyl-COA-carboxylase PYC2 Hyperglycinemia; intolerance to proteins 
Protoporphyrinogen oxidase Yer0l4w Variegate porphyria; light-sensitive dermatis 
Purine phosphorylase Ylr209c Immunodeficiency; neurodisorders 
Pyruvate carboxylase PYC1 Lactic acidosis; death 
Pyruvate dehydrogenase PDA1 Lactic acidosis; ataxia 
Pyruvate kinase PYK1 Non-spherocytic anaemia 
SA gene ACS1 Hypertension-associated gene 
Serine pyruvate aminotransferase Yfl030w Hyperoxaluria; urolithiase; nephrocalcinosis 
SLC4 (anion exchanger) Ynl275w Hereditary spherocytosis 
Sterol-26-hydroxylase ERG11 Cerebral cholesterinosis 
Succinate dehydrogenase SDH1 Flavoprotein subunit defect; Leigh syndrome 
Succinic semialdehyde 
dehydrogenase Ybr00Gw Mental retardation and ataxia 
Sucrose isomaltase Ybr229c Sucrose intolerance 
Sulfonylurea receptor YCF1/YHD5 ABC transporter; unregulated insulin secretion 
TAP1/TAP2 transporters MDL2 ABC transporters; immunodeficiency 
α-Tocopherol transferase SEC14 Vitamin E deficiency; ataxia 
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Human Disease Gene Yeast Gene Brief disease description 
Triosephosphate isomerase TPI1 Chronic haemolytic anaemia and neuromuscular disorders 
Tyrosine transaminase Yjl060w Tyrosinemia 
Uroporphyrinogen decarboxylase HEM12 Porphyria, cutanea tarda 
Uroporphyrinogen synthase HEM4 Porphyria, congenital erythropoietic 
X. pigmentosum (XP-D, 1990) RAD3/RAD25 DNA helicase; TFIIH complex subunit; photosensitivity; cancer 
X. pigmentosum (XP-G, 1990) RAD2 Structure specific endonuclease; photosensitivity; cancer 
X. pigmentosum (XP-A, 1992) RAD14 Zinc finger damaged DNA binding protein; photosensitivity; cancer 
X. pigmentosum (XP-C, 1992) RAD4 125 kDa ssDNA binding protein; photosensitivity; cancer 
Cockayne syndrome (CS-B, 
1992) RAD26 
Progressive neurological dysfunction; 
photosensitivity 
Cockayne syndrome (CS-A, 
1995) Ydr030c 
WD-repeat protein; same phenotype 
as above 
Achondroplasia (FGFR3) IPL1 Membrane Ser/Thr protein kinase 
Adrenoleukodystrophy (ADL) PAL1 ABC transporter; neurodegenerative disease 
Amyotrophic lateral sclerosis 
(SOD1) SOD1 Superoxide dismutase 
Ataxia telangiectasia (ATM) TEL1/MEC1 Phosphatidylinositol kinase-related protein 
Barth syndrome (G4.5.) Ypr140w Unknown function; cardioskeletal myopathy 
Bloom syndrome (BLM) SGS1/YABC 
RecQ DNA helicase-related protein; 
growth defect; predisposition to all 
types of cancer 
Chediak-Higashi syndrome (CHS) Ycr032w  `Beige' protein; decreased pigmentation; immunodeficiency 
Choroideremia (CHM) GDI1k Component A of RAB geranylgeranyltransferase 
Cystic fibrosis (CFTR) YCF1 ABC transporter; impaired clearance in a variety of organs 
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Deafness, DFN-1 (DDP) Yjr135a Unknown function; neurodegenerative syndrome 
Diastrophic dysplasia (DTD) SUL1 Sulfate transporter; undersulfation of proteoglycans 
Fanconi syndrome (CLCN5) GEF1 Kidney chloride channel; nephrolithiasis 
Fragile histidine triad protein 
(FHIT) Ydr305c 
Dideadenosine tetraphosphate 
hydrolase; cancer 
Friedreich ataxia (FRD) Ydl120w Neurodegenerative disease 
Glycerol kinase (GK) GUT1 Hyperglycerolaemia; poor growth; mental retardation 
HNPCC (MSH2) MSH2 Mismatch-repair; hereditary nonpolyposis colon cancer 
HNPCC (MLH1) MLH1 Mismatch repair; hereditary nonpolyposis colon cancer 
Lissencephaly (LIS1) MET30 Subunit of platelet-activating factor acetylhydrolase 
Lowe syndrome (OCRL) Yil002c 
Inositol polyphosphate 5 
phosphatase-related protein; 
cataracts and glaucoma 
Menkes disease (MNK) CCC2 Copper-transporting ATPase; neurodegenerative disease and death 
Migraine (CACNL1-A4) Ygr2l7w Calcium channel; familial hemiplegic migraine and episodic ataxia 
Multiple endocrine neoplasia  PHO85 
Related to transmembrane receptors 
with a cytoplasmic tyrosine kinase 
domain 
Myotonic dystrophy (DM) Ynl161w Ser/Thr protein kinase; neurodegenerative disease 
Myotubular myopathy (MTM1) Yjr110 Probable tyrosine phosphatase; muscle-specific disease 
NBCC syndrome (PTC) Ypl006w 
Homologue of Drosophila patched; 
nevoid basal cell carcinoma 
syndrome 
Neurofibromatosis (NF1) IRA2 GTPase-activating protein 
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Human Disease Gene Yeast Gene Brief disease description 
Retinitis pigmentosa (RPGR) SRM1 RCC1-related protein; progressive retinal degeneration 
Thomsen disease (CLCN1) GEF1 Muscle chloride channel; myotonic disorders 
Werner syndrome (WRN) SGS1 Premature ageing and strong predisposition to cancer 
Wilms tumour (WT1) FZF1 Zinc finger protein; nephroblastoma 
Wilson disease (WND) CCC2 
Copper transporting ATPase; toxic 
accumulation of copper in liver and 
brain 
Wiskott-Aldrich syndrome 
(WASP) LAS17 
Eflector for CDC42H GTPase; 
immunodeficiency 	  
Adapted	   from:	  Chervitz,	   S.	   A.,	   L.	   Aravind,	   G.	   Sherlock,	   C.	   A.	   Ball,	   E.	   V.	  
Koonin,	   S.	   S.	   Dwight,	   M.	   A.	   Harris,	   K.	   Dolinski,	   S.	   Mohr,	   T.	   Smith,	   S.	  
Weng,	  J.	  M.	  Cherry,	  and	  D.	  Botstein.	  1998.	  Comparison	  of	  the	  complete	  
protein	   sets	   of	   worm	   and	   yeast:	   orthology	   and	   divergence.	   Science	  
282:2022-­‐8.	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Table S2: Oligonucleotides used in the Real-Time PCR Analyses 
ARN1 5’-GGGTGTGGGCACTACTTTGT-3’ 
5’-GAACCGACAGCAGAACCAAT-3’ 
ARN2 5’-AGGTATGCTGCTGGAGCTGT-3’ 
5’-GAGGGCCATGAAGGTATCAA-3’ 
FTR1 5’-GATTCAACCTTGCCAGTGGT-3’ 
5’-ATTGTCCAGTTCTGGGTTGC-3’ 
FET3 5’-ACGGTGTGAATTACGCCTTC-3’ 
5’-TTGGAAAGCGTGACCATGTA 
CTH2 5’-CAAAAGCCCAAAAATGATGC-3’ 
5’-TTCGCACAGCTCTGTCTTGT-3’ 
ACT1 5’-CTATTGGTAACGAAAGATTCAG-3’ 
5’-CCTTACGGACATCGACATCA-3’ 
 
!!
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Table S3 
Iron homeostasis genes whose mRNA levels were down- or up-regulated in a WT strain 
upon As treatment. 
ORF Gene Function Fold change 
Iron Regulon   
YPL202C AFT2 Iron-regulated transcriptional activator 3.3 
YKR052C MRS4 Mitochondrial iron transporter of the mitochondrial carrier  
family (MCF 
2.49 
    
YER174C GRX4 Hydroperoxide and superoxide-radical responsive glutathione- 
dependent oxidoreductase 
-2.76 
YMR308C PSE1 Importin for specific proteins, including Pdr1, Yap1, Ste12, and 
Aft1 
-2.24 
    
YDR534C FIT1 Cell wall mannoprotein involved in siderophore-iron uptake -2.55 
YOR382W FIT2 Cell wall mannoprotein involved in siderophore-iron uptake 1.2 
YOR383C FIT3 Cell wall mannoprotein involved in siderophore-iron uptake 1.73 
    
YHL040C ARN1 Ferrirubin, ferrirhodin, and related Fe-siderophores transporter 2.17 
YHL047C ARN2/TAF1 Triacetylfusarinine C transporter 2.07 
YOL158C ARN4/ENB1 Enterobactin transporter 1.63 
    
YMR058W FET3 Multicopper ferroxidase involved in high-affinity Fe uptake -2.14 
YER145C FTR1 High-affinity Fe permease that forms a complex with Fet3 -1.55 
    
YLR214W FRE1 Ferric and cupric reductase 1.36 
YOR381W FRE3 Ferric reductase that reduces siderophore bound Fe 1.43 
YNR060W FRE4 Ferric reductase, reduces a specific subset of siderophore- 
bound iron  
1.22 
YLL051C FRE6 Putative ferric reductase 3.29 
YLR047C FRE8 Protein with sequence similarity to iron/copper reductases 2.76 
    
YMR319C FET4 Low-affinity Fe transport protein -2.94 
    
YBR207W FTH1 Vacuolar Ftr1 homologue 1.7 
    
YMR177W MMT1 Putative metal transporter involved in mitochondrial iron  
accumulation 
2.57 
YPL224C MMT2 Putative metal transporter involved in mitochondrial iron  
accumulation 
2.15 
    
YDR151C CTH1 Member of the CCCH zinc finger family,has a role in mRNA  
degradation 
3.72 
YLR136C CTH2/TIS11 mRNA-binding protein expressed during iron starvation 5.69 
    
YLR205C HMX1 Heme-binding peroxidase 1.87 
YOR176W HEM15 Ferrochelatase, catalyzes insertion of Fe(II) into protoporphyrin 
IX 
-1.2 
YLR256W HAP1 Zinc finger transcription factor involved in response to levels of  
heme and oxygen 
-2.09 
Iron-sulfur Proteins 
Fe-S Cluster Synthesis 
YKL040C NFU1 NifU-like protein 4.28 
YDR091C RLI1 Essential Fe/S protein required for ribosome biogenesis and  
translation initiation 
-5.32 
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YPL135W ISU1 Member of Fe-S cluster bisynthesis machinery 2.17 
YOR226C ISU2 Member of Fe-S cluster bisynthesis machinery 3.23 
YPR067W ISA2 Member of Fe-S cluster bisynthesis machinery 2.97 
YCL017C NFS1 Cysteine desulfurase involved in iron-sulfur cluster (Fe/S)  
biogenesis 
2.47 
YPL059W GRX5 Mitochondrial matrix protein involved in the  
synthesis/assembly of Fe/S centers 
2.23 
YMR301C ATM1 (ABC) transporter, exports mitochondrially synthesized  
precursors of iron-sulfur (Fe/S) clusters to the cytosol 
2.98 
YER048W
-A 
ISD11 Protein required for mitochondrial iron-sulfur cluster 
biosynthesis 
2.18 
YGL018C JAC1 Specialized J-protein that functions with Hsp70 in Fe-S cluster  
biogenesis in mitochondria 
2.02 
YNL240C NAR1 Component of the cytosolic iron-sulfur (FeS) protein assembly  3.01 
YPR048W TAH18 Component of an early step in the cytosolic Fe-S protein 
assembly (CIA) machinery 
2.54 
    
Fe-S Cluster-containing proteins  
YGL009C LEU1 Isopropylmalate isomerase, catalyzes the second step in  
the leucine biosynthesis pathway 
-2.96 
YOR196C LIP5 Protein involved in biosynthesis of the coenzyme lipoic acid 1.78 
YPL252C YAH1 Fe-S cluster protein homologous to human adrenodoxin -1.26 
YGR286C BIO2 Biotin synthase -1.97 
YIL003W CFD1 Highly conserved, iron-sulfur cluster binding protein  
localized in the cytoplasm 
4.46 
YLR304C ACO1 Mitochondrial aconitase, Fe-S cluster protein -3.86 
YJL200C ACO2 Mitochondrial aconitase, Fe-S cluster protein -1.61 
    
Mitochondrial respiraion/electron transport chain  
Cytochrome c oxidase   
YNL111C CYB5 Cytochrome b5 -5.53 
YML054C CYB2 Cytochrome b2 (L-lactate cytochrome-c oxidoreductase) 3.04 
YOR065W CYT1 Cytochrome c1 -1.82 
YJR048W CYC1 Iso-1-cytochrome c -1.1 
YAL039C CYC3 Cytochrome c heme lyase (holocytochrome c synthase) 1.07 
YEL039C CYC7 Cytochrome c isoform 2 1.69 
YKL087C CYT2 Cytochrome c1 heme lyase 1.57 
YHR051W COX6 Subunit VI of cytochrome c oxidase -1.04 
YKR066C CCP1 Mitochondrial cytochrome-c peroxidase 2.08 
    
Sterol and fatty acid synthesis and metabolism  
YHR042W NCP1 NADP-cytochrome P450 reductase involved in ergosterol  
biosynthesis 
-2.08 
YLR056W ERG3 C-5 sterol desaturase -9.03 
YMR015C ERG5 C-22 sterol desaturase -3.49 
YHR007C ERG11 Lanosterol C-14 demethylase  -1.58 
YGR060W ERG25 C-4 methyl sterol oxidase -5.31 
YGL055W OLE1 Fatty acid desaturase -5.06 
YMR272C FAH1/SCS7 Hydroxylation of C-26 fatty acid in ceramide -3.85 
    
Other Functions   
YJR070C LIA1 Deoxyhypusine hydroxylase -4.85 
YPL207W TYW1 Protein required for the synthesis of wybutosine -4.56 
YGR123C PPT1 Protein serine/threonine phosphatase with similarity to human  
phosphatase PP5 
-3.33 
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YJR016C ILV3 Dihydroxyacid dehydratase -2.78 
YGL256W ADH4 Alcohol dehydrogenase isoenzyme type IV -2.69 
YPL086C ELP3 Subunit of Elongator complex -2.45 
YDL171C GLT1 NAD(+)-dependent glutamate synthase (GOGAT) -1.79 
YJR025C BNA1 Required for biosynthesis of nicotinic acid  2.1 
YJR078W BNA2 Required for biosynthesis of nicotinic acid 1.31 
YER051W JHD1 JmjC domain family histone demethylase specific for H3-K36 1.63 
YGR234W YHB1 Nitric oxide oxidoreductase, flavohemoglobin involved in nitric  
oxide detoxification 
1.63 
YML016C PPZ1 Serine/threonine protein phosphatase Z 1.76 
YML057W CMP2 Calcineurin A, regulates Crz1p (a stress-response transcription 
factor) 
1.9 
YDR436W PPZ2 Serine/threonine protein phosphatase Z 2 
YDR402C DIT2 Microsomal enzyme involved in the production of N,N- 
bisformyl dityrosine  
2.08 
YNR032W PPG1 Putative serine/threonine protein phosphatase 2.79 
YOL043C NTG2 DNA N-glycosylase and apurinic/apyrimidinic (AP) lyase 2.83 
YBR018C GAL7 Galactose-1-phosphate uridyl transferase 4.13 
YJR137C ECM17 Sulfite reductase beta subunit, involved in amino acid  
biosynthesis 
7.93 
YDR256C CTA1 Catalase A, breaks down hydrogen peroxide in the  
peroxisomal matrix  
9.16 
YLL057C JLP1 Fe(II)-dependent sulfonate/alpha-ketoglutarate dioxygenase 23.9 
The average fold induction of triplicate samples is represented. An increase of 1.2-fold 
and a p-value <0.005were used. 
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Deciphering Human Heat Shock Transcription Factor 1
Regulation via Post-Translational Modification in Yeast
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Abstract
Heat shock transcription factor 1 (HSF1) plays an important role in the cellular response to proteotoxic stresses. Under
normal growth conditions HSF1 is repressed as an inactive monomer in part through post-translation modifications that
include protein acetylation, sumoylation and phosphorylation. Upon exposure to stress HSF1 homotrimerizes, accumulates
in nucleus, binds DNA, becomes hyper-phosphorylated and activates the expression of stress response genes. While HSF1
and the mechanisms that regulate its activity have been studied for over two decades, our understanding of HSF1
regulation remains incomplete. As previous studies have shown that HSF1 and the heat shock response promoter element
(HSE) are generally structurally conserved from yeast to metazoans, we have made use of the genetically tractable budding
yeast as a facile assay system to further understand the mechanisms that regulate human HSF1 through phosphorylation of
serine 303. We show that when human HSF1 is expressed in yeast its phosphorylation at S303 is promoted by the MAP-
kinase Slt2 independent of a priming event at S307 previously believed to be a prerequisite. Furthermore, we show that
phosphorylation at S303 in yeast and mammalian cells occurs independent of GSK3, the kinase primarily thought to be
responsible for S303 phosphorylation. Lastly, while previous studies have suggested that S303 phosphorylation represses
HSF1-dependent transactivation, we now show that S303 phosphorylation also represses HSF1 multimerization in both
yeast and mammalian cells. Taken together, these studies suggest that yeast cells will be a powerful experimental tool for
deciphering aspects of human HSF1 regulation by post-translational modifications.
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Introduction
All organisms are exposed to proteotoxic stresses that result in
the accumulation of misfolded proteins. In response to these
stresses cells have evolved adaptive responses to protect and
stabilize cellular proteins until more favorable conditions for cell
proliferation are encountered [1]. The heat shock transcription
factor, HSF, is a homotrimeric transcription factor that activates
gene expression in response to a variety of stresses including heat
and oxidative stress, as well as inflammation and infection [2].
Recent evidence has shown that the S. cerevisiae HSF directly
activates the expression of genes whose protein products are
involved in protein folding and degradation, ion transport, signal
transduction, energy generation, carbohydrate metabolism, vesic-
ular transport, cytoskeleton formation and other cellular functions
[3].
While mammalian cells express four distinct HSF proteins
encoded by separate genes, HSF1 is the primary factor responsible
for stress responsive gene transcription [2]. In the absence of stress,
mammalian HSF1 is repressed through mechanisms that are not
well understood. HSF1 is thought be maintained in an inactive
monomeric state through intramolecular interactions between a
hydrophobic coiled-coil domain in the carboxyl-terminus of the
protein and three amino-terminal coiled-coils required for
homotrimerization and transcriptional activation [4,5,6]. HSF1
is also thought to be bound and repressed by the protein
chaperones Hsp90 and Hsp70, though it is not clear how these
chaperones repress HSF1 activity [7,8,9,10]. Studies suggest that
during the initial phase of the stress response, the inactive HSF1
monomer dissociates from Hsp90, homotrimerizes, is transported
to the nucleus and binds to heat shock elements (HSE) found in the
promoters of HSF target genes [10,11]. The DNA-bound
homotrimer, remains relatively transcriptionally inert [12],
potentially due to the continued interaction with Hsp70 and the
HSF1-transactivation domain [9]. Stress-dependent hyperpho-
sphorylation of HSF1 by potentially multiple protein kinases has
been proposed to, in part, promote HSF1 dependent transactiva-
tion [13,14,15].
The activity of HSF1 is also thought to be negatively regulated
through a number of post-translational modifications including
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phosphorylation, sumoylation and acetylation [16,17,18,19]. Mass
spectrometry analyses have shown HSF1 to be phosphorylated on
at least 12 serine residues [13] and phosphorylation of S121, S303,
S307 and S363 have been correlated with a repression in HSF1
activity [18,20,21]. The most comprehensively studied of these
phosphorylation events are the phosphorylation of S303 and S307.
However, much of what is known about S303 and S307
phosphorylation stems from in vitro phosphorylation experiments
and in vivo studies using either lexA or Gal4-HSF1 fusion proteins
lacking the native HSF1 DNA binding domain. As such, many of
the earlier studies exploring S303 and S307-dependet regulation of
HSF1 activity have resulted in conflicting results. For example,
previous phosphorylation experiments suggested that S307 was
phosphorylated by ERK which, in turn, acted as an essential
priming step for GSK3-dependent phosphorylation of S303 [22].
However, subsequent in vitro studies suggested that S303 could also
be phosphorylated by a variety of mitogen activated protein
kinases (MAPK) including the stress responsive MAPK p38
[17,18]. In addition, subsequent in vivo data suggested S303
phosphorylation could occur independently of S307 phosphory-
lation [16].
While the specific mechanism by which S303 and S307
phosphorylation repress HSF1 activity remains unclear, evidence
has suggested that S303 and S307 phosphorylation represses the
transactivation potential of HSF1 [18,22,23]. S303 and S307 are
constitutively phosphorylated in the absence of stress and S303
phosphorylation levels increase after exposure to stress, suggesting
that this phosphorylation event might also contribute to HSF1
inactivation during the recovery phase [16,17]. Interestingly,
phosphorylation of S303, but not S307, promotes sumoylation of
K298 [16] which, like S303 phosphorylation, also increases in
response to stress exposure and represses HSF1-dependent
transactivation [24]. However, it remains unclear if the repressive
effects of S303 phosphorylation on HSF1 activity are exclusively
mediated through K298 sumoylation or occur through additional
mechanisms.
While HSF1 and the cognate HSEs are quite well conserved
from yeast to humans, our previous results demonstrated that
human HSF1 expressed in S. cerevisiae is unable to complement for
the loss of the essential yeast HSF protein [25]. Further analysis
showed that human HSF1 expressed in yeast was unable to form a
homotrimer and consequently unable to activate HSE-dependent
gene expression to support cell viability. Human HSF1 homo-
trimerized, became active and complemented for the loss of yeast
HSF when three derepressing mutations, collectively known as
LZ4m, were introduced into the repressive carboxyl-terminal
coiled-coil domain [6,25]. Further studies in yeast identified an
amino-terminal linker-domain as well as a loop in the DNA
binding domain as repressive elements that contributed to HSF1
repression in both yeast and mammalian cells [26,27]. We have
also used to the yeast assay system to screen for and indentify novel
pharmacological activators of human HSF1 [28]. Together, these
results suggest that human HSF1 expressed in yeast is maintained
in a constitutively repressed state through mechanisms similar to
those of mammalian cells and that the yeast system can serve as a
simplified assay system to decipher the complex mechanisms
regulating human HSF1 activity.
Here we report the use of the yeast assay system to further
understand the mechanisms that regulate human HSF1 through
phosphorylation of serine 303. Our results suggest that S303
phosphorylation blocks human HSF1 homotrimerization thereby
preventing human HSF1 activation and complementation of the
loss of yeast HSF. Furthermore, we demonstrate that S303
phosphorylation also blocks HSF1 homotrimerization in mam-
malian cells. We show that phosphorylation of HSF1 S303 in yeast
occurs via the action of the MAPK Slt2 and not via the action of
GSK3 and we extend these findings to show that S303
phosphorylation also occurs independent of GSK3 in mammalian
cells.
Results
Phosphorylation of S303 contributes to repression of
human HSF1 in yeast
When human HSF1 is expressed in yeast it is unable to
homotrimerize, promote gene expression and complement for the
loss of the essential yeast HSF protein [25]. Because our previous
work suggested that when HSF1 is expressed in yeast it exists in a
constitutively repressed monomeric state, we sought to use the
yeast assay system to better understand the complex mechanisms
regulating HSF1 activity in mammalian cells. An important
component of HSF1 repression occurs through the phosphoryla-
tion of serine 303 and serine 307 [17,18]. Because S303 and S307
are constitutively phosphorylated in mammalian cells and alanine
substitution of S303 or S307 promotes constitutive activation of
HSF1 in mammalian cells in reporter assays [17,18] we tested
whether S303 and/or S307 contribute to HSF1 repression in
yeast. Wild-type HSF1 or the individual S303A, S307A or S303/
307A double mutants were expressed in yeast strain PS145 which
lacks a chromosomal copy of the essential yeast HSF gene and
constitutively expresses yeast HSF episomally from a galactose
inducible and dextrose repressible promoter [29]. When PS145 is
grown in the presence of dextrose as the sole carbon source, yeast
HSF expression is extinguished and growth becomes solely
dependent on HSF1 which is episomally expressed [28]. While
wild-type human HSF1 was unable to complement for the loss of
yeast HSF, expression of the S303A, S307A or S303/307A HSF1
mutants allowed for human HSF1-dependent yeast growth
(Figure 1A, B). Interestingly, the S303/307A double HSF1 mutant
did not display enhanced activity over the S303A mutant
(Figure 1B) suggesting that phosphorylation of both S303 and
S307 modulate HSF1 repression through similar mechanisms.
To ascertain whether HSF1 is being phosphorylated in yeast,
we employed a commercially available antibody specific for
phospho-S303 (pS303). Because this antibody has not previously
been characterized in the literature, we tested its specificity in
human HeLa cells where S303 is known to be constitutively
phosphorylated [17]. As shown in Figure 1C, using this antibody
we detected that endogenous HSF1 was constitutively phosphor-
ylated in HeLa cells in the absence of stress. We also observed an
increase in S303 phosphorylation in response to a heat shock,
which correlated with previous reports [16]. Importantly, the
pS303-specific antibody did not detect HSF1 when HeLa extracts
were treated with lambda protein phosphatase prior to immuno-
blot analysis (Figure 1C), nor does it detect HSF1 when S303 is
mutated to alanine (Figure 1D). Together, these data suggest that
the antibody is specific for HSF1 that is phosphorylated on S303.
The detection of HSF1 using a polyclonal anti-HSF1 antibody
demonstrates that there are no significant differences in the steady
state levels of HSF1 either treated or untreated with lambda
phosphatase (Figure 1C).
Consistent with a contribution to HSF1 repression (Figure 1A,
B) S303 is robustly phosphorylated when HSF1 is expressed in
yeast (Figure 1D, E). Interestingly, phosphorylation of S303 was
also observed when the S307A mutant was expressed in yeast
though it was reduced by approximately 50% when compared to
wild-type HSF1 (Figure 1D, E). While this observation supports a
previous report indicating that S303 phosphorylation could occur
Phosphorylation of Human HSF1 in Yeast
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independently of S307 phosphorylation in mammalian cells [16],
these data also suggests that under certain circumstances S303
phosphorylation may be enhanced by S307 phosphorylation. In
addition, although a correlation between S303 and S307
phosphorylation and HSF1 protein stability has not been
previously reported, we repeatedly observed two to three-fold
higher steady state levels of HSF1 when the S303A, S307A and
S303/307A mutants were expressed in yeast (Figure 1D, F). While
an antibody specific for phospho-S307 is commercially available,
we have been unable to detect S307 phosphorylation of human
HSF1. As such we focused our investigation on S303-phosphor-
ylation dependent repression of human HSF1.
Human HSF1 S303 phosphorylation is known to promote
sumoylation of lysine 298, which also contributes to the repression
of HSF1 activity [16]. Therefore, to further investigate the idea
that human HSF1 is being actively repressed in yeast, we explored
the possibility that K298, like S303, contributes to HSF1
repression in yeast. However, unlike the S303A HSF1 mutant,
Figure 1. S303 phosphorylation represses HSF1 activity in yeast. (A) PS145 yeast strains expressing wild-type HSF1 (WT) or the S303A, S307A
or S303/307A mutants were plated on either galactose or dextrose supplemented medium. (B) PS145 expressing either wild-type HSF1 or the S303A
or S303/307A mutants were grown in dextrose containing medium for 4 d. Growth was monitored by measuring O.D.600. (C) HeLa cells were grown
at 37uC (C) or heat shocked for 2 h at 42uC (HS). Total protein extracts were treated with lambda protein phosphatase and analyzed for phospho-S303
(pS303) and total HSF1 levels by immunoblotting. (D) PS145 was transformed with a plasmid expressing wild-type HSF1 (WT) or mutant alleles of
HSF1 and grown on galactose containing medium. Total protein extracts were analyzed for pS303, HSF1 and Pgk1 by immunoblotting. (E) Levels of
HSF1 phosphorylated at S303 were quantified and are shown as a percent of total HSF1, from panel D. (F) Protein levels of HSF1 were normalized to
Pgk1, from panel D. (G) PS145 expressing either wild-type HSF1 or mutant HSF1 alleles were assayed for HSF1-dependent growth as in B.
doi:10.1371/journal.pone.0015976.g001
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the K298R mutant did not promote HSF1-dependent growth
(Figure 1E), suggesting that at least in yeast, K298 does not
significantly contribute to HSF1 repression. We also did not
observe a reduction in human HSF1-dependent yeast growth for
the S303A/K298R double mutant, indicating that K298 is also
not required for HSF1 activity in yeast (Figure 1E).
S303 represses trimer formation of HSF1 in yeast and
mammalian cells
Previous reports have suggested that phosphorylation of S303
represses the ability of HSF1 to transactivate gene expression
[18,22,23]. Here we show that the HSF1 S303A mutant
functionally complements for the lost of yeast HSF (Figure 1A,
B). Based on our previous work this indicates that S303
phosphorylation might also regulate the ability of human HSF1
to homotrimerize [25]. To test this hypothesis we carried out EGS
cross-linking experiments in conjunction with immunoblot analysis
to ascertain if S303 phosphorylation regulates the homotrimeriza-
tion of human HSF1 in yeast. When the S303A HSF1 mutant was
expressed in yeast we detected approximately 2-fold higher levels
of trimerized HSF1 at the intermediate EGS concentration than
when wild-type HSF1 was expressed in yeast (Figure 2A).
However, trimerization of the S303A HSF1 mutant was lower
than trimerization of the LZ4 HSF1 mutant, previously demon-
strated to be constitutively trimerized in yeast and mammalian
cells and able to complement for the loss of yeast HSF [6,25]. We
observed similar results for the S307A and S303/307A HSF1
mutants (data not shown) further supporting the notion that S303
and S307 phosphorylation repress HSF1 activity through similar
mechanisms. We next evaluated whether HSF1 S303 phosphor-
ylation could also function to repress homotrimer formation in
mammalian cells. To test this hypothesis we expressed wild-type
HSF1 or the S303A, S307A or S303/307A mutants in hsf12/2
mouse embryonic fibroblasts (MEF) [30] and assayed for HSF1
trimerization in the absence of thermal stress by EGS crosslinking
and immunoblotting. While wild type HSF1 could be detected as a
multimer in these extracts, we observed approximately 2-fold
higher levels of the HSF1 trimer for the HSF1 S303A mutant
(Figure 2B) as well as the S307A and S303/307A mutants (data
not shown).
S303 phosphorylation and coiled-coil interactions
synergize in HSF1 repression
In addition to post-translational modifications, HSF1 activity is
also thought to be repressed through intramolecular interactions
between carboxyl- and amino-terminal coiled-coil domains and
mutations in these domains render HSF1 constitutively trimerized,
nuclear localized and bound to DNA in mammalian cells [6].
Because our results suggest that S303 phosphorylation might also
regulate homotrimer formation, we tested the combined affects of
both the S303A as well as the LZ4m mutations on human HSF1
activity in yeast. A human HSF1 mutant containing both the
S303A and LZ4m mutations was created and its ability to promote
human HSF1-dependent yeast growth was compared to the
individual HSF1 mutants as well as wild-type HSF1 in quantitative
cell growth assays. The individual S303A and LZ4m HSF1
mutants promoted human HSF1-dependent yeast growth to a
similar extent, though neither the LZ4m nor the S303 mutant
were fully derepressed, as the S303A/LZ4m double mutant
displayed enhanced human HSF1-dependent yeast growth
(Figure 3A). While we currently do not know if the S303A/
LZ4m double HSF1 mutant has an increased propencity to
trimerize, previous studies have shown that the LZ4m mutant,
when expressed in yeast is not maximally trimerized and
trimerization can be further enhanced via the addition of
pharmacological HSF1 activators [28]. While we observed higher
steady state protein levels for both the S303A and LZ4m mutants
in comparison to wild-type HSF1 when expressed in yeast, no
further increases in protein levels were observed for the double
mutant (Figure 3B, C). These results suggest that while both HSF1
S303 phosphorylation and coiled-coil interactions regulate human
HSF1 multimerization in yeast, they do so via distinct mecha-
nisms. We also did not observe changes in HSF1 S303
phosphorylation when the LZ4m mutant was expressed in yeast,
consistent with the notion that HSF1 trimerization does not affect
HSF1 S303 phosphorylation.
Gsk3 regulates human HSF1 activity in yeast
independent of S303 phosphorylation
Previous reports using in vitro phosphorylation experiments have
suggested that HSF1 is phosphorylated at S303 by glycogen
synthase kinase 3 (GSK3) [20,22,31]. However, it remains unclear
Figure 2. S303 represses trimer formation of HSF1 in yeast and
mammalian cells. (A) PS145 was transformed with wild-type HSF1,
the LZ4m mutant or the S303A mutant and grown on galactose
containing medium. Total protein extracts were evaluated for HSF1
multimerization by EGS crosslinking, SDS-PAGE, and immunoblotting
using an HSF1 specific antibody. The positions of molecular weight
markers are indicated on the left, and circles indicating the expected
migration of HSF1 monomers and trimers are on the right. Levels of
HSF1 trimer as percent of total HSF1 are shown below. (B) hsf12/2MEFs
were transfected with a plasmid expressing wild-type HSF1 or the
S303A mutant and analyzed for HSF1 multimerization by EGS cross-
linking as in A.
doi:10.1371/journal.pone.0015976.g002
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if GSK3 phosphorylates and represses HSF1 via S303 phosphor-
ylation in vivo. To test if GSK3 contributes to HSF1 repression, we
assayed human HSF1-dependent yeast growth in a strain also
lacking the yeast GSK3 homolog Rim11. Supporting the notion
that yeast GSK3 can repress human HSF1 activity in yeast we
observed human HSF1-dependent yeast growth as well as HSF1
multimerization in the rim11D strain (Figure 4A, B). However,
HSF1-dependent yeast growth in the rim11D strain was less robust
than growth of a wild-type strain expressing the S303A HSF1
mutant (Figure 4A). Furthermore, when we expressed the S303A
HSF1 mutant in the rim11D strain we observed HSF1-dependent
growth at a rate similar to the growth of the S303A mutant in
wild-type cells. This suggested the possibility that HSF1 might not
be fully derepressed in the rim11D strain. Consistent with this idea,
we did not detect a reduction in S303 phosphorylation in the
rim11D strain (Figure 4C). S. cerevisiae encodes four separate yet
partially functionally redundant GSK3 homologues [32], suggest-
ing the possibility that S303 remains phosphorylated in the rim11D
strain due to phosphorylation through other GSK3 proteins. To
test this hypothesis we assayed the phosphorylation state of HSF1
at S303 in a yeast strain lacking all four isoforms of yeast GSK3.
As shown in Figure 4D, no reduction in S303 phosphorylation was
observed in the 4xgsk3D strain suggesting that while yeast GSK3
does contribute to HSF1 repression, it does so independently of
S303 phosphorylation.
Results shown here for the S303A HSF1 mutant and previously
published for the LZ4m HSF1 mutant suggest that mechanisms
that regulate HSF1 in mammalian cells are at least partially
conserved with regulation of human HSF1 expressed in yeast cells.
Therefore, we carried out experiments to ascertain if GSK3 might
also repress HSF1 independently of S303 phosphorylation in
mammalian cells. To explore this possibility HeLa cells were
treated with the GSK3 inhibitor SB-216763 [33] and assayed for
HSF1 S303 phosphorylation as ascertained by immunoblotting
with the anti-pS303 antibody. While SB-216763 treatment
strongly inhibited GSK3 activity as shown by increased b-catenin
levels [34], no reduction in S303 phosphorylation was observed
(Figure 5A). However, similar to the results obtained from our
yeast experiments, SB-216763 did promote activation of HSF1
under normal growth conditions, as determined by immunoblot
analysis of Hsp70 expression (Figure 5A). This result is consistent
with a previous report showing increased Hsp70 expression in
response to lithium treatment, which also inhibits GSK3 function
[35]. siRNA mediated knock-down of the two GSK3 isoforms in
mammals, GSK3a and GSK3b, either singly or in combination,
further confirmed that, while b-catenin expression was elevated,
HSF1 S303 was not appreciably phosphorylated by GSK3 in
unstressed mammalian cells (Figure 5B). Together, data from
experiments in both yeast and mammalian cells support a model in
which GSK3 inhibits HSF1 activity through a mechanism that is
independent of S303 phosphorylation.
Slt2 represses human HSF1 activity via S303
phosphorylation in yeast
To begin to identify which protein kinase(s) in yeast phosphor-
ylate human HSF1 at S303 to promote HSF1 repression, we
assayed S303 phosphorylation in several previously generated
protein kinase deletion strains obtained from the yeast gene
Figure 3. Phosphorylation of S303 and coiled-coil domains synergize in the repression of HSF1 in yeast. (A) PS145 expressing either
wild-type HSF1 or mutant alleles of HSF1 were grown in dextrose supplemented medium for 4 d. Growth was monitored by measuring O.D.600. (B)
PS145 was transformed with a plasmid expressing wild-type HSF1 (WT) or mutant alleles of HSF1 and grown on galactose containing medium. Total
protein extracts were analyzed for pS303, total HSF1 and Pgk1 by immunoblotting. (C) Protein levels of HSF1 were normalized to Pgk1, from panel B.
(D) Levels of HSF1 phosphorylated at S303 were quantified and are shown as a percent of total HSF1, from panel B.
doi:10.1371/journal.pone.0015976.g003
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deletion collection [36]. One strain in which we detected severely
reduced levels of human HSF1 S303 phosphorylation was a strain
deleted for the SLT2 gene, encoding a stress-responsive MAPK
[37,38], consistent with S303 lying within a consensus site for
MAPK-dependent phosphorylation (Figure 6A) [39]. This suggests
that Slt2 either directly or indirectly promotes the phosphorylation
of human HSF1 expressed in yeast. This hypothesis was further
supported by the observation that an slt2D strain allowed wild type
human HSF1-dependent yeast growth at a rate similar to the
HSF1 S303A mutant, while no growth was observed in the SLT2
wild-type strain (Figure 6B). Homotrimerization of wild-type
human HSF1 was observed in the slt2D strain at levels similar to
the S303A and LZ4m HSF1 mutants, further supporting the
notion that the Slt2 MAPK represses human HSF1 multi-
merization in yeast (Figure 6C). In mammalian cells the most
closely related homolog of Slt2 is the MAPK ERK5 [40].
However, using siRNA-mediated knock-down of ERK5 we were
unable detect an effect of ERK5 on HSF1 S303 phosphorylation
in mammalian cells (data not shown). This may suggest that in
mammalian cells S303 can be phosphorylated by multiple
MAPKs. This hypothesis is supported by previous data showing
that ERK1/2 as well as the stress-responsive MAPK p38 could
phosphorylate HSF1 at S303 in vitro [18]. In addition, our data
showing reduced, but not eliminated phosphorylation of S303 in
the slt2D strain (Figure 6A) also support a model where S303 may
be phosphorylated by multiple MAPKs.
Expression of S303A and S307A mutants in hsf12/2 cells
results in constitutive activation of Hsp70 expression
Previous studies have assayed the function of S303 and S307
phosphorylation in HSF1 regulation via in vitro phosphorylation
experiments [22], in vivo using lexA/Gal4-HSF1 fusion proteins
lacking the native HSF1 DNA binding domain [17,18] or via
overexpression of a S303A HSF1 mutants in mammalian cells
expressing endogenous wild-type HSF1 [16]. We tested the
consequences of loss of S303 and S307 phosphorylation on
HSF1 activity in the context of the entire protein using hsf12/2
MEFs which lack endogenous HSF1. When we expressed S303A,
S307A or S303/307A HSF1 mutants in hsf12/2 MEFs we
observed a modest elevation of Hsp70 expression under normal
growth conditions (Figure 7A, B) consistent with the hypothesis
that S303 phosphorylation modulates both homotrimerization as
well as transactivation by HSF1. However, HSF1 was not fully
activated through the S303A and S307A mutations, as expression
of Hsp70 was further enhanced when the transfected cells were
exposed to low levels of the proteasome inhibitor MG132
Figure 4. GSK3 represses HSF1 activity in yeast independent of S303. (A) PS145 (WT) expressing wild-type HSF1 or the S303A HSF1 mutant
and LNY1 (rim11D) expressing wild-type HSF1 were grown in dextrose supplemented medium for 4 d. Growth was monitored by measuring O.D.600.
(B) PS145 (WT) and LNY1 (rim11D) expressing wild-type HSF1 were grown on galactose containing medium and were evaluated for HSF1
multimerization by EGS crosslinking, SDS-PAGE, and immunoblotting using an HSF1 specific antibody. The positions of molecular weight markers are
indicated on the left, and circles indicating the expected migration of HSF1 monomers and trimers are on the right. Levels of HSF1 trimer as percent
of total HSF1 are shown below. (C) PS145 (WT) and LNY1 (rim11D) were transformed with a plasmid expressing wild-type HSF1 and were grown on
galactose containing medium. Total protein extracts were analyzed for pS303, total HSF1 and Pgk1 by immunoblotting. (D) YPH499 (WT) and LNY3
(4xgsk3D) were transformed with a plasmid expressing wild-type HSF1 and were grown in dextrose containing medium. Total protein extracts were
analyzed for pS303, total HSF1 and Pgk1 by immunoblotting.
doi:10.1371/journal.pone.0015976.g004
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(Figure 7A, B). This is consistent with our data generated in yeast
demonstrating that while the S303A mutation did activate human
HSF1-dependent yeast growth, this was further enhanced when
the S303A HSF1 mutant was combined with the LZ4m mutation
(Figure 3A). Interestingly, in hsf12/2 cells we observed a faster
electrophoretic mobility on SDS-PAGE gels for the HSF1 S303A
and S303/307A mutant proteins that was not observed for wild-
type HSF1 or the S307A mutant (Figure 7A), nor did we observe
this change in mobility in the yeast system (Figure 1D). While the
nature of this electrophoretic mobility shift is unknown, the HSF1
S303A and S303/S307A mutant alleles also exhibited lower
steady state levels when exposed to MG132, suggesting that these
proteins, despite having increased activity, might be less stable
(Figure 7A, C). Because S303 phosphorylation has been proposed
to promote HSF1 sumoylation in mammalian cells [16] it is
possible that lack of sumoylation results in the altered electropho-
retic mobility. Despite the fact that equal amounts of plasmid
DNA were transfected for each mutant, we observed elevated
steady state protein levels for the HSF1 S307A mutant (Figure 7A,
C). While we have not definitively demonstrated that the S307A
mutant protein has increased stability in comparison to wild-type
HSF1, this finding correlates with the increased protein levels we
observed for the HSF1 mutants expressed in yeast (Figure 1D, F)
and will require further investigation. Interestingly, when we
expressed the HSF1 S307A mutant in hsf12/2 cells we did not
observe a reduction in S303 phosphorylation (Figure 7A, D) as was
observed in yeast cells (Figure 1D, E) suggesting that priming
requirements for S303 phosphorylation may change in different
expression systems.
Discussion
Mammalian HSF1 activity is regulated via complex regulatory
mechanisms that include post-translation modifications as well as
inter- and intra-molecular protein-protein interactions [2]. While
our understanding of these regulatory mechanisms remains
incomplete, earlier work has suggested that many of these
mechanisms may be conserved in yeast [25,26,27,28]. This is
evident, in part, by repression of the human HSF1 protein when it
is expressed in S. cerevisiae via coiled-coil domain and HSF1 loop
interactions. In this report we show that evaluation of the
mechanisms that regulate HSF1 activity in yeast via post-
translational modifications can lead to important insights into
the mechanisms that regulate HSF1 in mammalian cells.
Previous experiments using HSF1 fusions with the constitutively
bound Gal4 or lexA DNA-binding domains demonstrated that
phosphorylation of S303 contributed to the repression of HSF1
transactivation [17,18]. In this report we show that alanine
substitution of S303, in the context of full length HSF1, also results
in increased levels of trimerized HSF1 both in un-stressed yeast
and in mammalian cells. This suggests that aside from repressing
transactivation, S303 phosphorylation can also repress earlier
points in the HSF1 activation pathway. Interestingly, we also show
that repression of HSF1 activity through S303 phosphorylation
may occur independent of K298 sumoylation in yeast, as arginine
substitution of K298 does not promote HSF1 activation in yeast. It
should be noted that not all of the mechanisms that regulate
human HSF1 in mammalian cells are conserved in yeast. While
human HSF1 is repressed in both yeast and mammalian cells
through an amino-terminal coiled-coil as well as a carboxyl-
terminal linker domain, the ability of wild type human HSF1 to
respond to proteotoxic compounds or thermal stress, for example,
appears to be strikingly absent in yeast [25,27,28]. Nevertheless,
the ability of S303 phosphorylation to promote repression of
human HSF1 in yeast independent of K298 sumoylation suggests
that our understanding of the mechanisms by which S303
phosphorylation represses HSF1 activity remains incomplete.
S303 and S307 are located in the regulatory domain of HSF1, a
proposed binding site for the protein chaperone Hsp90 [41]. As
such, it is tempting to speculate that phosphorylation of these
residues might affect binding to Hsp90.
An understanding of how phosphorylation regulates HSF1
activity and what protein kinases phosphorylate HSF1 remains
largely incomplete [20,22]. Early reports showed that in vitro,
HSF1 S307 phosphorylation acted as an essential priming event
for S303 phosphorylation [22]. However, a subsequent report
showed this priming event was not required in vivo and that HSF1
S303 phosphorylation occurred independent of S307 phosphor-
ylation in K562 cells [16]. The work presented here using the yeast
model system furthers our understanding of these regulatory
mechanisms and may begin to clarify the conflicting mechanisms
underlying S303 phosphorylation. Specifically, our data suggest
that while phosphorylation of S303 can occur independently of
S307 phosphorylation in both yeast and mammalian cells, S303
phosphorylation may be enhanced by S307 phosphorylation in the
non-native yeast system. While a mechanistic basis for this
difference in the requirements for S303 phosphorylation remains
unknown when HSF1 is expressed in yeast, structural differences
could change the priming requirements for S303 phosphorylation.
Such changes in HSF1 might occur due to different protein
interactions and as such it is not surprising that in in vitro
experiments, using only recombinant HSF1 protein, phosphory-
lation of S303 is fully dependent on S307 phosphorylation.
However, further studies will be required to fully test these
hypotheses.
Here, we demonstrate that in both yeast and mammalian cells
phosphorylation of HSF1 S303 appears to occur independently of
GSK3, previously thought to be the primary kinase responsible for
S303 phosphorylation [20,22]. Rather, as suggested by loss of
function analysis, we propose that the MAPK Slt2 is one candidate
that phosphorylates HSF1 at S303 in yeast though residual
phosphorylation of HSF1 at S303 in an slt2D strain suggests that
Figure 5. GSK3 represses HSF1 activity in HeLa cells indepen-
dent of S303 phosphorylation. (A) HeLa cells were treated with
DMSO solvent or the GSK3 inhibitor SB-216763 (25 mM) for 15 h. Total
protein was analyzed for pS303, HSF1, and b-catenin by immunoblot-
ting. GAPDH serves as a loading control. (B) HeLa cells were treated
with siRNA specific for GSK3a and GSK3b either individually or together
or a scrambled siRNA for 72 h. Total protein was analyzed for pS303,
total HSF1, b-catenin, GSK3a/b and GAPDH by immunoblotting.
doi:10.1371/journal.pone.0015976.g005
Phosphorylation of Human HSF1 in Yeast
PLoS ONE | www.plosone.org 7 January 2011 | Volume 6 | Issue 1 | e15976
other MAPKs may also contribute to S303 phosphorylation.
Differences in HSF1 structure between the in vivo and in vitro
systems may also explain why different kinases can target S303 for
phosphorylation under different conditions. We speculate that
under some cellular conditions, for example physiological stress or
different cell types, HSF1 structure may be altered, thereby
shifting the S303-kinase specificity from a MAPK to GSK3. This
might, in part, contribute to the complexity in identifying all of the
mammalian kinases that phosphorylate S303. While GSK3 does
not appear to phosphorylate HSF1 at S303 in vivo, data presented
here nevertheless support a role for GSK3 as a repressor of HSF1
activity. It should be noted that several other serine residues in the
HSF1 coding sequence, including S307, are located within
putative GSK3 consensus sites [39].
The importance in understanding HSF1 regulation is under-
scored by recent findings showing that pharmacological activation
of HSF1 can increase protein chaperone expression and
ameliorate cytotoxicity in models of protein folding disease
[28,42,43,44,45]. As such, it is important to further our
understanding of the mechanisms that repress HSF1 activity as
potential points of therapeutic intervention in disease. For
example, our data has shown that the loss of S303-dependent
HSF1 repression can lead to the accumulation of protein
chaperones and as such could be efficacious in the treatment of
protein folding diseases. In support of this possibility Rimoldi et al
showed that over-expression of the HSF1 S303G mutant in HeLa
cells reduced aggregation and inclusion formation of an aggrega-
tion prone Ataxin1-31Q mutant protein [46] In addition,
Fujimoto et al showed that overexpression of a constitutively
active HSF1 mutant lacking the regulatory domain, which
includes S303 and S307, suppressed the aggregation and
cytotoxicity of a mutant Huntingtin protein in both cell culture
and mice [47]. Furthermore, Carmichael et al suggested that
GSK3-inhibitors might prove useful in the treatment of polyQ-
expansion diseases [48].
Materials and Methods
Yeast Strains, Plasmids
S. cerevisiae strains used in this study are listed in Table 1. Yeast
expression plasmids pRS424-GPD-HSF1 and pRS424-GPD-
HSF1LZ4m were described previously [25]. Point mutations were
introduced into the HSF1 coding sequence using the Quick-
Change Site-directed mutagenesis kit (Stratagene) and confirmed
by DNA sequencing. YEp351-Slt2-FLAG was kindly provided by
Dr. David E. Levin [49]. Mammalian expression plasmids were
Figure 6. S303 phosphorylation of HSF1 in yeast is modulated by Slt2. (A) PS145 and LNY2 (slt2D) were transformed with a plasmid
expressing wild-type HSF1 and were grown on galactose containing medium. Total protein extracts were analyzed for pS303, total HSF1 and Pgk1 by
immunoblotting. (B) PS145 (WT) expressing wild-type HSF1 or the S303A mutant or LNY2 (slt2D) expressing wild-type HSF1 were grown in dextrose
supplemented medium for 4 d. Growth was monitored by measuring O.D.600. (C) PS145 (WT) expressing wild-type HSF1, the LZ4m mutant or the
S303A mutant and LNY2 (slt2D) expressing HSF1 were evaluated for HSF1 multimerization by EGS cross-linking, SDS-PAGE, and immunoblotting. The
positions of molecular weight markers are indicated on the left and circles indicating the expected migration of HSF1 monomers and trimers are on
the right. Levels of HSF1 trimer as percent of total HSF1 are shown below.
doi:10.1371/journal.pone.0015976.g006
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generated by subcloning the HSF1 open reading frame from yeast
vectors into the mammalian vector pcDNA3.1.
Cell culture maintenance, transfection and siRNA
Mammalian cell lines used in the study were hsf12/2MEF cells
[30] and HeLa cells (ATCC, CCL-2). The MEF cells were
maintained in DMEM supplemented with 10% fetal bovine serum
(FBS), 0.1 mM nonessential amino acids, 100 U/ml penicillin/
streptomycin and 55 mM 2-mercaptoethanol. HeLa cells were
maintained in DMEM supplemented with 10% FBS and 100 U/
ml penicillin/streptomycin. MEF cells were transfected with HSF1
expressing plasmids using a Nucleofector (Lonza) and Nucleofec-
tor solution MEF2. siRNA was purchased from Dharmacon and
2 nmoles of each siRNA were transfected into HeLa cells using
Dharmafect 1. Knock-down of proteins was assayed 72 h after
siRNA transfection by immunoblot analysis.
Complementation assays
Growth curve experiments were carried out in 96-well plates as
described previously [28]. For spot assays yeast cells were grown
Figure 7. S303 and S307 repress HSF1 activity in hsf12/2 MEFs. (A) hsf12/2 MEFs were transfected with an empty vector or plasmids
expressing wild-type HSF1 or the S303A, S307A or the S303/307A mutants. The transfected cells were treated with DMSO solvent or MG132 (10 mM)
for 5 h. Total protein extracts were analyzed for Hsp70, pS303 and HSF1 by immunoblotting. GAPDH serves as a loading control. (B) Protein levels of
Hsp70 were normalized to GAPDH, from panel A. (C) Protein levels of HSF1 were normalized to GAPDH, from panel A. (D) Levels of HSF1
phosphorylated at S303 were quantified and are shown as a percent of total HSF1, from panel A.
doi:10.1371/journal.pone.0015976.g007
Table 1. Yeast strains used in this study.
Strain Genotype
PS145 MATa ade2-1 trp1-1 can1-100 leu2-3, 112 his3-11,15 ura3-1 hsf1D::LEU2 Ycp50gal-yHSF
YPH499 MATa ura3-52 lys2-801 ade2-101 trp1-D63 his3-D200 leu2-D1
BY4741 MATa his3D1 leu2D0 met15D0 ura3D0
LNY1 MATa ade2-1 trp1-1 can1-100 leu2-3, 112 his3-11,15 ura3-1 hsf1D::LEU2 Ycp50gal-yHSF rim11D::HIS3
LNY2 MATa ade2-1 trp1-1 can1-100 leu2-3, 112 his3-11,15 ura3-1 hsf1D::LEU2 Ycp50gal-yHSF slt2D::HIS3
LNY3 MATa ura3-52 lys2-801 ade2-101 trp1-D63 his3-D200 leu2-D1 rim11D::TRP1 mck1D::HIS3 mrk1D::URA3 ygk3D::kanMX
doi:10.1371/journal.pone.0015976.t001
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overnight in galactose-containing medium to allow for expression
of GAL1-yHSF and reseeded the following day at O.D.600 = 0.2
and spotted on either galactose or dextrose supplemented growth
media.
Immunoblot and Crosslinking Analysis
Protein extracts were generated from yeast cultures using glass
bead lysis in cell lysis buffer (25 mM Tris, 150 mM NaCl, 1%
Triton X-100, 0.1% SDS, 1 mM EDTA) supplemented with
protease inhibitors (Roche) and Halt phosphate inhibitor cocktail
(Thermo Scientific Pierce). Proteins extracts were generated from
mammalian cell culture using cell lysis buffer supplemented with
protease and phosphatase inhibitors. Protein concentrations were
quantified using the BCA assay and 80–100 mg of total protein was
resolved by SDS-PAGE and transferred to a nitrocellulose
membrane. HSF1 oligomerization was assessed using the amine-
specific cross-linker ethylene glycol bis-succinimidyl succinate
(EGS) (Pierce). Crosslinking analysis were carried out as described
previously [28]. Antibodies used in this study were anti-phospho-
S303(pS303) (ab47369, Abcam), anti-HSF1 [28], anti-Pgk1, anti-
FLAG (M2, Sigma), anti-Hsp70 (C92, Stressmarq), anti-b-catenin
(6B3, Cell Signaling), anti-GAPDH (6C5, Ambion) and anti-
GSK3a/b (D75D3, Cell Signaling). Quantification of immunoblot
data was done using Photoshop.
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In the budding yeast Saccharomyces cerevisiae, arsenic detoxi-
fication involves the activation of Yap8, a member of the Yap
(yeast AP-1-like) family of transcription factors, which in turn
regulates ACR2 and ACR3, genes encoding an arsenate reductase
and a plasma-membrane arsenite-efflux protein respectively. In
addition, Yap1 is involved in the arsenic adaptation process
through regulation of the expression of the vacuolar pump
encoded by YCF1 (yeast cadmium factor 1 gene) and also contri-
buting to the regulation of ACR genes. Here we show that Yap1
is also involved in the removal of ROS (reactive oxygen species)
generated by arsenic compounds. Data on lipid peroxidation and
intracellular oxidation indicate that deletion of YAP1 and YAP8
triggers cellular oxidation mediated by inorganic arsenic. In spite
of the increased amounts of As(III) absorbed by the yap8 mutant,
the enhanced transcriptional activation of the antioxidant genes
such as GSH1 (γ - glutamylcysteine synthetase gene), SOD1
(superoxide dismutase 1 gene) and TRX2 (thioredoxin 2 gene)
may prevent protein oxidation. In contrast, the yap1 mutant
exhibits high contents of protein carbonyl groups and the GSSG/
GSH ratio is severely disturbed on exposure to arsenic compounds
in these cells. These results point to an additional level of Yap1
contribution to arsenic stress responses by preventing oxidative
damage in cells exposed to these compounds. Transcriptional
profiling revealed that genes of the functional categories related
to sulphur and methionine metabolism and to the maintenance of
cell redox homoeostasis are activated to mediate adaptation of the
wild-type strain to 2 mM arsenate treatment.
Key words: arsenic stress, oxidative stress, transcriptional regul-
ation, yeast AP-1-like transcription factor Yap1 gene (YAP1),
yeast AP-1-like transcription factor Yap8 gene [YAP8; ACR1
(arsenic compound resistance protein 1 gene), ARR1 (arsenical-
resistance protein 1 gene)].
INTRODUCTION
Arsenic (As) is a highly toxic metalloid widely distributed in
Nature and mostly found in drinking water. The first step of inor-
ganic As(V) removal from the cytoplasm consists of its two-
electron reduction to As(III) using glutathione as the source of
reducing potential [1]. Chronic exposure to this compound is
generally associated with an increased risk of multiple cancers,
vascular diseases, developmental anomalies and neurological
disorders [2–4]. To counteract the deleterious effects caused by
arsenic compounds, almost all living organisms have developed
mechanisms to eliminate it. In the budding yeast Saccharomyces
cerevisiae, resistance to arsenic is achieved through the activ-
ation of the transcriptional regulator Yap8 [yeast AP-1-like
transcription factor Yap8, also called Acr1 (arsenic compound
resistance protein 1)] [5], which in turn, induces the expression
of an arsenate reductase and a plasma-membrane arsenite-efflux
protein encoded by the genes ACR2 and ACR3 respectively [6-
10]. In addition, the YCF1 gene product, yeast cadmium factor 1,
also facilitates the vacuolar extrusion of glutathione-conjugated
arsenite molecules [11]. Although Yap8 is the main regulator
of arsenic stress responses, Yap1 is also involved to a lesser extent
through YCF1 activation under these conditions and contributes
to the full activation of enzymes encoded by the ACR genes [12].
Both regulators belong to the Yap family of bZIP (basic domain/
leucine zipper) transcription factors, formed by eight members
[10], which modulates the activation of specific genes in response
to various stress (for a review, see [5]).
Arsenic toxicity and carcinogenicity in animals has been sug-
gested to be probably due to the generation of an oxidative
stress, thus provoking a deleterious effect by this metal [13].
Yeast mutants in genes related to several mitochondrial processes,
which show sensitive phenotypes to arsenic compounds, were
recently identified. A total of 20 specific-As(V)- sensitive mutants
were found, from which 13 genes have orthologues in humans
[14]. On the other hand, high-throughput arsenite-triggered
changes in transcriptional profiling [15,16] indicate that cell
antioxidant defences are up-regulated in yeast. Furthermore, other
investigators have shown a dose-dependent increase in the levels
of peroxidation of membrane lipids as a consequence of arsenite
exposure [17]. Yap1, the best-characterized member of the Yap
family and the major regulator in oxidative stress, is involved in
arsenic stress responses. These facts together led to the hypothesis
that arsenic induces oxidative stress in which Yap1 plays a major
role. It is indeed known that arsenite [As(III)] can react with the
thiol groups of proteins, inhibiting many biological pathways,
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whereas the pentavalent form [As(V)] of arsenic is a phosphate
analogue interfering with phosphorylation reactions [1]. Although
the toxic effect of both oxidation states, As(V) and As(III), appears
to be very similar, the elimination of As(V) requires its reduc-
tion to As(III) using the redox potential of GSH and thus inter-
fering with the GSH pool of the cell [1]. As recently pointed by
other investigators [14], tolerance to either arsenate or arsenite
also involves specific sets of mitochondrial genes.
We decided to evaluate, using biochemical and molecular
approaches, the damage caused by As(V) and As(III). We show
that oxidative stress is generated as an effect of arsenic exposure
in strains defective in the arsenic-extrusion machinery and in the
antioxidant defence system. By measuring the GSH/GSSG ratios,
we provide evidence indicating that arsenic compounds trigger
the disruption of the redox equilibrium (being the homoeostasis
rapidly achieved through the enhancement of GSH generation).
Transcriptional profiling of the wild-type strain under exposure to
arsenate reveals the induction of many Yap1-dependent genes and
genes involved in sulphur metabolism. Our results show that the
antioxidant defences are up-regulated in the mutant yap8, which
absorbs increased amounts of arsenite, in comparison with the
parental strain. Since the status of protein carbonylation is not
changed in the wild-type and yap8 strains, we conclude that the
activation of the antioxidant system under arsenic stress prevents
the accumulation of oxidized proteins. Consistent with this no-
tion, the yap1 mutant displays high levels of protein oxidation.
EXPERIMENTAL
Strains, plasmids and growth conditions
The yeast strains used in the present study were: BY4741
MAT a; his31; leu20; met150; ura30 (EUROSCARF),
BY4741 Δyap1 MAT a; his31; leu20; met150; ura30;
YML007w::kanMX4 (EUROSCARF), BYΔyap8 MAT a;
his3Δ1; leuΔ0; met15Δ; lys2Δ0; ura3Δ0; YPR199c::kanMX4
[12], BY Δyap1Δyap8 MAT a; his3Δ1; leuΔ0; met15Δ0;
lys2Δ0; ura3Δ0; YPR199c::kanMX4; YML007w::HIS [12] and
FT4 yap1 MAT a; ura3-52; trp1Δ63; his3-Δ200; leu2::PET56;
yap1Δ [18]. The complete coding region of YAP8 gene was de-
leted by the microhomology PCR method [19] to create the strain
FT4 yap8 MAT a; ura3-52; trp1Δ63; his3-Δ200; leu2::PET56;
yap8::KAN. Deletion was confirmed by PCR analysis of genomic
DNA using upstream and downstream primers. To overexpress
YAP8, the corresponding chromosomal region was amplified
by PCR using the primers 5′-CCATTGTAGGAGAGTAACCT-3′
and 5′-CATCGAATACTCCACATCGATC-3′. The product was
first cloned using the Zero Blunt® TOPO® PCR cloning Kit
(Invitrogen) and the XbaI/BamHI fragment was subcloned into the
2 μ vector YEplac195 [20]. The construct was sequenced using
the ABI Prism DyeDeoxy Terminator Cycle Sequencing Kit
(Applied Biosystems) and ABI Prism 373A Automatic Sequencer
(PerkinElmer). The plasmid overexpressing YAP1 was available
in our laboratory [18]. The CEN plasmids expressing the myc-
tagged YAP1 and GFP (green fluorescent protein)-tagged
YAP1 and YAP8 versions were obtained from Dr M.B.
Toledano’s group [21], from Kuge and colleagues [22] or was
available in our laboratory [12] respectively. Strains were grown
in complete YPD [1% yeast extract, 2% (w/v) bactopeptone
and 2% (w/v) glucose] or selective media [SC (synthetic
complete) or SD (minimal synthetic defined): 0.67% ammonium
sulfate/yeast nitrogen base without amino acids (Difco) and 2%
(w/v) glucose] supplemented with the appropriate selective amino
acids. Early-exponential-phase cells [attenuance (D600) 0.4–0.5]
were stressed by the addition of 2 mM As(V) (Na2HAsO) or
As(III) (NaAsO2) and samples were collected at the indicated
time points. Phenotypic growth assays were carried out by
spotting 5 μl of an early-exponential-phase sequentially diluted
culture (approx. 2000–20 cells) in selective medium con-
taining up to 2 mM Na2HAsO or NaAsO2. Growth was recorded
after 2 days at 30 ◦C. The bacterial Escherichia coli strain XL1-
Blue recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac
[F′proAB lacIqZDM15 Tn10 (Tetr)] (Stratagene) was used as the
host for routine cloning purposes. Standard methods were used
for genetic analysis, cloning and transformation [23].
Intracellular oxidation, lipid peroxidation and protein carbonylation
Measurements of intracellular oxidation and lipid peroxidation
were performed with 50 mg (dry weight) of mid-exponential-
phase cells grown under physiological conditions or exposed to
arsenate or arsenite stress. Intracellular oxidative stress generated
by arsenic compounds was monitored by measuring changes in
fluorescence resulting from the oxidant-sensitive probe DCF-
DA (2′,7′-dichlorofluorescein diacetate) [24]. A fresh ethanol
stock solution of DCF-DA was added to the culture to a final
concentration of 10 μM and cells were incubated for 15 min
to allow uptake of the probe. Cells from each aliquot were
cooled on ice, harvested by centrifugation at 2000 g for 5 min
at 22 ◦C and washed twice with distilled water. The cell pellets
were resuspended in 500 μl of water and lysed by vortex-
mixing in the presence of 1.5 g of glass beads. The extracts
obtained after centrifugation at 15 000 g for 5 min were diluted
and fluorescence was measured using a Photo Technology
International spectrofluorimeter set at an excitation wavelength
of 504 nm and an emission wavelength of 524 nm with a slit
width of 5 nm. The effect of deletions alone was measured
under physiological conditions and the results under arsenic stress
were expressed as the relation between the fluorescence of
stressed and unstressed cells. Lipid peroxidation was determined
by quantifying TBARS (thiobarbituric acid-reactive substances).
After 24 h incubation with As compounds, cells were cooled on
ice, harvested by centrifugation and washed twice with 20 mM
Tris/HCl buffer, pH 7.4. The pellets were resuspended in 500 μl
of the same buffer containing 10% (w/v) trichloroacetic acid
and 1.5 g of glass beads were added. The samples were lysed
using six cycles of 20 s agitation on a vortex-mixer, followed by
20 s on ice. Lipid peroxidation of cell extracts was monitored
spectrophotometricaly at 532 nm in an EDTA/thiobarbituric
acid/NaOH solution as described in [25], which determines the
accumulation of TBARS in cells. The control data for each mutant
strain grown under physiological conditions was expressed as
the amount of MDA (malondialdehyde)/mg of cell dry weight
formed and the results under arsenic stress are expressed as the
relation between the values of stressed and non-stressed cells.
Several authors have recently used this technique [26,27]. All
these experiments were carried out at least three times, with no
fewer than three replicate measurements in each experiment and
the results are presented are means +− S.D. To detect the presence
of carbonyl groups introduced in proteins as a result of arsenic
stress, an OxyBlotTM protein oxidation detection kit (Intergen)
was used. The samples were analysed by immunoblotting and
processed as described in [28], using rabbit anti-dinitrophenol
antibody as the primary antibody. As a loading control, levels of
the co-chaperone Sba1 were measured [29].
Glutathione determination
Measurements of thiols were performed by the spectrophoto-
metric GR–DTNB [glutathione reductase–5,5-´dithiobis-(2-nitro-
benzoic acid)] recycling method originally described by Griffith
c© The Authors Journal compilation c© 2008 Biochemical Society
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[30]. The wild-type and mutant strains grown to early exponential
phase were induced with 2 mM As(V), and samples collected at
the indicated time points were extracted in a solution consist-
ing of 0.1 M HCl and 1 mM EDTA, pH 1.35 [28]. The kinetics
of TNB [5-thio-2-nitrobenzoate] formation was monitored photo-
metrically at 405 nm. GSSG concentrations were determined in
the same extracts after a 30 min incubation of the supernatant with
2-vinylpyridine at room temperature (20–22 ◦C) to derivatize GSH
[30]. The concentration was determined by reference to a standard
prepared in HCl and was expressed as nmol of glutathione/mg cell
dry weight. Measurements were carried out three times, with three
replicates in each experiment and results are means +− S.D.
Determination of As (III) retention by atomic absorption
Analysis of the capacity of S. cerevisiae wild-type cells and Δyap1
and Δyap8 mutant versions to absorb and accumulate As(III) was
determined using atomic-absorption spectrophotometry, as prev-
iously described [31]. Arsenite, to a final concentration of 2 mM,
was added to the medium containing 1 mg (dry weight) of mid-
exponential-phase cells, and the culture was incubated at 28 ◦C in
a rotating bath for 4 h and 24 h. For measuring residual As(III)
present in the medium, 5 ml aliquots were centrifuged at 2000 g
for 5 min at 22 ◦C and the supernatant was collected and subjected
to atomic-absorption spectrophotometry using a PerkinElmer
3100 atomic-absorption spectrometer. As(III) absorption was
calculated by determining the difference in metalloid content
between the control medium without cells and the test medium
containing cells. Percentages of As(III) absorption were calcul-
ated by use of the following equation:
Absorption (%) = [(initial concentration–final concentration)/
initial concentration] × 100
The measurements were carried out three times, with three
internal replicates and the results presented are means +− S.D.
Protein extraction and immunoblot analysis
Δyap1 mutant cells transformed with the plasmid encoding c-
myc–YAP1 [21] were grown to early exponential phase and
induced or not with 2 mM As(V). Samples collected at the
indicated time points were harvested by centrifugation at 4 ◦C and
the protein extracts were prepared by the trichloracetic acid-lysis
method and immunoblotted as described in [32]. To follow the
kinetics of the recombinant c-Myc-Yap1 protein under arsenic
stress, immunoblotting was performed with 50 μg of proteins
that were probed with the 9E10 anti-c-Myc monoclonal antibody.
Sba1 (p23), encoded by the SBA1 gene [33], was used as a load-
ing control [29,34]. Detection was performed using an ECL®
(enhanced chemiluminescence) Western-blotting reagent kit
(Amersham Pharmacia).
Fluorescence microscopy
FT4 yap8 and FT4 yap1 strains transformed with pRS encoding
cp-GFP-HA-YAP8 [12] or cp-GFP-HA-YAP1 [22] respectively
(where cp is centromeric plasmid and HA is haemagglutinin),
were grown to early exponential phase and induced with either
2 mM As(V) or As(III) at the indicated time points. DAPI (4,´6-
diamidino-2-phenylindole) was added as a DNA marker at a
final concentration of 5 μg/ml, 5 min before microscopy. After
washing with PBS, cells were resuspended in a solution of
200 mM DABCO (1,4-diazadicyclo[2.2.2]octane) in 75% (v/v)
glycerol and 0.25 × PBS (Sigma–Aldrich). Both we and Delaunay
et al. [21] have shown that DABCO does not affect the localization
of the GFP fusions. GFP signals were analysed in living cells
with a Leica DMRXA fluorescent microscope equipped with a
Roper Scientific Micro-Max cooled CCD (charge-coupled device)
camera and MetaMorph software (Universal Imaging Inc.).
Northern Blot, real-time PCR and microarray analysis
RNA procedures were performed as described in [32]. RNA was
isolated from cultures that were either untreated or exposed to
2mM Na2HAsO or NaAsO2 at the indicated time points. For
Northern-blot analysis, approx. 40 μg of total RNA was separated
in formaldehyde gels and transferred on to nylon membranes
(Hybond XL;Amersham Pharmacia Biotech). Intragenic PCR
fragments of GSH1 and SNR17A/small nucleolar RNA U3 were
used as probes. For real-time quantitative PCR the RNA samples
were treated with DNase (TURBO DNAse-free; Ambion)
according to the manufacturer’s instructions. cDNAs were syn-
thesized by reverse transcription from 0.5 μg of total RNA,
using 50 pmol of (dT)15, 1 mM dNTP and 5 units of Transcriptor
Reverse transcriptase as described by the manufacturer (Roche).
cDNA amplification was quantitatively analysed by incorpor-
ation of SYBR Green I (LightCycler FastStart DNA Master
SYBR Green I; Roche) into double-stranded DNA, according
to the manufacturer’s instructions, on a Roche LightCycler II
Instrument, using the ACT1 (actin) gene as a loading control.
The fold change was determined by the 2CT method [35]. The
primers used were as follows: GSH1: 5′-GCTGCTGGTAAAA-
GAGACAATG-3′ and 5′-ACTCACATCGTTAGCCTCACAA-3′;
TRX2: 5′-GGTCACTCAATTAAAATCCGCTTC-3′ and 5′-CG-
ACGACTCTGGTAACCTCCTTAC-3′; SOD1: 5′-AGCCAACC-
ACTGTCTCTTACGA-3′ and 5′-ACACCATTTTCGTCCGTCT-
TTA-3′; and ACT1: 5′-CTA TTG GTA ACG AAA GAT TCA
G-3′ and 5′-CCT TAC GGA CAT CGA CAT CA-3′. For
transcript profiling, total RNA was purified using the RNAeasy
kit (Qiagen), followed by the RNA clean-up procedure. A
10 μg portion of RNA was used to generate labelled cDNA,
which was hybridized on the DNA arrays as described in [36].
We used arrays containing probes for most of the yeast open
reading frame, obtained from the plate-forme transcriptome of
the IFR36 (www.transcriptome.ens.fr). Slides were read using a
Genepix 4000B scanner from Axon. The images were analysed
with the Genepix pro 6.0 software. Data were normalized
using global lowess followed by print tip group median from
Goulphar software [37]. Complete microarray data are available
as Supplementary Table S1 at http://www.BiochemJ.org/bj/414/
bj4140301add.htm. The gene-ontology analyses were performed
by submitting the whole set of microarray results to the t-profiler
tool [38] using default parameters. Redundant or meaningless
functional categories were hidden (Table 1). The results presented
in Table 1 and Supplementary Tables S1 and S2 (at http://www.
BiochemJ.org/bj/414/bj4140301add.htm) are from three inde-
pendent experiments. Only genes measured at least twice were
kept for further functional analyses.
Statistical analysis
The results reported in the present study are the averages for
at least three independent experiments, with three replicates in
each experiment, and are expressed as the mean +− S.D. Statistical
differences among treatments were analysed by one-way ANOVA
with Tukey’s HSD (honest significant difference) multiple com-
parisons test (α = 0.05) using STATISTICA for Windows
(StatSoft Inc., Tulsa, OK, U.S.A.).
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Table 1 Gene-ontology analyses of the arsenate transcriptional response
T-profiler [38] was used to conduct gene-ontology analyses from the global set of microarray data (see the Experimental values). The T-values and E-values are directly taken from the t-profiler
output. The T-test is to assess whether the means of two groups are statistically different from each other. E-value is a parameter that describes the number of hits one can ‘expect’ to see by chance
when searching a database of a particular size. It decreases exponentially as the score (S) of the match increases.Redundant or meaningless gene-ontology categories were hidden. Examples of
genes belonging to each category are indicated, together with their fold induction.
Category T-value E-value Genes
Heat-shock-protein-activity 10.46 <1.0 × 10−15 HSP42 (11.2), SSA4 (11.0, HSP26 (7.5). SSE2 (5.9), HSP12 (5.5), HSP78 (5.1, HSP30 (5.1), SSA3 (3.5), SSA1 (3.0), HSP60 (2.2),
HSP104 (2.2). . . .
Sulfur metabolism 6.61 5.3 × 10−8 CYS3 (5.4), MET16 (5.2), MET10 (4.9), MET22 (4.0), HOM3 (4.0), MET6 (3.7), STR3 (3.7), MET28 (3.5), MET32 (3.3), MET2 (2.8),
MET8 (2.7), CYS4 (2.1). . . .
Response to stimulus 5.89 5.4 × 10−6 CUP1-2 (19.4), CUP1-1 (18.8), HSP42 (11.2), SSA4 (11.0), ARR2 (9.7), HSP26 (7.5), GRE2 (6.6), HSP12 (5.5), HSP78 (5.1), HSP30
(5.1), TRX2 (4.5), MXR1 (4.4), MET22 (4.0), FLR1 (3.7), SSA3 (3.5), HSP82 (3.5), TTR1 (3.4), DDR2 (3.0), POS5 (2.5), STF2 (2.4),
ATR1 (2.3), TSL1 (2.3), UBC4 (2.2), HSP104 (2.2), SNG1 (2.1), RDS1 (2.1), GRE3 (2.0), GPX2 (2.0). . . .
Oxidoreductase activity 5.67 2.0 × 10−5 OYE3 (14.2), ARR2 (9.7), AAD6 (8.3), AAD16 (7.1), AAD14 (6.8), GRE2 (6.6), SER33 (5.5), MET16 (5.2), MET10 (4.9), TRX2 (4.5),
MXR1 (4.4), OYE2 (4.0), TTR1 (3.4), PRX1 (3.1), YPR1 (2.9), TSA2 (2.8), MET8 (2.7), SER3 (2.5), ADE3 (2.4), ZWF1 (2.3), FMO1
(2.2), DLD3 (2.1), ALD4 (2.1), GRE3 (2.0), GPX2 (2.0) . . .
Response to oxidative stress 4.70 3.6 × 10−3 HSP12 (5.5), TRX2 (4.5), MXR1 (4.4), FLR1 (3.7), TTR1 (3.4), POS5 (2.5), GPX2 (2.0), GLR1 (1.9), GRX1 (1.8), TRX1 (1.7) . . .
Proteasome complex 4.31 2.2 × 10−2 UBC4 (2.2), RAD6 (1.9), RPN8 (1.9), RPN4 (1.9), SCL1 (1.8), UBP6 (1.7), PRE8 (1.7) . . .
Figure 1 Arsenic-sensitivity phenotypes and respective recovery by overexpression of YAP1 and YAP8
Wild-type (WT), Δyap1 and Δyap8 mutant strains were transformed with YEplac195 (empty vector), YEpYAP1 or YEpYAP8 and serially diluted cultures were spotted on selective medium supplemen-
ted with increasing concentrations of arsenate or arsenite (up to 2 mM). Plates were grown for 2 days at 30◦C. A representative experiment is shown. Abbreviation: PHY, physiological conditions.
RESULTS
YAP8 overexpression does not alleviate yap1 sensitivity
under As(V)
It has been suggested that Yap1 and Yap8 play distinct and well-
defined roles in the arsenic stress response by regulating dis-
tinct sets of genes [15,16]. In order to evaluate the physiological
relevance of this specificity, we performed growth complement-
ation assays (Figure 1). The yap8 mutant reveals a severe growth-
sensitive phenotype to both arsenate and arsenite, which is rescued
by the overexpression of YAP8. The yap1 mutant shows a mild
growth-sensitive phenotype under arsenate conditions. In contrast,
under arsenite treatment this phenotype is more accentuated. The
overexpression of YAP8 in the yap1 mutant partially alleviates
the growth-sensitivity of this strain under arsenite treatment, a
finding consistent with the notion that Yap1 and Yap8 exert
specific roles in arsenic stress responses. On the other hand,
YAP1 overexpression is not able to rescue the sensitive phenotype
of the yap8 mutant strain either under As(V) or As(III) con-
ditions (Figure 1). Altogether, these results suggest some level of
specificity of YAP1 and YAP8 in arsenic detoxification.
Induction of antioxidant defences by arsenate
In order to characterize global changes in cells subjected to arsen-
ate treatment, we performed microarray analysis. We therefore
compared the transcriptome of cells submitted to a 30 min
exposure to 2 mM of arsenate with the one of cells mock-treated
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Figure 2 Increase in intracellular oxidation and lipid peroxidation caused by arsenic stress
(A) Changes in DCF-DA fluorescence caused by deletions were monitored under physiological conditions. The values are expressed as photons/s. (B) Control and mutant strains were stressed with
2 mM arsenate or arsenite for 24 h and the enhancement of the intracellular oxidation was expressed as ratio of the fluorescences of stressed and non-stressed cells. (C) The effect of deletions in
the lipid-peroxidation content was measured as pmol of MDA/mg cell dry weight by the TBARS method. (D) The enhancement of lipid peroxidation was measured as the ratio of the levels observed
for stressed and non-stressed cells. The horizontal line corresponding to a ratio of 1.00 in (B) and (D) indicates the relative value under non-stressed conditions. Values are means +− S.D. for three
independent experiments. ∗∗P < 0.01. WT, wild-type; white bars, arsenate; black bars, arsenite.
with water. We made a global gene-ontology search using the
t-profiler software [38] to identify the cellular pathways that
were affected by arsenate (see Table 1 and Supplementary
Tables S1 and S2). This analysis indicated that arsenate
up-regulated genes involved in protein folding, sulfur and
methionine metabolism (mainly target genes of the transcription
factor Met4p), redox homoeostasis (including most of the
target genes of Yap1) and proteasome activity (including the
proteasome gene transcriptional regulator RPN4). This pattern
is indeed very characteristic of the oxidative stress response
and is similar to what has been described in the case of
cell exposure to arsenite [15,16] or cadmium [39]. Further-
more, the cellular pathway of response to stimulus, including the
genes ACR2 and ACR3, is also shown to be induced by arsenate
treatment.
Arsenic treatment generates oxidative damage in the yap1 mutant
Once having established that As(V) induces expression of genes
involved in redox homoeostasis, we adopted several biochemical
approaches to verify whether 2mM arsenate or arsenite treatment
was associated with an oxidative environment in yeast cells.
Intracellular oxidation was determined using the probe DCF-
DA, which is sensitive to ROS (reactive oxygen species). Time-
course experiments had been previously carried out in order to
determine the maximum levels of intracellular oxidation, which
occurred at 24 h of arsenic treatment (results not shown). The
results in Figure 2(A) reveal that deletion of YAP1, but not of
YAP8, interferes with the redox state of the cytoplasm under
physiological conditions. The direct exposure of wild-type cells
to either arsenate or arsenite does not lead to any detectable
increase in the intracellular oxidation levels (Figure 2B), the
level being identical in the absence of either YAP8 or YAP1
but increasing, however, when compared with the parental
strain. This value is still more accentuated in the case of the
double mutant. Furthermore, under physiological conditions,
increased peroxidation levels of cellular lipids, as compared with
the wild-type strain, were detected in the yap1 mutant through the
formation of MDA (Figure 2C). Exposure of wild-type cells to
both arsenate and arsenite stress does not cause any significant
increase in lipid peroxidation compared with the unstressed
cells (Figure 2D), a finding that is in good agreement with the
intracellular oxidation results. In single and double mutants these
levels are increased about 1.6- and 2.6-fold respectively. Taken
together, these results show that arsenic compounds generate
oxidative stress under conditions where the arsenate extrusion
system and/or the antioxidant machinery are deficient. Protein
carbonyl content is an indicator of oxidative stress and is by far
the most commonly used biomarker of protein oxidation [40].
To monitor the possible oxidative effects of arsenic treatment at
the protein level, the changes in protein carbonyl status during
exposure of yeast cells to both arsenate and arsenite were moni-
tored up to 4 h. The resulting OxyBlotsTM show that the amount of
carbonylated proteins does not vary significantly in the wild-type
strain and the mutant yap8, although in the latter the levels of
oxidized proteins are slightly increased at all time points studied
(Figure 3). A more severe effect was, however, observed in the
yap1 strain. When these cells are treated with arsenate, the pro-
tein carbonyl content is slightly enhanced compared with the
untreated cells. By contrast, exposure to arsenite caused a strong
increase in the protein oxidation levels. This effect is even more
severe during the first hour of treatment. Furthermore, additional
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Figure 3 Immunological detection of protein carbonyl groups in the
Saccharomyces cerevisiae wild-type (WT) and Δyap1 and Δyap8 mutant
strains
The carbonyl groups introduced in proteins as a consequence of arsenate and arsenite treatment
were derivatized to 2,4-dinitrophenylhydrazone (DNP) and were immunoblotted with anti-DNP
antibodies. Sba1 was used as an internal loading control. C, OxyBlotTM Protein Standard
(Intergen). A representative experiment is shown.
carbonylated proteins, most of high molecular mass, were
observed in the yap1 strain. These findings suggest that the effects
of oxidative stress generated by arsenic compounds lead to protein
oxidation only in the absence of yap1.
YAP1 deletion interferes with the redox equilibrium under arsenate
Our transcriptome analysis showed that arsenate up-regulates
genes in the cellular pathway of sulphur and methionine metabol-
ism. Furthermore, it has been shown that arsenite-exposed cells
channel a large part of assimilated sulfur into glutathione biosyn-
thesis [16]. Yap1 is an important regulator of GSH1, which
encodes the enzyme responsible for catalysing the condensation
of cysteine on to the γ -carbon atom of glutamate in the limiting
step of glutathione biosynthesis. This prompted us to evaluate
how the requirement of Yap1 couples with the induction of GSH
biosynthesis mediated by arsenate and arsenite. It was observed,
by measuring the GSH and GSSG contents in the wild-type
and mutant strains subjected to arsenate stress, that in all strains
Figure 4 Antioxidant defences during arsenic treatment
(A) The wild-type (WT) and Δyap1, Δyap8 and Δyap1Δyap8 mutant cells were grown to
mid-exponential phase and were exposed to 2 mM arsenate. Extracts were obtained at the
time points indicated and GSH levels were determined as described in the Experimental section.
Values are means +− S.D. for three independent experiments. (B) Levels of GSSG were determined
in the same extracts after its derivatization to GSH and the GSSG/GSH ratio was calculated.
∗∗P < 0.01.
the GSH levels diminish about 2-fold during the first 1 h of
treatment with 2 mM As(V) (Figure 4A). These values rise
gradually over time, reaching physiological levels after 4 h. A
similar pattern was observed under As(III) treatment (results not
shown). The GSSG/GSH ratio increases after 1 h of treatment
and reflects the decrease in GSH (compare Figures 4A and 4B).
Notably, the double mutant Δyap1Δyap8 takes a longer time to
recover the GSH levels of the parental strain. Our results show
that the redox equilibrium is disrupted in strains bearing YAP1
deletions, although homoeostasis is rapidly achieved through the
enhancement of GSH generation.
Yap1 is maintained in the induced state in long-term arsenate
exposure
The biochemical assays clearly show that the wild-type strain, in
contrast with the mutant yap1, does not suffer the deleterious
effects of oxidative stress on exposure to inorganic arsenic.
Indeed, the microarrays revealed that many of the antioxidant
defences, as well as the arsenic detoxification system, were
induced under As(V) treatment (see Supplementary Tables S1 and
S2) to facilitate cell adaptation. In order to analyse the c-Myc–
Yap1 protein levels in cells induced or not with arsenate, Western-
blot analyses were performed. As Figure 5(A) shows, the levels
of Yap1 were rather higher in arsenate-treated cells than in cells
grown under physiological conditions. Yap1 protein levels peak
at about 45 min after arsenate addition and a slight induction
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Figure 5 Yap1 is activated in a long-term arsenate exposure
(A) Strain BY (EUROSCARF) yap1 mutant cells transformed with a CEN-plasmid encoding the fusion c-myc–YAP1 were grown under physiological conditions or in the presence of 2 mM arsenate
and sample were harvested at the indicated time points. Protein extraction, separation, transfer and immunoblotting were performed as described in the Experimental section. The protein levels
for Sba1 were used as an internal loading control against which all protein levels were normalized (lower panel). (B) Kinetics of Yap1 and Yap8 nuclear localization. Δyap1 and Δyap8 mutants
expressing the fusions GFP–YAP1 and GFP–YAP8 respectively, were induced with 2 mM arsenate and analysed for GFP staining at the indicated time points. Representative experiments are shown.
is maintained even up until 12 h of treatment. Furthermore,
localization assays revealed that GFP–Yap1, as well as GFP–
Yap8, are accumulated in the nucleus until 24 h of arsenate
treatment (Figure 5B).
GSH1, SOD1 and TRX2 are highly induced under arsenic treatment
To evaluate whether Yap1 activation reflects the induction of
the antioxidant cell defences such as GSH1, SOD1 and TRX2,
we monitored their transcriptional activation by real-time PCR.
Figure 6 reveals that, in the wild-type strain, these genes are highly
induced by 2 mM arsenite or arsenate. Strikingly, transcriptional
activation of GSH1, SOD1 and TRX2 is even higher in the yap8
mutant than in the wild-type strain. Under conditions of exposure
to arsenate, all of these genes display a first peak of induction
at 90 min, although after 24 h incubation with the metalloid the
mRNA levels keep increasing in yap8 (see Figure 6A). The pattern
of mRNA induction in the wild-type and yap8 strains is very
similar up to 4 h exposure to arsenite. However, after this point
a strong transcriptional activation of the three genes is observed
only in the yap8 mutant (Figure 6B). Expression of SOD1 and
TRX2 is completely abolished in the yap1 mutant (results not
shown), a finding consistent with the fact that Yap1 regulates them.
Some level of Yap1-independent GSH1 induction was observed
(Figure 6C), suggesting that other factors might be regulating its
expression under arsenic stress.
The yap8 mutant absorbs increased levels of As(III)
As Yap8 regulates As(III) detoxification, we hypothesized that
the strong transcriptional activation of the antioxidant genes in the
mutant yap8 was caused by arsenite accumulation. In order to
verify this, we used atomic-absorption spectroscopy. After adding
2 mM arsenite to wild-type and yap8 cultures, the residual
amounts of the metalloid in the supernatant at the time points indi-
cated in Figure 7 were determined. We also performed measure-
ments in the yap1 mutant in order to evaluate the contribution
of Yap1 to arsenite detoxification. As Figure 7 shows, arsenite
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Figure 6 Effect of As(V) and As(III) on the transcriptional activation of GSH1, SOD1 and TRX2 in the wild-type (WT) and Δyap8 mutant strains
Cells upshifted to arsenate (A)- or arsenite (B)-supplemented medium were harvested at the indicated time points. RNA extraction and real-time PCR were performed as described in the Experimental
section. (C) GSH1 expression in the Δyap1 mutant was monitored by Northern blotting as described in the text. The mRNA levels for small nucleolar RNA U3 were used as an internal loading control.
Representative experiments are shown.
absorption in S. cerevisiae wild-type cells is very low (around
5%). The yap8 mutant absorbs higher levels of As(III) (8%)
than those observed in the wild-type. Increased As(III) absorption
in the yap8 mutant may explain why the antioxidant genes are
more activated in this strain than in the wild-type (see Figure 6).
Surprisingly, yap1 As(III) absorption is slightly decreased com-
pared with the wild-type, suggesting that either the uptake is
compromised in this strain, that extrusion is enhanced or that
both events are occurring.
DISCUSSION
It has been accepted that, among the various modes of action for
arsenic carcinogenesis in human cells, the oxidative stress relev-
ance is the one that assumes that ROS can directly or indirectly
damage DNA and proteins [13,41]. Indeed, the property of the
organic arsenicals to inhibit the GSH and thioredoxin reductases,
as well as to bind GSH [42,43], perturbs the redox equilibrium
of the cytoplasm, leading to the accumulation of ROS. Here we
report that Yap1, the major regulator of oxidative stress response
in S. cerevisiae, is involved in the removal of ROS generated
by arsenic compounds. Our data on lipid peroxidation, together
with those on intracellular oxidation, indicate that yap1 and yap8
mutant cells are more oxidized than those of the wild-type strain
upon treatment with arsenic compounds (Figure 2). The increased
lipid peroxidation levels that we observed upon As(III) exposure
is consistent with the notion that arsenite has the ability to release
Fe(II) from its complexes with proteins, potentially stimulating
the peroxidation of cellular lipids in yeast [44] (Scheme 1).
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Figure 7 Effect of YAP1 and YAP8 deletion on As(III) absorption
Atomic-absorption analyses of As(III) were carried out in buffer solution containing 1 mg (dry
weight) of S. cerevisiae wild-type (WT) or mutant cells and the amount of As(III) absorbed was
estimated by determining the difference between the initial As(III) added (2 mM) and the residual
As(III) present in the medium after 4 (white bars) and 24 (black bars) h. The percentage of As(III)
absorbed was caculated by determining the ratio of As(III) taken up by cells and the initial As(III).
Values are means +− S.D. for three independent experiments. ∗∗P < 0.01.
This may, in turn, give rise to the highly reactive superoxide
radical. Moreover, enhanced lipid peroxidation levels are also in
agreement with the assumption that its induction by arsenite may
be responsible for the toxic effect of this compound in eukaryotic
cells [17]. Both yap1 and yap8 strains exhibit high levels of lipid
peroxidation and intracellular oxidation; however, yap1 is the
only one displaying high contents of oxidized proteins (Figure 3).
The antioxidant genes GSH1, SOD1 and TRX2 are induced in
the wild-type strain their induction being even higher in the yap8
mutant (see Figures 6A and 6B). The antioxidant machinery is
therefore activated by Yap1, which prevents protein damage in
these strains.
Redox-inactive toxic metals such as arsenic react with GSH,
the reduced form of glutathione, which is the major antioxidant
reserve of the cell [45]. We have in fact observed that, during the
first 1 h of treatment with arsenate, the levels of GSH are decreased
in all strains (Figure 4), with a consequent increase in the oxidized
form (GSSG). As GSSG is formed, cells must, in order to main-
tain redox homoeostasis, induce the generation of GSH. This
occurs either via its recycling through the glutathione reductase
Glr1 or synthesis de novo, in which the activity of Gsh1 is
essential. The transcriptomic analyses fully support the activation
of both pathways in the wild-type strain (see Table 1 and
Supplementary Tables S1 and S2). We show that genes grouped
in functional categories related to sulfur metabolism, sulfur-
amino-acid biosynthesis and metabolism, as well as GLR1, are
induced when this strain is treated with 2 mM arsenate for 30 min
(Table 1). Indeed, it had already been shown that arsenite-exposed
cells channel a large part of assimilated sulfur into glutathione
biosynthesis [16]. In the case of yap1 the recycling pathway
is impaired, since GLR1 is a Yap1 target. Interestingly, even
in cells harbouring YAP1 deletion, the GSH levels upon 2 h of
exposure to arsenic compounds increased, a finding consistent
with the observation that GSH1 mRNA levels were not completely
abolished in the yap1 mutant treated with both arsenate and
arsenite (Figure 6C). Similarly, under glutathione depletion [46]
and cadmium injury [47], GSH1 has been shown to be regulated
by both Yap1 and Met4. Furthermore, the fact that induction of
GSH1 is only partially decreased in yap1 cells treated with the
superoxide-anion generator menadione [48] might suggest that
treatment of yeast cells with arsenic compounds also leads to the
formation of superoxide radicals, which, in turn, could trigger the
Yap1-independent basal transcription of GSH1. Yap1 contributes,
therefore, to arsenic stress responses by relieving the deleterious
effects of ROS in the cells (Scheme 1) through at least the
transcriptional activation of antioxidant enzymes encoded by
genes such as TRX2, GSH1 and SOD1 (Figure 6). Indeed, as
suggested by others [17], the enhanced SOD1 transcription is one
of the most important factors responsible for triggering the
Scheme 1 Contribution of Yap1 and Yap8 to arsenic stress responses
Yap8 is the key regulator of this response by mediating the efficient removal of arsenite from the cytoplasm. Yap1 activity is also required at this level, its major contribution being the induction of
the antioxidant defences in order to scavenge the ROS generated as a secondary effect of arsenic exposure.
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adaptation process to mitigate the toxic effect of arsenite in euk-
aryotic cells. Genes involved in protein folding are also induced
by arsenate stress, a phenomenon that is common to many forms
of stress (see Table 1 and Supplementary Tables S1 and S2).
The absence of a significant increase in intracellular oxid-
ation, lipid peroxidation and protein carbonylation, as well the
changes in the GSSG/GSH ratio, in the wild-type cells reflects
the ability of the wild-type strain to counteract the direct and/or
indirect deleterious effects of the metal and to adapt to the stress
condition (see Scheme 1). Phenotypic assays reveal, indeed, that
the wild-type cells are able to grow in the presence of 2 mM
arsenate and arsenite (Figure 1). Furthermore, YAP8 and YAP1
are both necessary to trigger the adaptation response, exerting a
complementary role, though at different levels. Because YAP8 is
the key regulator of arsenic stress responses by controlling the
expression of the arsenite efflux protein encoded by ACR3, its
absence leads to the accumulation of As(III), enhancing the gene-
ration of ROS, as suggested from the atomic-absorption, lipid-
peroxidation and intracellular-oxidation assays (see Figures 2, 3
and 7 and Scheme 1).
The YAP1 gene is shown to be essential in preventing protein
oxidation (Figure 3). On the other hand, Yap1 also contributes to
the regulated expression of ACR2 and ACR3, through recogniz-
ing the cis-element GATTAATAATCA positioned in the divergent
promoter of these genes (results not shown). It also regulates
the expression of the vacuolar pump encoded by YCF1, which
composes a parallel arsenite detoxification pathway by catalysing
the ATP-driven uptake of As(III)–GSH conjugates into the
vacuole [1,49]. It is noteworthy that the yap1 mutant absorbs
lower levels of arsenite than does the wild-type strain. Assuming
that arsenite vacuolar extrusion mediated by Ycf1 might be at least
partially compromised in this mutant, a plausible explanation for
the low values observed could be related to an impaired uptake
of the metal. It was in fact shown that Hog1 kinase, which in turn
modulates the uptake of As(III) dependent on the aquaglycero-
porin Fps1, is activated by the metalloid [50]. It is possible that,
in the yap1 strain, this process is not fully operating.
In conclusion, we have identified an oxidative pathway depend-
ent on Yap1 involved in the response of S. cerevisiae to arsenic
compounds.
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ABSTRACT 27 
Although arsenic is notoriously poisonous to life its utilization as therapeutics 28 
brings many benefits to human health being therefore essential to uncover the 29 
molecular mechanisms underlying arsenic stress responses in eukaryotic cells. 30 
Aiming to determine the contribution of Ca2+-signalling pathways to arsenic 31 
stress responses, we took advantage of the use of Saccharamomyces 32 
cerevisiae as a model organism. Here we show that Ca2+ enhances tolerance of 33 
the wild type and arsenic-sensitive yap1 strains to arsenic stress in a Crz1-34 
dependent manner, thus providing the first evidence that Ca2+-signalling 35 
cascades are involved in arsenic stress responses. Moreover, our results 36 
indicate that arsenic shock elicits a cytosolic Ca2+-burst in these strains, without 37 
the addition of Ca2+ exogenous sources, strongly supporting the notion that 38 
Ca+2 homeostasis is disrupted by arsenic stress. In response to arsenite-39 
induced increase of Ca2+ in the cytosol Crz1 is dephosphorylated, translocated 40 
to the nucleus and stimulates CDRE-driven expression of the lacZ reporter 41 
gene in a Cnb1-dependent manner. The activation of Crz1 by arsenite 42 
culminates with the induction of the endogenous genes PMR1, PMC1 and 43 
GSC2. Taken together, these data establish that activation of Ca2+-signalling 44 
pathways and the downstream activation of Crz1 transcription factor contribute 45 
to arsenic tolerance in the eukaryotic model Saccharomyces cerevisiae. 46 
 47 
 48 
  49 
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INTRODUCTION 50 
Arsenic (As) is a naturally occurring metalloid in the Earth’s crust. Highly toxic 51 
arsenic ion species are released into the environment primarily through the 52 
leaching from geological formations into aquifers, although anthropogenic 53 
sources also account for environmental contamination. Although it is used as 54 
therapeutics, chronic exposure to arsenic compounds constitutes a global 55 
health problem and has been associated with many diseases, including cancer 56 
(Tseng 2007). It is therefore important to clarify the cellular and molecular 57 
mechanisms involved in the response of eukaryotic cells to arsenic stress. In 58 
this context, the remarkably high degree of conservation between 59 
Saccharomyces cerevisiae and higher eukaryotes makes yeast a valuable 60 
model organism to unravel the complex and fundamental mechanisms 61 
underlying arsenic stress responses.  62 
Eukaryotic cells, from yeast to humans, respond promptly and precisely to 63 
adverse stimuli by a complete reprogramming of gene expression. This process 64 
is tightly orchestrated by specific transcription factors, which mediate the 65 
induction of genes conferring protective activity. Indeed, microarray 66 
transcriptional profiling of yeast cells exposed to arsenic compounds performed 67 
by us and others revealed that many cellular pathways, including those involved 68 
in oxidative stress defence, redox maintenance, glutathione biosynthesis and 69 
arsenic detoxification are enriched in arsenic-treated cells (Haugen et al., 2004; 70 
Thorsen et al., 2007; Menezes et al., 2008). The activity of Yap1, a member of 71 
the YAP (Yeast AP1-like) family of transcription factors, was shown to be 72 
essential to regulate the induction of ROS homeostasis machinery in cells 73 
exposed to arsenic stress (Menezes et al., 2004; Menezes et al., 2008). 74 
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Although multiple arsenic adaptation pathways, involving transcription factors 75 
such as Yap8, Met4, Hog1 and Abf1 have been described (Rodrigues-Pousada 76 
et al., 2010), the complex mechanism of arsenic stress responses is still far 77 
from being completely understood.  78 
Calcium ion (Ca2+) is an essential element playing a central role as intracellular 79 
messenger in eukaryotic cells. The utilization of Ca2+ to regulate a wide range of 80 
cellular processes, in response to a variety of environmental insults, is a 81 
strategy exploited by virtually all eukaryotic organisms. In yeasts, it has been 82 
reported that exposure of cells to many stress conditions including iron overload 83 
and ethanol shock, disrupts Ca2+-homeostasis (Batiza et al., 1996; Kanzaki et 84 
al., 1999; Matsumoto et al., 2002; Peiter et al., 2005; Araki et al., 2009; Popa et 85 
al., 2010; Li et al., 2011). However, in some conditions such as H2O2, tBOOH 86 
and aluminium treatment, Ca2+ regulates cytotoxicity instead of adaptation 87 
(Popa et al., 2010; Li et al., 2011).  88 
The stress-induced increase of cytosolic free Ca2+ is triggered either by the 89 
mobilization of extracellular sources, mainly via the high affinity Cch1/Mid1 90 
channel (Matsumoto et al., 2002; Peiter et al., 2005; Popa et al., 2010), or the 91 
release of vacuolar sources through the Yvc1 ionic channel (Denis and Cyert, 92 
2002). Homeostasis is restored by the sequestration of Ca2+ into the vacuole, 93 
through the action of the Ca2+-ATPase Pmc1 and the Ca2+/H+ exchanger Vcx1 94 
(Palmer et al., 2001). Alternatively, Pmr1 and Cod1 can direct Ca2+ to the 95 
secretory pathway in the ER and Golgi. Under conditions of high cytosolic Ca2+ 96 
concentrations, the essential Ca2+-receptor protein calmodulin (CaM) binds to 97 
Ca2+ undergoing a conformational change that allows the activation of target 98 
proteins such as the CaM-regulated kinases Cmk1/Cmk2 and calcineurin (CaN) 99 
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(Cyert, 2001). CaN is a highly conserved serine/threonine phosphatase 100 
composed by a catalytic and a regulatory subunit, encoded by CNA1 and 101 
CNB1, respectively, being the latter essential for enzyme activity and induction 102 
by CaM (Cyert et al., 1991; Cyert & Thorner 1992; Cyert 2003). CaN carries out 103 
multiple functions in yeast, standing out the regulation of the zinc-finger 104 
transcription factor Crz1. Like the mammalian ortholog NFAT (Yoshimoto et al., 105 
2002), upon dephosphorylation by CaN, Crz1 rapidly relocates to the nucleus 106 
(Stathopoulos-Gerontides et al., 1999) and mediates transcriptional activation 107 
through the CDRE (CaN-dependent Response Element). PMC1 and PMR1, 108 
encoding Ca2+ transporters, and GSC2, encoding a cell wall biosynthetic 109 
enzyme, are among the Crz1 target genes (Matheos et al., 1997; Stathopoulos 110 
& Cyert 1997; Denis & Cyert 2002).  111 
Interestingly, our recent microarray data suggests that arsenic stress affects the 112 
expression of genes involved in Ca2+-signalling pathways and these findings 113 
prompted us to investigate the role of Ca2+ ion in the yeast stress response to 114 
arsenite. Here we report that arsenite disrupts Ca2+-homeostasis and triggers 115 
the activation of Crz1, which in turns regulates the induction of genes encoding 116 
the Ca2+-transporters Pmr1 and Pmc1 and encoding a protein involved in the 117 
biosynthesis of cell wall, Gsc2.  118 
 119 
 120 
 121 
 122 
MATERIALS AND METHODS  123 
 124 
Bacterial and yeast strains, plasmids and growth conditions  125 
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The Escherichia coli strain XL1-Blue recA1 endA1 gyrA96 thi-1 hsdR17 supE44 126 
relA1 lac [F  proAB lacIqZΔM15 Tn10 (Tetr)] (Stratagene, Agilent Technologies, 127 
USA) was used as the host for routine plasmid amplification purposes. 128 
Outgrowth was performed in SOC medium at 37º C. Plasmids were selected on 129 
LB plates supplemented with 100 μg ampicillin ml-1.  130 
A list of S. cerevisiae strains and oligonucleotide primers used in this work are 131 
presented in tables 1 and S1 (see Supplementary material), respectively. The 132 
microhomology PCR method (Guldener et al., 1996) was used to generate the 133 
double mutant strains as follows: (1) crz1cnb1, deletion of CRZ1 coding region 134 
in the cnb1 mutant; (2) yap1crz1, deletion of CRZ1 coding region in the yap1 135 
mutant; and (3) YAA3-yap1, deletion of complete YAP1 coding region in the 136 
YAA3 strain. The double mutant yap1cbn1 was generated through the 137 
transformation of linearized pLF1 plasmid (encoding a YAP1 version where the 138 
HIS3 gene was inserted in the internal BamHI site of YAP1) in the cnb1 strain. 139 
Gene disruptions were confirmed by PCR analysis of genomic DNA using 140 
upstream (A1) and downstream (A4) specific primers (Table S1, Supplementary 141 
Material). The pEVP11-APOAEQUORIN (Batiza et al., 1996) was used to 142 
measure cytosolic free Ca2+ levels. Strains were grown in synthetic medium 143 
[SM - 0.67% (w/v) ammonium sulfate/yeast nitrogen base without amino acids, 144 
2% (w/v) glucose, supplemented with 20 μg L-histidine-HCl monohydrate ml-1, 145 
60 μg leucine ml-1, 20 μg uracil ml-1 and 20 μg L-methionine ml-1]. Selective 146 
synthetic media were prepared omitting the aminoacid corresponding to the 147 
auxotrophic marker. For solid media, agar was added to a final concentration of 148 
2% (w/v). All spectrophotometric measurements of yeast biomass were 149 
performed using a polystyrene 45 mm path length cuvette and the BIO-RAD 150 
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SmartSpecTM 3000 Spectrophotometer. Exponential growth phase cells were 151 
attained through the dilution of overnight cultures to an optical density at 600 152 
nm (OD600) of 0.1 ± 0.01 in fresh media followed by incubation to an OD600 of 153 
0.5 ± 0.05. For each experiment cells were treated with NaAsO2 (Sigma-Aldrich) 154 
and/or CaCl2 (Merck) under the conditions indicated in the respective figures. 155 
For RNA extraction samples were washed with appropriated buffers and stored 156 
at -80ºC. Standard methods were used for genetic analysis, transformation and 157 
gene disruption procedures (Ausubel et al., 1995).
 
158 
 159 
Growth assays 160 
Phenotypic growth assays were carried out by spotting 5 μl of sequentially 161 
diluted cultures (approx. 5x103, 1x103, 5x102, 1x102, 5x10 and 1x10 cells) in 162 
synthetic medium containing up to 1.5 mM NaAsO2 and/or 50 mM CaCl2. 163 
Growth was recorded after 2 days of incubation at 30º C. To monitor cell growth 164 
in liquid media early exponential phase cultures (OD600 0.5 ± 0.05) were diluted 165 
to 0.1 ± 0.01 and were treated with 1.5 mM NaAsO2. The cultures were 166 
incubated during 28 h at 30° C with orbital agitation (200 rpm) and the OD600 167 
was monitored in intervals of 2 h. 168 
 169 
 170 
Microarray analysis 171 
Total RNA was isolated as described previously (Puig et al., 2005) from 172 
exponentially growing BY4741 yeast cells that were either exposed or not to 173 
sodium arsenate 2 mM for 60 minutes; 50 µg of total RNA were sent for 174 
labelling and hybridization to Affymetrix Yeast Genome S98 arrays. For further 175 
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information about sample preparation visit the Duke Microarray Core Facility at 176 
http://www.genome.duke.edu/cores/microarray/. The data were analysed by 177 
using both Partek® Genomics SuiteTM and dChip softwares. The microarray data 178 
have been deposited in the microarray database Gene Expression Omnibus 179 
(GEO; http://www.ncbi.nlm.nih.gov/geo/) with the accession number GSE33427. 180 
 181 
In vivo monitoring of Ca2+-pulse induced by arsenic stress  182 
Monitoring of cytosolic Ca2+ was performed using the Apoaequorin reporter 183 
system (Batiza et al., 1996). For this purpose, the yeast strains BY4742 and 184 
yap1 were transformed with the plasmid pEVP11-Apoaequorin, kindly provided 185 
by Dr. Patrick H. Masson. For the luminescence assays, stationary pre-cultures 186 
were diluted to an OD600 of 0.1 ± 0.01 in fresh synthetic medium and were 187 
grown to an OD600 of 1 ± 0.1. To reconstitute functional aequorin, 50 μM native 188 
coelenterazine (Sigma; dissolved in methanol) were added to the cell 189 
suspension and the cells were incubated for 2 h at 30° C in the dark. Cells were 190 
harvested by centrifugation and were washed three times with phosphate 191 
buffered saline (PBS; 10 mM phosphate, pH 7.4, 138 mM NaCl, 2.7 mM KCl) to 192 
remove the excess of coelenterazine. The pellet was resuspended in synthetic 193 
medium and the cell suspension was transferred to a 96-wells microplate. 194 
Before the induction of arsenic stress, the base-line luminescence was 195 
determined by 1 min of recording at 10 s intervals using a Perkin Helmer 196 
VICTOR3 luminometer. NaAsO2, to a final concentration of 1.5 mM, was injected 197 
into the samples and light emission was recorded for further 9 min at  10 s 198 
intervals. The light emission was reported as relative luminescence units (RLU), 199 
expressed as counts per second (cps) OD600-1. Multiple tests were performed 200 
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for each condition and a representative experiment is shown. 201 
 202 
Protein extraction and immunoblot assays 203 
Strains encoding the CRZ1-GFP fusion were grown in synthetic media until 204 
exponential growth phase and were induced with 1.5 mM As(III). To specifically 205 
inhibit calcineurin function, the immunosuppressant cyclosporin A (Sigma) was 206 
used to a final concentration of 10 μg ml-1 30 min prior to cell induction with 207 
arsenite. Samples were collected at the time points indicated in the respective 208 
figure. Proteins were extracted by the TCA lysis method and 150 µg of total 209 
proteins were immunoblotted as previously described (Menezes et al., 2008). 210 
Crz1-GFP was detected using the anti-GFP (Serrano et al., 2011) and anti-211 
Rabbit (Santa Cruz) as a primary and secondary antibodies, respectively. Pgk1 212 
was used as the internal loading-control. Protein detection was performed using 213 
the kit SuperSignal West Pico Chemoluminescent Substrate (Thermo 214 
Scientific). 215 
 216 
Fluorescence microscopy 217 
Yeast strains expressing the green fluorescent protein (GFP)-tagged CRZ1 218 
were grown to early exponential growth phase in synthetic medium and cells 219 
were induced with 2.5 mM NaAsO2 for 15 min. DAPI (4´,6-diamidino-2-220 
phenylindole) (Sigma-Aldrich) was added to a final concentration of 5 μg ml-1, 5 221 
min before the end of the incubation with arsenite. Cells were collected, were 222 
fixed with 3.7% (v/v) formaldehyde (Sigma-Aldrich) for 10 min at room 223 
temperature and were washed twice with PBS. After washing, cells were 224 
resuspended in 200 mM DABCO [(1,4-diazadicyclo[2.2.2]octane) - dissolved in 225 
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75% (v/v) glycerol and 25% (v/v) PBS]. GFP signals were analysed in living 226 
cells using a Leica DMRXA fluorescent microscope equipped with a Roper 227 
ScientificMicro-Max cooled CCD (charge-coupled device) camera and the 228 
MetaMorph software (Universal Imaging Inc.). 229 
 230 
β–Galactosidase assays 231 
β-galactosidase activity measurements in cells harbouring the CDRE-lacZ 232 
reporter construct were performed as previously described (Menezes et al., 233 
2004). For this purpose BY4742, cnb1 and crz1 exponential-phase cells (OD600 234 
0.5 ± 0.05), encoding the CDRE-lacZ reporter construction, were treated either 235 
with 1mM NaAsO2 or 20 mM CaCl2 at 30ºC for 90 min. Cells were harvested by 236 
centrifugation, were permeabilized with chloroform and were assayed for 237 
enzyme activity using the Biotek Epoch Microplate Spectrophotometer. Miller 238 
units were calculated as previously described (Miller 1972). Experiments were 239 
performed using biological triplicates and the mean standard deviation (SD) is 240 
shown. 241 
 242 
 243 
Real-time PCR 244 
RNA was extracted from early log-phase cultures that were either untreated or 245 
exposed during 30 min to 1.5 mM NaAsO2. DNA was removed by on-column 246 
DNAse I digestion (RNase-Free DNase Set; Qiagen). Total RNA (1μg) was 247 
reverse transcribed with Transcriptor Reverse Transcriptase (Roche 248 
Diagnostics). qPCR reactions were performed in the LightCycler 480 Instrument 249 
(Roche), using LightCycler 480 Green I Master (Roche) and the 250 
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oligonucleotides listed in table S1. Relative standard curves were constructed 251 
for each gene, using triplicate serial dilutions of cDNA. The relative expression 252 
of the genes was calculated by the relative quantification method with efficiency 253 
correction, using the LightCycler 480 Software 1. Actin was used as a reference 254 
gene. All assays were made in triplicate. 255 
 256 
RESULTS AND DISCUSSION 257 
Genome-wide transcriptional analysis reveals that arsenic stress affects 258 
the expression of Ca2+-related genes  259 
Aiming to investigate the response of S. cerevisiae cells to mid-term arsenic 260 
exposure, we compared the mRNA expression profile of wild type cells up 261 
shifted to 2 mM Na2HAsO4-enriched medium for 60 min. Besides the up 262 
regulation of genes included in functional categories previously shown to be 263 
targeted by arsenic compounds, such as sulphur/methionine metabolism and 264 
redox homoeostasis (Haugen et al., 2004; Thorsen et al., 2007; Menezes et al., 265 
2008), our transcriptomic analysis revealed a significant alteration of the 266 
expression profile of genes related to Ca2+-signalling pathways (Table S2, 267 
Supplementary Material). In spite of several genome-wide experiments 268 
reported, this is the first time that such a response is detected, probably 269 
because none of previous works addressed the mid-term response (60 min) 270 
induced by arsenate. Among these genes are CRZ1, encoding the master 271 
transcriptional regulator of Ca2+-mediated signalling; RCN1 and CMP2, 272 
encoding proteins related to calcineurin function; CMD1, CMK2 and RCK2, 273 
encoding calmodulin and proteins directly regulated by calmodulin binding, 274 
respectively; and the calcium transporters encoded by MID1 and CCH1 (Table 275 
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2). Based on these results we hypothesized that Ca2+-signalling pathways could 276 
be involved in the response of yeast cells to arsenic stress.   277 
 278 
Exogenous Ca2+ increases arsenic tolerance in a Crz1-dependent manner 279 
To address the contribution of Ca2+-signalling to arsenic stress responses we 280 
first examined the growth phenotypes of the wild type, the arsenic-sensitive 281 
mutant yap1 (Menezes et al., 2004) and the respective isogenic crz1 and cnb1 282 
knockout strains in synthetic media supplemented with CaCl2. All the strains 283 
revealed similar growth patterns both in the absence and in the presence of 284 
CaCl2 concentrations up to 100 mM (Fig. 1a, upper panels). The crz1 and 285 
yap1crz1 strains did not exhibit any growth defect under Ca2+-replete condition 286 
compared to the wild type strain, indicating that cells were not under Ca2+ 287 
stress. Indeed, all the strains showed normal growth in media containing up to 288 
200 mM CaCl2 (Fig. S1, Supplementary Material). As already described, the 289 
yap1 mutant strain displayed high growth sensitivity to 1 mM As(III), whereas 290 
the wild type strain was shown to be resistant to 1 mM arsenite and moderately 291 
sensitive to the higher concentrations. Remarkably, arsenic-stressed wild type 292 
and yap1 cells, simultaneously treated with 50 mM CaCl2, were clearly more 293 
tolerant to arsenite stress (Fig. 1a, see middle and lower panels). Moreover, 294 
acquisition of tolerance mediated by Ca2+ was shown to be dose-dependent 295 
since media supplementation with 100 mM CaCl2 further enhanced the growth 296 
of these strains in the presence of arsenite. Our results therefore show that the 297 
increase in the availability of exogenous Ca2+ partially relieve arsenic toxicity 298 
and suggest that Ca2+ may be implicated in the adaptive response to arsenic 299 
stress. 300 
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The zinc-finger transcription factor Crz1 is a central player of the Ca2+-signalling 301 
cascade. To determine whether Ca2+ contributes to arsenic tolerance through 302 
the activation of Ca2+-signalling pathways we monitored, simultaneously, the 303 
growth of the respective crz1 isogenic strains. First, we found that the crz1 304 
mutant was moderately sensitive to 1 and 1.5 mM As(III) (see Fig. 1a - lower 305 
and middle panels, and Fig. 1b and 1c) revealing therefore a link between the 306 
Crz1 pathway and arsenic stress responses in yeast. Second, when CRZ1 was 307 
disrupted in the yap1 strain, the Ca2+-mediated phenotype recovery of the 308 
double mutant was compromised in the presence of 1 mM arsenite plus 100 309 
mM CaCl2, when compared to the yap1 single mutant, being completely 310 
abrogated in medium supplemented with only 50 mM CaCl2. Finally, the growth 311 
recovery of crz1 by Ca2+ was not as efficient as for the wild type strain in all the 312 
stress conditions tested. Altogether, these results provide strong evidences 313 
pointing out to the importance of Crz1 and Ca2+-signalling pathways to full 314 
adaptive S. cerevisiae arsenic stress responses.  315 
Under moderate arsenic stress conditions (1 mM NaAsO2), Ca2+ induced some 316 
degree of tolerance even in the absence of Crz1 (Fig. 1a – middle panel) 317 
implying that this ion may mediate arsenic tolerance also through the activation 318 
of Crz1-independent targets of the Ca2+-signalling cascade. The calmodulin-319 
kinase Cmk2, the related protein-kinase Rck2, the glutamate decarboxylase 320 
Gad1 and the endoplasmic reticulum-residing proteins Hph1/Hph2 are potential 321 
candidates, due to their protective functions under oxidative and cell wall stress 322 
(Cyert 2001; Sanchez-Piris et al., 2002; Heath et al., 2004), which are known 323 
cellular damages caused by arsenic stress (Menezes et al., 2008; Thorsen et 324 
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al., 2009). Indeed, we found that CMD1, CMK2 and RCK2 were up regulated by 325 
arsenic in our transcriptomic analysis (Table 2). 326 
Since the activation of Crz1 by Ca2+ is dependent on CaN function, we included 327 
in the phenotypic analysis the cnb1 mutant, which is defective in the regulatory 328 
subunit of the CaN complex. As cited before, inactivation of Cnb1 renders the 329 
phosphatase complex non-functional. Curiously, the cnb1 mutant exhibited 330 
increased tolerance to high-dose arsenite stress compared to the wild type 331 
strain, which was further increased when CaCl2 was added to the medium (Fig. 332 
1a - lower panel). The double mutant yap1cnb1 displayed similar growth 333 
patterns under low-dose arsenite stress (Fig. S2, Supplementary Material). 334 
Although yap1cnb1 was very sensitive to 1 mM arsenite, its growth was rescued 335 
through the supplementation of the medium with CaCl2. Under high arsenite 336 
dose (1.5 mM) yap1cnb1 growth recovery occurred only when media was 337 
supplemented with 100 mM CaCl2 (Fig. 1a – middle and upper panels).  338 
In order to understand the distinct behaviour of crz1 and cnb1 strains, we 339 
performed epistasis analysis. For this purpose, we constructed the double 340 
mutant crz1cnb1 and compared the growth phenotypes of the three strains 341 
exposed to arsenic stress in the presence and absence of CaCl2. The results in 342 
Fig. 1d clearly show that cnb1 mutation is dominant over crz1 mutation. This 343 
response is not specific to arsenic stress conditions since cnb1 is also dominant 344 
over crz1 in the presence of high CaCl2 concentrations (see Fig. S1, 345 
Supplementary Material). These results were not surprising since CaN is 346 
upstream of Crz1 in the Ca2+/CaM/CaN/-signalling pathway, regulating its 347 
translocation into the nucleus under conditions triggering the mobilization of 348 
Ca2+ in the cytosol. A plausible explanation for this phenotypic paradox may lie 349 
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on the fact that CaN regulates many substrates and therefore carries out 350 
multiple functions in yeast (Cyert 2001). Indeed, it was already reported that 351 
CaN mutants display defects that are not mimicked by the crz1 mutant, which 352 
reinforces its participation in the regulation of additional yeast proteins (Cyert 353 
2003). Our results suggest that CaN is possibly exerting dual effects: a) a 354 
protective function through the regulation of Crz1, and b) the mediation of 355 
arsenic toxicity either by activating proteins conferring toxicity or repressing 356 
those contributing to tolerance.  357 
 358 
Arsenite elicits a transient Ca2+ release into the cytosol 359 
The transient increase in free cytosolic calcium is a mechanism used by 360 
eukaryotic cells to activate the Ca2+-signalling pathways and thus to regulate 361 
many cellular processes in response to specific environmental cues (Viladevall 362 
et al., 2004; Tseng 2007; Araki et al., 2009). Given that an excess of 363 
extracellular Ca2+ favours cell adaptation to arsenic stress and that Crz1 activity 364 
is required to arsenic tolerance we next evaluated whether exposure to arsenite 365 
was accompanied by an increase of free cytosolic Ca2+ in media containing 366 
standard CaCl2 concentrations (approximately 0.8 mM) (Abelovska et al., 2007). 367 
For this purpose we used the apoaequorin-based methodology, which relies on 368 
the induction of aequorin activity by Ca2+ in a dose-dependent fashion (Batiza et 369 
al., 1996). To spontaneously reconstitute functional aequorin, wild type and 370 
yap1 cells transformed with the pEVP11-Apoaequorin plasmid were incubated 371 
in the presence of the coelenterazine cofactor as described under Materials and 372 
Methods. The base-line luminescence of both cultures, recorded during 10 min 373 
at 30ºC, did not increase over the time (Fig. 2, broken lines). The wild type and 374 
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yap1 cells promptly responded to an arsenite shock, displaying a sharp rise 375 
followed by a rapid fall in the luminescence, thus reflecting the arsenite-derived 376 
fluctuations in free cytosolic Ca2+ (Fig. 2, full lines). The Ca2+-pulse amplitude 377 
exhibited by the arsenic-sensitive mutant yap1 was slightly, but reproducibly, 378 
higher than that of the wild type strain (compare Fig. 2a and 2b). 379 
These results set forth that arsenic compounds disturb Ca2+-homeostasis and 380 
further support the hypothesis that the activation of the Ca2+-signalling cascade 381 
may represent a mechanism employed by yeast cells to deal with arsenic 382 
stress.  383 
Under stress conditions, the increase of cytosolic free Ca2+ can be generated by 384 
the mobilization of extracellular or vacuolar sources. The results on the 385 
phenotypic analysis here reported indicate that the enhancement of 386 
extracellular Ca2+ availability promotes tolerance, suggesting that the arsenic-387 
induced cytosolic Ca2+-burst might result from the mobilization of external 388 
sources. The fact that the mid1 mutant, which is defective in the plasma-389 
membrane high affinity Ca2+-channel, is sensitive to arsenic compounds and 390 
that Ca2+ media supplementation did not efficiently improve the tolerance of this 391 
mutant to 1.5 mM As(III) (Fig. 2c), as it happens with the wild type strain, further 392 
supports this hypothesis. Curiously, the cch1 mutant exhibited growth patterns 393 
similar to the wild type strain (Fig. 2c), suggesting that its role seems to be 394 
dispensable for the arsenic-mediated activation of Ca2+-signalling. The 395 
discrepancy between both mutants, whose genes encode proteins cooperating 396 
to form a high-affinity Ca2+ influx system, was already described and is 397 
attributed to the fact that Mid1 can also operate independently of Cch1 (Popa et 398 
al., 2010; Li et al., 2011). 399 
17 
 
 400 
Crz1 is induced by arsenite stress  401 
The stress-induced increase of cytosolic free Ca2+ leads to the formation of a 402 
Ca2+/CaM complex that binds to and activates the serine-threonine protein 403 
phosphatase calcineurin. One of the main functions of CaN is to 404 
dephosphorylate Crz1, thus triggering its nuclear accumulation when Ca2+ 405 
cytosolic levels rise. To provide additional evidences corroborating the 406 
importance of Ca2+-signalling and Crz1 activity to arsenic stress responses, we 407 
monitored Crz1-GFP protein phosphorylation status in the wild type and yap1 408 
strains and in conditions where CaN activity was specifically inhibited by 409 
cyclosporin A (CsA). As shown in Fig. 3a, Crz1 was mainly phosphorylated 410 
under the control condition in the wild type and yap1 mutant strain. Treatment of 411 
cells with As(III) induces a partial shift of the protein to a faster migrating form in 412 
the SDS-PAGE gel. This form corresponds to the dephosphorylated GFP-Crz1, 413 
since it completely disappeared when cells were treated with the calcineneurin 414 
inhibitor CsA. To provide further support of CaN-dependent Crz1 activation by 415 
arsenic, in vivo fluorescence microscopy was used to monitor Crz1-GFP 416 
dynamics in wild type, yap1 and cnb1 cells subjected to arsenite stress. Crz1-417 
GFP was found dispersed throughout the cytoplasm in the absence of arsenite 418 
(Fig. 3b). Exposure to 2.5 mM As(III) induces its rapid translocation into the 419 
nucleus of almost all wild type and yap1 cells within the first 15 min of 420 
incubation. Arsenite-induced Crz1-GFP nuclear accumulation was completely 421 
abrogated in the cnb1 strain, which is devoid of the regulatory subunit of CaN. 422 
Altogether, the results here reported are consistent with the notion that arsenite 423 
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mediates a cytosolic Ca2+ release leading to the induction of CaN, which in turn 424 
leads to Crz1 dephosphorylation and its consequent nuclear accumulation. 425 
 426 
Arsenite stimulates CDRE-dependent gene expression  427 
The Crz1 transcriptional activator regulates the expression of many genes 428 
whose products are involved in diverse cellular functions and the DNA motif 429 
designated as CDRE (CaN-dependent response element) mediates the 430 
activation of the large majority of these genes (Denis & Cyert 2002). To 431 
determine whether arsenite stimulates CDRE-driven gene expression we used 432 
a reporter construction where four in tandem CDRE cis-elements were 433 
positioned in the promoter controlling the expression of the lacZ gene (Araki et 434 
al., 2009). The β-galactosidase activity values observed for the wild type strain 435 
treated with 20 mM CaCl2 for 90 min revealed a ten-fold increase compared to 436 
the control condition (Fig. 4). The absence of both Crz1 and Cnb1 abrogated 437 
the induction of the reporter gene demonstrating the Ca2+-responsiveness of the 438 
system and its dependence on intact Crz1 and Cnb1 function. Exposure of wild 439 
type cells to 1 mM arsenite led to an eight-fold increase of β-galactosidase 440 
activity compared to the untreated condition (Fig. 4), being a similar pattern of 441 
induction observed in the yap1 strain (data not shown). Remarkably, some 442 
degree of lacZ activation was noticed in the crz1 mutant whereas in cells devoid 443 
of cnb1 no β-galactosidase activity was detected (Fig. 4). These observations 444 
suggest that in response to arsenite an additional activator protein, whose 445 
activity seems to be influenced by the absence of CaN activity, may partially 446 
contribute to the induction of lacZ expression. Taken together, these results 447 
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indicate that the CaN-dependent Crz1 activation by arsenite has the potential to 448 
induce the expression of endogenous CDRE-regulated genes. 449 
 450 
PMR1, PMC1 and GSC2 are induced by arsenite stress  451 
To verify whether CaN/Crz1 activation by arsenite stimulates the activation of 452 
endogenous target genes under the Ca2+-signalling cascade we monitored by 453 
qPCR the expression levels of the Crz1-regulated genes PMR1 and PMC1, 454 
involved in ion homeostasis, and GSC2, encoding a protein implicated in cell 455 
wall synthesis (Denis & Cyert 2002). Fully supporting our hypothesis, the 456 
treatment of cells with arsenite induced expression of the three genes in the 457 
wild type as well as in the yap1 strain (Fig. 5). Full activation of PMR1, PMC1 458 
and GSC2 by arsenite was clearly dependent on Crz1 activity, although 459 
significant levels of PMR1 expression were still observed in the crz1 strain (Fig. 460 
5a). These data are consistent with the β-galactosidase assay results, showing 461 
that CDRE-regulated expression is partially dependent on Crz1 (Fig. 4) and are 462 
similar to those described in a previous work (Araki et al., 2009). The 463 
comparison of PMR1 and PMC1 levels in the wild type and yap1 strains 464 
revealed that expression of these genes was enhanced in the latter (Fig. 5a/b), 465 
suggesting that either the maintenance of Ca2+-homeostasis in yap1 cells 466 
requires increased amounts of Pmr1 and Pmc1 or that Yap1 exerts a negative 467 
effect on the expression of these genes. The evidence showing that yap1 cells 468 
exhibited increased Ca2+-pulse amplitude (Fig. 2) support the first possibility. 469 
Collectively, these results reinforce the hypothesis that arsenic stress induces a 470 
Ca2+-cytosolic pulse activating the Ca2+-signalling pathways, which in turn 471 
culminates with the induction of at least PMR1, PMC1 and GSC2. 472 
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 473 
CONCLUDING REMARKS 474 
The deleterious effects and widespread distribution of arsenic metalloids in 475 
Earth’s crust led organisms to develop complex adaptation mechanisms and 476 
protection systems that are highly conserved between mammals and yeasts. 477 
However, the mechanisms underlying arsenic tolerance/toxicity are still far from 478 
being deciphered. Yet, despite the toxic effects of arsenic exposure there has 479 
been a resurgence of interest in the utilization of arsenic trioxide in the 480 
treatment of acute promyelocytic leukaemia (APL) (Kanzaki et al., 1999; 481 
Lallemand-Breitenbach et al., 2012). The mechanisms by which ATO selectively 482 
induces apoptosis of cancer cells are not yet fully understood, however, it was 483 
shown that ATO triggers endoplasmic reticulum (ER) stress responses and 484 
disturbs calcium Ca2+-homeostasis (Binet et al., 2010). Thus, to improve the 485 
effectiveness of arsenic-derived drugs in cancer therapy is essential to 486 
recapitulate the cellular and molecular processes affected by the treatment.  487 
In this work we took advantage of the use of the eukaryotic model yeast 488 
Saccharomyces cerevisiae to investigate how Ca2+-signalling pathways 489 
contribute to arsenic stress responses in eukaryotic cells. We report for the first 490 
time that an excess of extracellular Ca2+ relieves arsenic toxicity in two different 491 
genetic backgrounds of S. cerevisiae. Furthermore, we show that tolerance 492 
acquisition mediated by Ca2+ is dependent on the function of Crz1, directly 493 
implicating the Ca2+-signalling cascade in this process. Upon arsenic stress, the 494 
burst of Ca2+ in the cytosol triggers the CaN-dependent Crz1 dephosphorylation 495 
and nuclear accumulation, thereby leading to the induction of CDRE-driven 496 
expression and the PMR1, PMC1 and GSC2 endogenous genes.  497 
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Although required to Crz1 activation, Cnb1 seems also to mediate arsenic 498 
toxicity, either by activating proteins conferring toxicity and/or repressing those 499 
contributing to tolerance. Further work is in progress in order to clarify this 500 
issue.   501 
 502 
 503 
 504 
 505 
 506 
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LEGENDS TO FIGURES 521 
Figure 1. Exogenous Ca2+ supply improves tolerance of the wild type and 522 
yap1 strains to arsenite stress in a Crz1-dependent fashion. a) Wild type 523 
BY4742, yap1 and the respective crz1 and cnb1 knockout strains were grown to 524 
early exponential phase and were spotted onto synthetic medium supplemented 525 
with As(III) and/or CaCl2. Growth was recorded after 48 h incubation at 30oC. A 526 
representative experiment is shown. b and c) Exponentially growing wild type 527 
and crz1 cells were diluted to OD600 0.1±0.01, induced or not with 1.5 mM 528 
As(III) and growth was monitored during 28 h at 30oC. The growth curves show 529 
average values from at least three independent experiments. d) CRZ1/CNB1 530 
epistasis analysis. Wild type BY4742, crz1, cnb1 and crz1cnb1 knockout strains 531 
were grown to early exponential phase and the spot assays were performed as 532 
described above. WT – wild type, SM – synthetic medium. 533 
 534 
Figure 2. Arsenite stress elicits a transient cytosolic Ca2+-pulse.  Wild type 535 
BY4742 (a) and yap1 (b) cells expressing coelenterazine-reconstituted aequorin 536 
were injected or not with 1.5 mM As(III) directly in the luminometer plates and 537 
luminescence was recorded during 10 min. The arrows indicate the time of 538 
arsenite addition. Each determination was repeated at least 3 times with no 539 
significant variations. The broken lines correspond to the base-line 540 
luminescence. RLU – Relative Light Units, expressed as counts per second/OD, 541 
SM – synthetic medium. c) Mid1 is required to Ca2+-mediated enhancement of 542 
arsenic tolerance. Wild type BY4741 and the isogenic mid1 and cch1 strains 543 
were grown to early exponential phase and were spotted onto synthetic medium 544 
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supplemented with As(III) and/or CaCl2. Growth was recorded after 48 h 545 
incubation at 30oC. A representative experiment is shown. 546 
 547 
Figure 3. Arsenite stress triggers Crz1 activation. a) Wild type and yap1 548 
cells expressing CRZ1-GFP were grown to early exponential phase and 30 min 549 
prior induction with 1.5 mM As(III) were treated or not with cyclosporin A. 550 
Samples were collected at the indicated time points and proteins were analysed 551 
by immunoblotting using an anti-GFP antibody. Pgk1 protein levels were used 552 
as a loading control. b) Wild type, yap1 and cnb1 cells expressing CRZ1-GFP 553 
were grown to early exponential phase, induced for 15 min with 2.5 mM As(III) 554 
and analysed under a fluorescence microscope. A representative experiment is 555 
shown. SM – synthetic medium, CsA – cyclosporin A. 556 
 557 
Figure 4. Exposure to arsenite induces CDRE-driven expression. Wild type, 558 
crz1 and cnb1 cells expressing the CDRE-lacZ reporter construct were up-559 
shifted to 1 mM As(III) or 20 mM CaCl2 for 90 min at 30ºC. Cells were collected, 560 
permeabilized and β-galactosidase activity was monitored. Measurements were 561 
performed in triplicate and the mean standard deviation is shown. WT – wild 562 
type, SM – synthetic medium. 563 
 564 
Figure 5. PMR1, PMC1 and GSC2 are induced by arsenite stress. Early 565 
exponential phase wild type, yap1 and crz1 cells were up-shifted to 1.5 mM 566 
As(III) and harvested after 30 min incubation at 30ºC. The relative expression of 567 
PMR1 (a), PMC1 (b) and GSC2 (c) was monitored by qPCR, using the relative 568 
quantification method with efficiency correction and ACT1 as a reference gene. 569 
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Measurements were performed in triplicate and the mean standard deviation is 570 
shown. SM – synthetic medium. 571 
  572 
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Table 1: S. cerevisiae strains used in this work 573 
Strain Genotype Source 
 
BY4742 
crz1 
cnb1 
crz1cnb1 
 
yap1 
yap1crz1 
 
 
MATα his3 leu2 lys2 ura3 
MATα his3 leu2 lys2 ura3 YNL027W::kanMX4 
MATα his3 leu2 lys2 ura3 YKL190W::kanMX4 
MATα his3 leu2 lys2 ura3 YKL190W::kanMX4 
YNL027W::HIS3MX4 
MATα his3 leu2 lys2 ura3 YML007W:: kanMX4 
MATα his3 leu2 lys2 ura3 YML007W::kanMX4 
YNL027W::HIS3MX4 
 
EUROSCARF 
EUROSCARF 
EUROSCARF 
This study 
 
EUROSCARF 
This study 
 
yap1cnb1 
 
BY4741 
mid1 
cch1 
YAA3 
MATα his3 leu2 lys2 ura3 YKL190W::kanMX4 
YML007W::HIS3MX4 
MATa his3 leu2 met15 ura3 
MATa his3 leu2 met15 ura3 YNL291C::kanMX4 
MATa his3 leu2 met15 ura3 YGR217W::kanMX4 
MATa his3::CRZ1-GFP-HIS3 leu2 ura3 met15 
This study 
 
EUROSCARF 
EUROSCARF 
EUROSCARF 
(Araki et al., 2009) 
YAA3-yap1 
 
YAA4 
MATa his3::CRZ1-GFP-HIS3 leu2 ura3 met15 
YML007W::kanMX4 
MATa his3::CRZ1-GFP-HIS3 leu2 ura3 met15 
YKL190W:: kanMX4 
This study 
 
(Araki et al., 2009) 
YAA5 MATα his3 leu2 lys2 ura3 
aur1::AUR1-C-4xCDRE-lacZ 
(Araki et al., 2009) 
YAA6 MATα his3 leu2 lys2 ura3 YNL027W::HIS3MX4 
aur1::AUR1-C-4xCDRE-lacZ 
(Araki et al., 2009) 
YAA7 MATα his3 leu2 lys2 ura3 YKL190W:: kanMX4 
aur1::AUR1-C-4xCDRE-lacZ 
(Araki et al., 2009) 
 574 
  575 
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Table 2: Ca2+-related genes whose expression is affected by arsenic 576 
Category Gene Function Fold 
change 
 
Ca2+-Signalling 
 
 
CRZ1 
 
Transcription factor that activates 
transcription of genes involved in stress 
response 
 
 
2.09 
 
Calcineurin 
complex 
RCN1 
 
CMP2 
Protein involved in calcineurin regulation 
during calcium signalling 
Calcineurin A; one isoform (the other is CNA1) 
of the catalytic subunit of calcineurin 
2.78 
 
1.9 
 
Ca2+-binding 
 
CMD1 
 
Calmodulin; Ca
2+
 binding protein that 
regulates Ca
2+
  independent and dependent 
processes 
 
1.37 
 
Calmodulin 
binding 
 
CMK2 
 
  RCK2 
 
Calmodulin-dependent protein kinase 
 
Protein kinase involved in the response to 
oxidative and osmotic stress 
 
 
 
Ca2+-transport 
  
 MID1 
 
 
 CCH1 
 
N-glycosylated integral membrane protein of 
the ER membrane and plasma membrane  
Voltage-gated high-affinity calcium channel 
 
-1,64 
 
-1.77 
The average fold induction of triplicate samples is represented. A complete list of all Ca
2+
-577 
related genes whose expression is altered by arsenic compounds is shown in Table S2. 578 
 579 
 580 
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Accumulation of iron (Fe) is often detected in the brains of people suffering from neurodegenerative diseases. High Fe
concentrations have been consistently observed in Parkinson’s, Alzheimer’s, and Huntington’s diseases; however, it is not clear
whether this Fe contributes to the progression of these diseases. Other conditions, such as Friedreich’s ataxia or neuroferritinopathy
are associated with genetic factors that cause Fe misregulation. Consequently, excessive intracellular Fe increases oxidative stress,
which leads to neuronal dysfunction and death. The characterization of the mechanisms involved in the misregulation of Fe
in the brain is crucial to understand the pathology of the neurodegenerative disorders and develop new therapeutic strategies.
Saccharomyces cerevisiae, as the best understood eukaryotic organism, has already begun to play a role in the neurological disorders;
thus it could perhaps become a valuable tool also to study the metalloneurobiology.
1. Iron Neurotoxicity
Iron (Fe) is the most important element for almost all types
of cells, including brain cells. It is an essential cofactor for
many proteins involved in the normal function of neuronal
tissues, such as the non-heme Fe enzyme tyrosine hydrox-
ylase required for the synthesis of myelin and the neuro-
transmitters dopamine, norepinephrine, and serotonin [1].
In a normal brain, Fe appears widely distributed by region
and cell-type and it accumulates progressively during aging
and neurodegenerative processes [2]. Fe is an originator of
reactive oxygen species (ROS). Ferric iron (Fe3+) can be
reduced to ferrous iron (Fe2+) by the superoxide radical
(O•2
−) (Fe3+ + O•2
− → Fe2+ + O2). Fe2+ can also react with
H2O2 generating the highly reactive hydroxyl free radical
(•OH) (Fe2+ + H2O2 → Fe3+ + •OH + OH−, Fenton reac-
tion) [3]. The combination of these reactions results in
the so-called Haber-Weiss reaction (O•2
− + H2O2 → O2 +
•OH + OH−), which together with dopamine oxidation can
trigger neurotoxicity [4]. Therefore, the control of Fe home-
ostasis is essential to keep a healthy brain.
1.1. Iron Homeostasis. In mammals, the regulatory mecha-
nism for Fe homeostasis is mediated by the iron-regulatory
proteins IRP1 and IRP2, which posttranscriptionally mod-
ulate the expression of specific mRNAs in response to
intracellular Fe [5, 6], mainly transferrin (Tf) and ferritin. Tf
is an Fe-binding blood plasma glycoprotein that controls the
level of free Fe, and ferritin is an Fe storage protein composed
of H and L subunits that assemble to form a hollow sphere
in which ferric iron (Fe3+) precipitates are sequestered [7].
The ferritin subunits have different functions. The H chains
are involved in the rapid oxidation of Fe2+ to Fe3+, and the L
chains function in the nucleation of Fe3+ within the protein
shell. While the L-rich ferritins are associated with iron
storage, the H-chain ferritins are associated with responses
to stress [8].
In Fe-depleted cells, IRPs bind to the IREs cis-elements in
the 5′UTR (untranslated region) of ferritin and in the 3′UTR
of TfR1. By binding to the IRE in the 5′UTR, of ferritin, IRPs
prevent translation, whereas by binding to IRE in the 3′UTR
of TfR1, the IRPs protect the transcript from degradation
[9]. In Fe-replete cells, IRPs do not bind to IREs, and
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ferritin and other transcripts are freely translated, whereas
TfR1 undergoes cleavage and subsequently degradation [6,
10, 11].
Although Femetabolism inmammals is mainly regulated
at the level of absorption, changes in gene expression in
response to Fe overload have been observed in a variety of
eukaryotes from yeast to mammals [12, 13].
Ferroportin (Fpn), the basolateral membrane Fe export-
er, is the only Fe exporter to date identified in mammals [14–
16]. Fpn mediates the release of the Fe in conjunction with
ceruloplasmin (Cp), whichmust oxidize the Fe2+ transported
by Fpn to Fe3+ before release into the extracellular medium
[17]. Fpn expression has also been detected on the
blood-brain barrier (BBB) endothelial cells, neurons, oligo-
dendrocytes, astrocytes, the choroid plexus and ependymal
cells. Since Cp is essential for stabilization of Fpn, under
conditions of Cp deficiency or malfunction Fpn is not
expressed, which results in a decreased Fe efflux potentiating
cellular Fe overload [18]. These observations indicate that Cp
plays a major role in maintaining Fe homeostasis in the brain
and in protecting it from Fe-mediated free radical injury.
The Fe uptake pathway starts in the intestines, where Fe3+
is reduced to Fe2+ that then is transported to the blood by
Fpn. In the blood, Cp oxidizes Fe2+ to Fe3+ and promotes its
binding to the serum iron carrier, Tf [19]. In order to enter
the brain, Fe needs to cross two distinct barriers, the BBB and
BCSF (blood-cerebrospinal fluid) [20]. The most common
pathway for Fe transference across the BBB is through the
TfRs expressed in the endothelial cells. The circulating Fe
bound to Tf is captured by TfR, entering the brain by
endocytosis and then is translocated across the endosomal
membrane, probably through the divalent metal transporter
1 (DMT1) [21]. In addition to the Tf-TfR pathway, it has
been suggested that the lactoferrin receptor-lactoferrin (LfR-
Lf) pathway might also play a role in Fe transport across the
BBB. Fe2+ in the cytoplasm can also be transported inside
the mitochondria by mitoferrin or participate in electron
exchange reactions [22, 23]. Figure 1 summarizes the brain
Fe uptake pathways.
Fe-related neurodegenerative disorders can result from
both iron accumulation in specific brain regions or defects
in its metabolism and/or homeostasis.
As the brain ages, Fe accumulates in regions that exhibit
pathologic characteristics of Alzheimer’s disease (AD) [24],
Parkinson’s disease (PD) [25], or Huntington’s disease (HD)
[26, 27]. In younger individuals, the largest amounts of Fe
are in the oligodendrocytes whereas in older individuals
over 60 years old most of the Fe is found in the microglia
and astrocytes of the cortex, cerebellum, hippocampus, basal
ganglia, and amygdala [27]. In these regions Fe is either
bound to neuromelanin, a dark brown pigment that accu-
mulates essentially iron, or to ferritin [28]. Interestingly,
neurons express mostly H-ferritin, microglia express mostly
L-ferritin, and oligodendrocytes express similar amounts of
both subunits [29, 30]. Additionally neurons excrete the
nonrequired Fe through the carrier Fpn (Figure 1).
It has been widely accepted that abnormal high con-
centrations of Fe contribute to neurodegenerative processes;
however, a major question has not yet been answered. Is the
excessive Fe accumulation in the brain an initial event that
causes neurodegeneration or a consequence of the disease
process?
Fe accumulation has been shown to lead to neuronal
death [31]. Available Fe interacts with molecular oxygen and
generates reactive oxygen species (ROS) through Fenton and
Haber-Weiss reactions [32, 33], which leads to oxidative
stress. Mitochondrial dysfunction has also been raised as a
common cause for a number of neurodegenerative diseases.
Since mitochondria has an important role in the Fe-S clusters
formation [34], malfunction can result in a low Fe-S cluster
synthesis and consequent activation of DMT1 and decrease
of Fpn1, Fe accumulation, and oxidative stress [4]. Oxidative
injury induces lipid peroxidation, nucleic acid modification,
protein misfolding and aggregation, and cell dysfunction and
death [35].
1.2. Alzheimer’s Disease (AD). AD is themost common cause
of age-related neurodegeneration and is characterized by the
progressive loss of memory, task performance, speech, and
recognition of people and objects. AD is characterized by the
accumulation of aggregates of insoluble amyloid-β protein
(Aβ), and neurofibrillary tangles (NFTs) consisting of precip-
itates/aggregates of hyperphosphorylated tau protein [36].
In AD, Fe accumulation has been observed in and around
the amyloid senile plaques (SP) and neurofibrillary tangles
(NFTs) [37]. The excessive Fe can lead to alterations in the
interaction between IRPs and their IREs [38] and disruption
in the sequestration and storage of Fe by ferritin [39]. Further
studies have suggested that high Fe toxicity may be due to
the propensity of Fe2+ to generate ROS [40], and postmortem
analysis of AD patients’ brains has revealed activation of
two enzymatic indicators of cellular oxidative stress: heme
oxygenase-1 (HO-1) [41] and NADPH oxidase [42]. In addi-
tion, other evidence suggests that in AD the Fe metabolism
is disrupted. Tf is not found in the oligodendrocytes but
rather trapped within senile plaques and ferritin is expressed
within reactive microglial cells that are present both in and
around the senile plaques [43]. A decade ago Rogers et al.
[44] provided another link between iron metabolism and
AD pathogenesis by describing the presence of an IRE in the
5′UTR of the amyloid precursor protein (APP) transcript.
APP 5′UTR is responsive to intracellular iron levels, which
regulate translation of APP holo-protein mRNA by a
mechanism similar to the translation of ferritin-L and -H
mRNAs via IREs in their 5′UTRs. Recently, Duce et al. [45]
have described that APP is a ferroxidase that couples with
Fpn to export Fe. In AD APP ferroxidase activity appears
inhibited, thereby causing neuronal Fe accumulation.
1.3. Parkinson’s Disease (PD). PD is a progressive disorder
that manifests as tremor at rest, bradykinesia, gait abnor-
malities, rigidity, postural dysfunction, and loss of balance
[46]. It is the most prevalent neurodegenerative disorder
after AD affecting about 2% of people over 65 years old. PD is
characterized by the loss of the substantia nigra dopaminergic
neurons [47] and the deposition of intracellular inclu-
sion bodies known as Lewy bodies. The principal protein
Oxidative Medicine and Cellular Longevity 3
Tf
Lf
Fe(III) Fe(II)
Nucleus
Ferritin
Endosome
DMT1
TfR1LfR
Neuromelanin
Mitochondrion
Fpn
Ceruloplasmin
Figure 1: The brain iron homeostasis. Iron (Fe) binds to transferrin (Tf), enters the brain through the transferrin receptors (TfR) by
endocytosis, and translocates across the endosomal membrane through the divalent metal transporter 1 (DMT1). Lactoferrin receptors
(LfR) provide another pathway to transport Fe from Fe containing lactoferrin across the cell membranes. Inside the cell Fe binds to H-ferritin
and accumulates around the neuromelanin. Ferroportin (Fpn) transports Fe2+ outside the neuron that is oxidized to Fe3+ by ceruloplasmin
promoting its binding to Tf.
component of these bodies is α-synuclein (α-syn) that is
ubiquitously expressed in the brain [48].
Several studies have confirmed an increase of Fe in the
substantia nigra of most severe cases of PD [49–51]; however,
there are still some conflicting reports about the stage during
disease progression at which nigral Fe changes occur.
Nevertheless, there is a general agreement that total nigral
Fe levels increase in PD, possibly leading to nigrostriatal
dopamine neuron degeneration as a result of its ability to
produce ROS and cause lipid peroxidation [52, 53].
The elevated Fe content, besides contributing to the
increase of oxidative stress, also enhances α-syn aggregates
[54]. It has been shown that α-syn harbors an IRE in its 5′-
UTR. Thus high intracellular Fe might also regulate α-syn
aggregation through the IRE/IRP system, therefore, causing
the death of dopaminergic neurons [55]. As Fe deposits are
commonly found in the Lewy bodies, Fe might play a role on
the pathogenicity of α-syn in PD.
1.4. Huntington’s Disease (HD). HD is a neurodegenerative
disorder characterized by progressive motor, cognitive, and
psychiatric deterioration. Typically, onset of symptoms is
in middle-age (30 and 50 years old), but the disorder can
manifest at any time between infancy and elderliness. HD
is caused by a dominant glutamine expansion (CAG repeat
coding) within the N-terminal of the huntingtin protein that
initiates events leading to neuronal loss primarily within the
striatum and cerebral cortex. Full-length huntingtin is large
(∼350 kD), but it is the smaller N-terminal fragments that
are the main mediators of disease progression [56]. These
fragments have aberrant interactions with themselves and
other biomolecules that lead to the molecular hallmarks
of HD including aggregates, transcriptional repression [57],
oxidative damage, and metabolic dysfunction [58].
For individuals with HD, increased Fe levels have pri-
marily been observed in the basal ganglia, namely, in the
striata and the globus pallidus [59]. In addition, ferritin-Fe
levels are increased in striata of early clinical HD patients as
measured by magnetic resonance imaging (MRI) [60]. Fe
levels increase early stage in HD and continue to increase
with age, which suggests that Fe may play a role in the pro-
gression of the disease. However, the mechanisms involved in
this process are not yet understood. Although both AD and
PD are characterized by Fe accumulation, the Fe regulation
patterns seem to be different from HD [59]. For instance,
Parkinson’s disease is characterized by Fe accumulation in
the substantia nigra, which has not been observed in HD.
It is possible that in HD Fe accumulation occurs because
after neuronal loss, cells with higher Fe content replace the
dead cells. Thus Fe accumulation in HD is most probably a
secondary effect of the disease [60].
1.5. Other Neurological Disorders. The accumulation of Fe
has also been implicated in a series of other neurological dis-
eases, such as Neuroferritinopathy, Hallervorden-Spatz syn-
drome, and Aceruloplasminemia that are characterized by
mutations in genes that encode for ferritin light polypeptide
(FTL), pantothenate kinase (PANK2), and ceruloplasmin,
respectively.
Neuroferritinopathy is dominantly inherited and is a
late-onset disease of the basal ganglia that presents extrapyra-
midal features similar to HD and PD. It is caused by a single
adenine insertion at position 460-461 that is predicted to
change the C-terminal residues of the gene encoding L-chain
ferritin [61]. Brain histochemistry of patients with neurofer-
ritinopathy showed abnormal aggregates of ferritin and Fe
and low serum ferritin concentrations. The C-terminus of
the aberrant L chain might interfere with the formation of
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the hollow sphere allowing inappropriate release of Fe from
the loaded ferritin [62].
Another evidence for the involvement of Fe in neu-
rodegeneration is provided by the study of Hallervorden-
Spatz syndrome (HSS), also referred to as neurodegeneration
with brain-iron accumulation 1 (NBIA) or pantothenate-
kinase-2-associated neurodegeneration (PANK2) [63]. HSS
is an autosomal recessive disorder characterized by dystonia,
pigmentary retinopathy in children and neuropsychiatric
defects in adults. The HSS patient’s MRI has a characteristic
pattern in the globus pallidus, known as “the eye of the
tiger” because of its appearance [64]. Zhou et al. [63]
identified the genetic basis for this neurodegenerative disease
in which Fe accumulation is most dramatic by detecting
the underlying mutations in the gene that encodes for
pantothenate-kinase. This enzyme is essential for the coen-
zyme A biosynthesis [65], which in turn catalyzes the phos-
phorylation of pantothenate (vitamin B5), N-pantothenoyl-
cysteine, and pantetheine [63]. The product of this reac-
tion, 4′-phosphopantothenate, is then converted to 4′-
phosphopanthetheine in a reaction that consumes cysteine.
HSS results from 4′-phosphopantothenate deficit, which is
caused by genetic defects in PANK2. Given that cysteine is
consumed in the conversion of 4′-phosphopantothenate, an
absence of functional PANK2 might explain the observed
accumulation of cysteine in the degenerating brain areas of
HSS patients. Consequently the cysteine Fe-chelating prop-
erties might account for the observed regional Fe accumu-
lation, and cysteine-bound Fe may promote Fe-dependent
oxidative damage in these regions [66]. Even though PANK2
is not directly involved in Fe metabolism, its absence may
contribute for Fe accumulation in the brain, leading to
neuronal death via oxidative stress.
Finally, aceruloplasminemia, an autosomal recessive dis-
order caused by mutations in the ceruloplasmin gene, also
results in Fe overload in the brain characterized mainly by
retinal neurodegeneration [17]. Cp is a multicopper fer-
roxidase responsible for the Fe homeostasis by promoting
Fe incorporation into Tf, therefore, playing a key role in
releasing Fe from the cells [67]. Consequently, mutations in
the ceruloplasmin gene may cause Fe metabolism misregu-
lation in the brain. Due to the low release of cellular Fe and
the high nontransferrin-bound Fe uptake, the intracellular
Fe concentration becomes abnormally high. This induces
oxidative stress and formation of ROS triggering a cascade
of pathological events that lead to neuronal death.
1.6. Fe-Chelation Therapies. Oxidative stress, protein aggre-
gation, and active redox Fe have been considered promising
pharmacological targets for the treatment of AD and PD.
BBB permeable Fe chelators can be used as potential thera-
peutic agents in the treatment of neurodegenerative diseases.
A promising Fe chelator is desferrioxamine (Desferal), which
has been shown to prevent up to 60% of dopaminergic
neurons from death in a rat model of PD [68]. The main
disadvantage of desferrioxamine is that it cannot cross the
BBB, due to its size and hydrophobicity [65]. Clioquinol, a
small lipophilic Fe chelator that can cross the BBB, has also
proved to have beneficial effects in patients with AD [69].
However, clioquinol is not iron selective and has very toxic
effects. Aroylhydrazones are the new nontoxic lipophilic Fe
chelators that can form a neutral complex with Fe and
diffuse out of the membrane [70]. Other important class
of compounds proposed for therapy is the polyphenols that
have antioxidant properties and can bind Fe [71]. A major
limitation is their capacity to be absorbed at the gastroin-
testinal tract and subsequently be transported through the
BBB.
The development of an effective non-toxic therapeutic
agent for such complex brain disorders still represents a
challenging task.
2. The Yeast Model
In the last decade, the budding yeast Saccharomyces cerevisiae
has been used as a model system to gain insights about the
mechanisms of neurodegenerative disorders such as Parkin-
son’s, Huntington’s, and Alzheimer’s [72]. Yeast cells are
generally used to study key proteins involved in the etiology
and/or pathology of these diseases. When a yeast homologue
exists, the corresponding gene can be easily disrupted or
overexpressed to determine the loss or gain of function
phenotypes, respectively. When a yeast homologue is not
present, the human gene can be expressed in yeast and any
relevant phenotype that results from this expression can be
analyzed. The latter has been called humanized yeast models
[73]. Despite their simplicity, yeast cells possess most of
the same basic cellular machinery as neurons in the brain,
including pathways required for protein homeostasis and
energy metabolism. Also their easy genetic manipulation
makes these cells an ideal tool for molecular biology.
Many of the genes and biological systems that function in
yeast Fe homeostasis are conserved throughout eukaryotes to
humans [74]. S. cerevisiae expresses three genetically distinct
transport systems for Fe, two reductive systems and one
nonreductive system. The reductive Fe uptake system con-
sists in a low-affinity pathway defined by Fet4, that can also
transport other metals and in a high-affinity pathway that is
mediated by a protein complex composed of a multicopper
ferroxidase Fet3, the mammalian Cp homologue, and a
permease Ftr1. The Fet3-Ftr1 complex is specific for Fe and
is regulated both transcriptionally and posttranscriptionally
by this metal [75–77]. The nonreductive Fe uptake system
is mediated by the ARN family (Arn1-4) of membrane
permeases that transport siderophore-Fe3+ complexes [78,
79]. Additionally Harris et al. [80] showed for the first time
that Fet3 can functionally replace ceruloplasmin in restoring
Fe homeostasis.
Moreover, cells are able to spare Fe through the regula-
tion of Tis11 homologues and Cth1/2-mediated degradation
of mRNAs coding for Fe-binding proteins, thereby facilitat-
ing the utilization of limited cellular Fe levels [81, 82].
Since S. cerevisiae lacks the Fe storage protein, ferritin,
during Fe overload this is sequestered into the vacuole by
the Ccc1 transporter, which is under the control of the
Yap5 transcription factor [13]. On the other hand, Fet5/Fth1
complex mobilizes Fe out of the vacuole for use during Fe
limitation [83].
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Given the similarities between yeast and mammals and
the availability of humanized S. cerevisiae strains, yeast
could potentially become an effective model to dissect the
molecular pathway associated with the misregulation of Fe
homeostasis in the neurodegenerative diseases.
One good example of the use of yeast to study Fe accumu-
lation in a neurodegenerative disease was first reported for
Friedreich’s ataxia (FRDA). FRDA is an autosomal recessive
mitochondrial disorder that causes progressive damage to
the nervous system, resulting in gait disturbance, speech
problems, heart disease, and diabetes. It is caused by GAA
triplet expansion in the first intron of the frataxin gene (FA)
[84].
A gene with high sequence similarity to FA was initially
identified in yeast, the yeast frataxin homologue, YFH1
[85] and later it was shown that the two proteins were both
located in the mitochondria. Moreover, human FA could
complement for the absence of the yeast yfh1 [86]. However,
FA function was only discovered when Lodi and coworkers
[87] showed that the YFH1 knockout strain led to an
excessive Fe accumulation in the mitochondria resulting in
the generation of ROS and consequently oxidative damage.
The yeast frataxin homologue provided the evidence that
FRDA is indeed a mitochondrial disorder. The yeast model
allowed a better understanding of the FDRA pathophysiology
and provided a tool for assaying therapeutic targets.
3. Concluding Remarks
In this paper, we have summarized the role of Fe, a redox-
active transition metal, in neurodegenerative disorders.
Despite a considerable investigation already performed, it is
still not clear whether excessive Fe accumulation in the brain
is an initial event that causes neuronal death or is a conse-
quence of the disease process. The growing evidence suggests
that the abnormal high Fe levels in the brainmay have genetic
causes, as found in patients with aceruloplasminemia, or
sporadic causes that can disrupt the normal mechanisms
of Fe transport into the brain. In addition, elevated Fe
levels generate ROS and increase the levels of oxidative
stress, which is considered one of the pathways leading to
neuronal death. A new study from Lei et al. [88] shows that
loss of Tau impairs the Fpn Fe export by preventing the
proper trafficking of APP ferroxidase to the neuronal surface,
leading to Fe accumulation, which results in degeneration
of dopaminergic neurons in PD. These findings suggest the
involvement of a new mechanism associated with Tau’s role
in PD. However, the precise role of Fe transport proteins
in the brain is not completely understood, which impairs
the success of therapeutic strategies to prevent the damaging
effects of the Fe in the brain.
Finally, we believe that the use of the yeast neurodegen-
erative disease models might provide valuable insights into
key aspects of the Fe pathology in the brain and pave the way
towards the discovery of promising therapeutic targets.
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Alzheimer’s (AD) and Parkinson’s (PD) diseases are the two most common causes of dementia in aged population. Both are
protein-misfolding diseases characterized by the presence of protein deposits in the brain. Despite growing evidence suggesting that
oxidative stress is critical to neuronal death, its precise role in disease etiology and progression has not yet been fully understood.
Budding yeast Saccharomyces cerevisiae shares conserved biological processes with all eukaryotic cells, including neurons. This
fact together with the possibility of simple and quick genetic manipulation highlights this organism as a valuable tool to unravel
complex and fundamental mechanisms underlying neurodegeneration. In this paper, we summarize the latest knowledge on the
role of oxidative stress in neurodegenerative disorders, with emphasis on AD and PD. Additionally, we provide an overview of the
work undertaken to study AD and PD in yeast, focusing the use of this model to understand the effect of oxidative stress in both
diseases.
1. Introduction
Misfolded proteins are typically insoluble and tend to form
long linear or fibrillar aggregates known as amyloid deposits.
Amyloid-like protein fibrils are a well-known pathological
hallmark of age-related neurodegenerative diseases, includ-
ing Alzheimer’s disease (AD) and Parkinson’s disease (PD).
Alzheimer’s and Parkinson’s diseases are the most common
forms of dementia, currently affecting 30 and 4 million
people worldwide, respectively. In AD, the beta-amyloid (Aβ)
peptide accumulates mainly extracellularly, whereas in PD,
the α-Synuclein (α-Syn) protein accumulates, within neu-
rons, inside the Lewy bodies (LB) and Lewy neurites (LN).
Although there is a plethora of factors interfering in those
pathological depositions, it is clear that oxidative stress may
play a crucial role in neuronal death in neurodegenerative
disorders [1–3].
Reactive oxygen species (ROS) are chemically reactive
molecules containing oxygen and are produced in all aerobic
cells. Oxidative stress occurs when the generation of ROS
in a system exceeds that system’s ability to neutralize and
to eliminate them. All organisms have developed adaptive
responses to oxidative stress that involve defensive enzyme
and molecular chaperones—the expression of both being
orchestrated by stress-responsive transcription factors—as
well as antioxidant molecules [4]. Excessive production
of ROS, and the consequent disruption of cellular redox
balance, drives the oxidation of biological macromolecules,
such as DNA, proteins, carbohydrates, and lipids, potentially
leading to failure of biological functions [4].
Many ROS possess unpaired electrons and are therefore
free radicals. The generation of free radicals is closely
linked with the involvement of trace metals, particularly
copper and irons [5, 6]. To cope with this potential hazard,
the concentration of cytosolic free metals is accurately
controlled through regulation of their uptake, storage, and
mobilization, in order to maintain redox-active metals in
normal physiological limits [7, 8]. Inside cells, “free pools” of
copper and iron are avoided through their effective sequester
by metal-binding proteins [5, 9]. The chelatable redox-active
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iron constitutes the so-called labile iron pool (LIP), which
serves as a transient source of iron [5, 9, 10]. Nevertheless,
whenever cells are subjected to stress conditions, an excess of
superoxide anion radical acts as an oxidant of Fe-S clusters of
several enzymes, releasing “free iron.” The released iron can
in turn participate in Fenton type reactions, producing the
highly reactive hydroxyl radical [11].
During the oxidative burst triggered during inflamma-
tory processes, cells of the immune system produce both
superoxide anion and nitric oxide (NO) free radicals. Nitric
oxide is produced by the NO synthase family of enzymes.
NO may directly react with its biological targets, as it is
known to regulate the catalytic activity of various enzymes
primarily by interacting with Fe-S clusters, oxidized copper
centres, heme, and tyrosyl radicals [12]. NO also reacts with
superoxide ion (O2
−) or oxygen to form the nitrogen radical
peroxynitrite (ONOO−). Reactive nitrogen species (RNS) are
highly reactive towards biological macromolecules and are
thought to be responsible for NO-mediated cell death.
The aim of this paper is to provide an overview on
the role of oxidative stress in neurodegenerative disorders,
with emphasis on AD and PD. Despite the absence of a
nervous system in yeast, several studies have shown that this
eukaryotic unicellular organism is a suitable model system
to understand the molecular mechanisms underlying neu-
rodegenerative diseases. The knowledge from those studies
is summarized herein. Finally, we discuss how yeast models
have been or may be used to extend our understanding on
the role of oxidative stress in AD and PD.
2. Oxidative Stress and
Neurodegenerative Diseases
The human brain is responsible for approximately 20% of
our body oxygen consumption and thus subjected to a high
metabolically derived level of ROS [13, 14]. An increasing
body of evidence suggests that oxidative stress is involved
in the etiology and pathogenesis of neurological disorders.
The lipid bilayer of the brain is rich in polyunsaturated
fatty acids and oxygen and is therefore highly susceptible
to lipid peroxidation, a complex process involving the
interaction of polyunsaturated fatty acids with free radicals
that results in production of reactive electrophilic aldehy-
des. Lipid peroxidation occurs in several neurodegenerative
diseases [15]. Evidence of oxidative stress in these diseases
is further supported by increased DNA (and often RNA)
base oxidation products and oxidative protein damages in
specific regions of the brain [4]. The destruction of cellular
components can induce a diversity of cellular responses
through generation of secondary reactive species and ulti-
mately lead to cell death via apoptosis and necrosis [16–
18]. Mitochondrion is the center of ROS production. About
90% of mammalian oxygen consumption is mitochondrial,
making mitochondria particularly important in neurons
due to their high demands for energy. This fact, together
with the observation that mitochondrial perturbation occurs
in multiple neurodegenerative disorders [19], suggests that
neurodegenerative diseases are mitochondrial diseases.
3. Alzheimer’s Disease and Oxidative Stress
Alzheimer’s disease (AD) is an age-related progressive neu-
rodegenerative disease caused by severe neurodegeneration
in the hippocampus and neocortical regions of the brain of
affected individuals [20].
AD pathological hallmarks include extracellular amyloid
plaques and intracellular aggregates (neurofibrillary tangles).
The major component of the amyloid plaques is the amyloid
peptide Aβ, which results from the proteolysis of the amyloid
precursor protein (APP). APP is a ubiquitously expressed
transmembrane protein exerting a critical role in neuron
growth and survival [21, 22]. APP proteolysis to form the
Aβ peptide involves the sequential action of aspartic protease
BACE1 (β-secretase) and of γ-secretase, a multiprotein
complex [23]. The length of Aβ peptide may range from
39 to 43 aminoacid residues, due to different γ-secretase
cleavage sites. Aβ appears to be unfolded, under physiological
conditions [24]. In amyloid plaques, the most frequent
species are Aβ40 and Aβ42, the latter being the most prone
to aggregation [23]. Neurofibrillary tangles are composed
of hyperphosphorylated tau protein, a microtubule-binding
protein thought to be involved in microtubules stabilization
and in regulation of axonal transport in the brain [25].
The causes of Alzheimer’s disease are not well under-
stood, except for a small percentage of cases that are linked
to familial genetic mutations [26]. Several hypotheses have
been put forward with the aim to explain the cause of the
sporadic form of the disease. One widely discussed of those
hypotheses assumes that amyloid deposits of Aβ peptides are
the causative agents of AD [27]. The “amyloid” theory is
further supported by the link between mutations in the APP
gene and some inherited forms of the disease [26].
Aβ toxicity is dependent on Aβ’s conformational state,
peptide length, and concentration [28, 29]. Moreover, it has
been described that Aβ toxicity is also related to Aβ’s ability
to form hydrogen peroxide and free radicals [30, 31]. These
findings are supported by the significant lipid peroxidation,
protein oxidation, andDNA oxidation observed in AD brains
[29, 32, 33]. In addition, two factors reinforce the role of
oxidative stress in AD pathogenesis: pro-oxidants increase Aβ
production, whereas several antioxidants, namely vitamin E,
melatonin, and several free radical scavengers, can protect
neurons from Aβ-induced toxicity [34].
Interestingly, the Aβ peptide is not toxic in the absence
of redox metal ions, and many recent studies implicate
biometals in the development or progression of Alzheimer’s
disease [6, 35–37]. Accordingly, sophisticated techniques
have shown an overaccumulation of copper, iron, and zinc
within the amyloid plaques compared with the surrounding
tissues [38]. Aβ has high affinity for redox-active metals
being able to reduce them and consequently lead to the
formation of hydrogen peroxide and oxidized amyloid [6].
Butterfield and Bush proposed that a single methionine
residue (Met35) of Aβ42 is critical for the oxidative and
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neurotoxic properties of this peptide [39, 40]. Substitution
of Met35 renders the Aβ peptide nonoxidative and nonneu-
rotoxic [40]. The sulphur atom ofMet35 is highly susceptible
to oxidation, forming the sulfide radicalMetS•+ and reducing
copper(II) to its high-active low-valency form [5, 40]. The
MetS•+ radical is able to undergo very fast reactions with
superoxide ion, leading to the formation of methionine
sulfoxide (MetO). In AD senile plaques, a significant fraction
of Aβ has Met35 in the form of MetO [41].
Another well-studied source of oxidative stress in AD
is mitochondria damage and its consequent functional
abnormality that favors the production of ROS. Indeed,
it was shown that neurons in AD exhibit a significantly
higher percentage of damaged mitochondria compared to
an aged-matched group [42]. Furthermore, mitochondrial
dysfunction has been widely implicated in the etiology
of AD, since early impairments of mitochondrial function
and oxidative stress may precede Aβ overproduction and
deposition [43]. Also inflammation can induce oxidative
damage in AD, especially via microglia, leading to increased
ROS and RNS formation and the resulting damage to lipid,
proteins, and nucleic acids [44–46].
4. Parkinson’s Disease and Oxidative Stress
Parkinson’s disease is an age-related neurodegenerative dis-
order affecting the central nervous system. It is characterized
by the progressive degeneration of nigrostriatal dopamin-
ergic neurons within the substantia nigra pars compacta,
which is the pathological process responsible for the motor
symptoms attributed to PD [47]. The pathological hallmark
of the disease is the presence of proteinaceous cytoplasmic
inclusions designated as Lewy bodies and Lewy neurites.
These are predominantly composed of the presynaptic
protein α-Synuclein (α-Syn) [48] together with proteasomal
and lysosomal subunits as well as molecular chaperones [49].
The ubiquitous α-Syn brain protein is implicated in both
hereditary and sporadic PD. Its encoding gene, SNCA, was
the first genetic determinant associated with the disease
and, for this reason, much of the work on PD converges
on α-Syn [50]. α-Syn was shown to interact with lipids
and membranes, accelerating amyloid fibril formation [51],
and it has been proposed to regulate the dynamics of
synaptic vesicles at the synapse [52]. Indeed, α-Syn exhibits
a remarkable conformational plasticity being its structure
largely dependent on the surrounding environment. The
monomeric α-Syn is a typical natively unfolded protein
under physiological conditions [53, 54]. However, under
specific conditions, such as the increase of its intracellular
levels, α-Syn can adopt different conformations, including
several α-helical and β-sheet species folded to different
degrees in both monomeric and oligomeric states [55].
Although PD is a recognized multifactorial disease, a
large body of evidence has implicated oxidative stress in the
pathogenesis of PD. The conclusive connection between PD
and oxidative stress is supported by the increased oxidative
damage of sugars, lipids, nucleic acids, and proteins observed
in postmortem dopaminergic neurons within the substantia
nigra pars compacta of PD brains [6, 56, 57].
Auluck et al. proposed that the impairment of α-
Syn function leads to its local accumulation, favoring the
formation of toxic oligomeric species that interfere with
ER-to-Golgi trafficking, mitochondria turnover—through
the abrogation of mitophagy—and generate oxidative stress.
Moreover, the abnormal interaction of α-Syn with mem-
branes has been implicated in the cytoplasmic retention
of catecholaminergic neurotransmitters yielding cytotoxicity
through the generation of dopamine adducts and ROS
[52]. This effect is potentiated in the presence of iron-rich
environments, as it is the case of Lewis bodies in the neurons
decorating the substantia nigra of PD patients [58–61].
Indeed, it is known that dopamine is able to coordinate iron
and regenerate Fe2+, possibly providing an equally important
source of hydroxyl radical production [62].
Mitochondria have been claimed as dominant sites for
oxidative stress-driven initiation and propagation in PD. The
direct implication of this organelle in PD was first suggested
by the use of the mitochondrial complex I (CI) inhibitor
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) [63,
64]. This chemical mimics human PD in animal models and
is associated with development of Parkinsonism in humans
subjected to accidental exposure [65]. Further corroborating
the relevance of mitochondria in PD, it was shown that
the well-known CI inhibitor rotenone induces death of
dopaminergic cells [66–69]. In addition, depletion of the
antioxidant peptide glutathione (GSH) in PD cells, which
may be caused by a decrease in its synthesis and recycling
[70], has been associated with a decrease of mitochondrial
CI activity, resulting in mitochondrial dysfunction [71, 72].
Moreover, defective mitochondrial CI function is observed
in the substantia nigra of PD brains [73, 74]. Recent studies
have also demonstrated that α-Syn monomers and oligomers
associate with the inner mitochondrial membrane where
they can physically associate with CI, thereby interfering
with the mitochondrial function and increasing free radicals
production [72, 75]. Further highlighting the relevance
of mitochondrial dysfunction and oxidative stress in the
pathological process of the disease, several genes associated
with familial cases of PD were shown to encode either mito-
chondrial proteins or mitochondria-associated proteins [6,
76]. Among the latter is DJ-1, a protein that shares structural
homology with the Escherichia coli chaperone Hsp31 and
is thought to have a protective role against oxidative stress
[77]. Under conditions of oxidative stress, DJ-1 is relocated
to the mitochondria, affecting the sensitivity of specific
neuron populations to compounds targeting mitochondrial
CI, namely, rotenone, paraquat, and MPTP [6, 78–80].
Several evidences support as well an unbalanced genera-
tion of RNS as a feature of PD pathology. First, nitrated α-
Syn accumulates in LB of PD cells. Secondly, the treatment
of GSH-depleted dopaminergic cells with RNS inhibitors
prevents mitochondrial CI inhibition [6], indicating that
RNS itself has a role in mitochondrial dysfunction and ROS
generation in PD. Lastly, glial cells within the substantia
nigra exhibit increased NO levels [81], possibly due to the
accumulation of interferon-γ (IFN-γ) [82], a cytokine which
was shown to promote induction of RNS in brain.
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5. S. cerevisiae as Model Organism to
Study Neurodegenerative Diseases
Budding yeast Saccharomyces cerevisiae has been introduced
as an experimental organism in the midthirties of the 20
century. Since then, its potential as a model organism has
been exploited in many areas of biology [83]. Despite lacking
the physiological complexity of the mammalian nervous
system, yeast was recently used in the study of neurode-
generative disorders, such as Alzheimer’s and Parkinson’s
Diseases. This became possible due to the development of
powerful yeast genetic tools as well as the high conservation
of fundamental biological processes and pathways associated
with neurodegeneration including protein folding, cellular
trafficking, and secretion [84]. It is noteworthy that about
one-fifth of yeast genes are members of orthologous gene
families associated with human diseases [85]. This is an
important aspect to consider when studying human diseases
in yeast. If a homologue of the gene implicated in the disease
is present in yeast genome, a unique opportunity to directly
study its function is offered, either through its deletion
or overexpression. Otherwise, if the disease-associated gene
does not have a yeast counterpart, functional analysis can
still be performed via heterologous expression [86, 87].
Equally important “humanized” yeasts are being used as
platforms for high-throughput screenings of compounds
with therapeutic potential.
6. Yeast as a Model for
Studying Alzheimer’s Disease
Yeast models have been extensively used to study several
molecular aspects of AD, even though yeast lacks for some
AD-associated genes. Studies in yeast have been mainly
focused on the in vivo APP processing, Aβ oligomerization,
and toxicity.
The usage of heterologous expression of human secre-
tases in yeast has greatly contributed to the understanding
of human APP processing. It has allowed the discovery of
BACE1 inhibitors and prompted the study of the individual
function of each component of the γ-secretase complex [88].
Growing evidence suggests that the oligomeric forms of
the Aβ peptide, rather than amyloid fibrils, are the most
toxic forms [89–92]. These findings have shifted the focus of
investigation towards the earliest stages of Aβ oligomeriza-
tion. As a result, the following described yeast systems were
developed and are now useful tools not only in the study
of Aβ-oligomerization, but also in the understanding of the
molecular events triggered by aggregation as well as in the
screening of potential therapeutic compounds that affect the
aggregation process.
The first yeast study on Aβ oligomerization used a two-
hybrid approach to analyze Aβ dimerization. Protein-protein
interactions were measured by fusing the Aβ peptide to a
LexA DNA-binding domain and also to a B42 transactivation
domain, and then monitoring the expression of a lacZ
reporter driven by a LexA-dependent promoter [93]. The
authors showed that Aβ peptide was able to form dimers, in
vivo, in the yeast cell nucleus.
Bagriantsev and Liebman and von der Haar et al.
implemented a different yeast model system that may
constitute a valuable tool to seek for agents that interfere
with the initial steps of Aβ42 oligomerization [94, 95]. In
this study, the ability of Aβ42 peptide to aggregate was
monitored by fusing it to the middle and C-terminal domain
of Sup35. The Sup35 yeast translational termination factor
can undergo spontaneous conversion into a prion state,
losing its function [96]. Sup35 loses the ability to aggregate
when its prion-forming (N-terminal) domain is deleted.
However, the insertion of Aβ peptide sequences in place
of the original prion domain of Sup35 protein restores its
ability to aggregate [94, 95]. Using this reporter system, it was
possible to confirm in vivo the impact of point mutations,
previously shown to inhibit Aβ42 aggregation in vitro [94,
97]. Furthermore, it was shown that the Hsp104 yeast
chaperone, a chaperone known to rescue proteins from the
aggregated state in other yeast models of neurodegenerative
diseases [98, 99], appears to have a contrary function in
AD, protecting Aβ-fusion protein from disaggregation and
degradation [94, 95].
Oligomerization of Aβ was also the subject of a third
yeast study, by the use of a reporter consisting of Aβ fragment
fused to GFP [100]. The assay was based on the premise
that aggregates of the fusion protein suppressed green flu-
orescence. The Aβ-GFP fusion was shown to cause slight but
significant yeast growth reduction and to induce a heat shock
response (HSR), as indicated by the cotransformation of
yeast with Aβ-GFP andHSE2 element fused to a downstream
lacZ gene. The authors put forward the hypothesis that HSR
could arise from Aβ inducing ROS and/or the presence of
misfolded proteins and suggested that HSR might be a target
for further studies seeking for inhibitors of Aβ effects [100].
Recently, Treusch et al. engineered a yeast model for
studying Aβ toxicity [101]. The overexpression of a construct
harboring the Aβ42 fragment fused at the N-terminus to an
endoplasmatic reticulum targeting sequence was driven by
a galactose-inducible promoter. Aβ oligomers localized to
secretory compartments and, like in neurons, contributed
to toxicity in yeast. A screen for genetic modifiers allowed
the identification of 40 genes that were able to modulate
Aβ toxicity. Among those, 12 had homologues in humans,
3 being related to clathrin-mediated endocytosis, and 7
functionally associated with the cytoskeleton. Interestingly,
all the former genes behaved as Aβ toxicity suppressors and
had been previously shown to be or interact with validated
risk factors for AD. The authors further showed that Aβ
affects clathrin-mediated endocytosis and proposed that Aβ
oligomers may interact with transmembranar receptors and
prevent their correct destination [101].
7. Yeast as a Model for
Studying Parkinson’s Disease
As a common feature of sporadic and familial cases of PD,
the understanding of the pathological processes associated
with α-Syn has attracted special attention. In order to gain
insight into α-Syn pathobiology, Outeiro and Lindquist
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exploited a myriad of advantages of using S. cerevisiae as
a model organism, by developing a powerful “humanized”
yeast system. As a means to study the α-Syn dynamics in
vivo, the authors overexpressed in yeast cells a construct
harboring the wild type or the mutant versions of human
SNCA gene fused to GFP [102]. This pioneering system
faithfully reproduces several features of PD in yeast, allowing
to thoroughly investigate the pathological processes involved
in the disease. Three strains, designated as NonTox, InTox,
and HiTox, were created to express α-Syn at different
levels [52]. As it happens in complex eukaryotic models,
the appearance of cytoplasmic foci, cytotoxicity, and α-
Syn-decorated vesicle accumulation was shown to be dose
dependent [102, 103]. Moreover, high doses of α-Syn lead
to increased toxicity, accumulation of cytoplasmic lipid
droplets, vesicle trafficking defects, ER stress, activation
of the heat-shock response, impairment of the ubiquitin-
proteasome pathway, and mitochondrial dysfunction in
the HiTox strain, therefore recapitulating the pathological
features displayed by PD patients whose genome encodes
duplications or triplications of SNCA locus [52].
The α-Syn yeast model developed by Outeiro and
Lindquist has been the basis of several genome wide and
high-throughput analyses aimed at unveiling the intricacies
of PD. The systematic screening of a galactose-inducible
overexpression library in the InTox strain revealed the
Rab GTPase Ypt1 (Rab1) as suppressor of α-Syn toxicity
[104], reinforcing the role of α-Syn in vesicle formation
and delivery. In addition, an unbiased genome-wide screen
for modifiers of α-Syn toxicity was performed in the
InTox strain, allowing the identification of the polyamine
transporter Tpo4 [105] and highlighting the significance of
polyamine pathway in PD pathogenesis. Using the Respon-
seNet algorithm to integrate α-Syn mRNA profiling and
genome-wide genetic data, it was found that trehalose might
be involved in the protection pathway against α-Syn toxicity
possibly promoting misfolded protein clearance. In addition,
mitochondrial dysfunction and oxidative/nitrosative stress
also appeared as consequences of α-Syn overexpression in
yeast [106]. Comparison of the transcriptome of HiTox and
NonTox strains provides further evidence supporting the
assumption that mitochondrial dysfunction and oxidative
stress are associated to conditions in which α-Syn is expressed
at high levels. It has also been verified that mitochondria
morphology is affected and ROS is accumulated in the HiTox
strain further suggesting that high levels of α-Syn elicit
global mitochondrial dysfunction [107]. This may suggest
that α-Syn accumulation is the origin of oxidative damage
of specific neuronal cells in PD.
More recently, overexpression of α-Syn in yeast revealed
that the knockout of genes encoding lipid elongases, namely,
ELO1, ELO2, and ELO3, impairs cell growth, dramatically
decreases the survival of aged cells, and leads also to ROS
accumulation and aberrant protein trafficking [108]. A
similar strategy, using a different plasmid to drive galactose-
inducible α-Syn expression in distinct S. cerevisiae back-
grounds, disclosed the significance of fatty acid synthase
activity and intracellular redox status in the mechanisms of
α-Syn toxicity [109].
α-Syn-humanized yeasts have also been exploited to
search for compounds with therapeutic potential. In this
context, the HiTox strain was used in a high-throughput
chemical screen to identify agents capable of rescuing the
robust toxicity of this strain. A class of small molecules of
1,2,3,4-tetrahydroquinolinones were identified and shown to
revert the formation of α-Syn foci, to reestablish ER-to-Golgi
trafficking, to amelioratemitochondria damage, to limit ROS
production, and consequently to reduce α-Syn toxicity not
only in yeast but also in other more complex PD models
[107].
8. Concluding Remarks
Although AD and PD have been extensively studied, the
exact mechanism of disease progression or pathogenesis
remains largely unknown. As outlined in this paper, several
in vivo and in vitro studies point towards a role of oxidative
stress in AD and PD pathogenesis. Nevertheless, whether
it is a primary cause or simply a consequence of the
neurodegenerative process is still an unanswered question.
In addition, specifically concerning AD, there are quite a few
contradictory reports regarding the role of oxidative stress
in the disease. Indeed, it has been described that oxidative
stress may as well lead to an increase in Aβ [14, 110], and in
vivo studies showed a negative correlation between oxidative
stress and Aβ, indicating an antioxidant role for Aβ [111].
Yeast can be a powerful tool as a means to clarify several
of these issues. Within this context, yeast models of AD may
in the future be used to monitor Aβ oligomerization and
toxicity under an oxidative environment or in the absence
of ROS (hypoxia). Interestingly, a yeast model consisting
of Aβ peptide fused to GFP has been successfully used to
test whether folate, an antioxidant, was able to prevent Aβ
aggregation [112]. To better understand the relationship
between oxidative stress and α-Syn aggregation, in the
pathological processes triggering PD, it would be interesting
to assess both the behavior of α-Syn in the “humanized”
NonTox strain under oxidative environments and in the
InTox and HiTox strains under hypoxia conditions.
Future studies combining yeast and animal models of AD
and PD will certainly provide valuable insights into the role
of oxidative stress in these neurodegenerative diseases.
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